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1.	PARVOVIRUS	B19	
1.1.	INTRODUCTION	
Parvovirus	B19	(B19V)	was	first	identified	in	1975,	during	tests	for	hepatitis	B	virus	surface	
antigen.	(1)	The	name	originates	from	the	coding	of	a	serum	sample,	number	19	in	panel	B	
that	 gave	 anomalous	 results.	 Electron	 microscopy	 showed	 the	 presence	 of	 particles	 of	
23nm-diameter	 resembling	 animal	 parvoviruses.	 In	 the	 early	 eighties,	 it	 was	 linked	 to	
transient	 aplastic	 crisis	 in	 patients	 with	 sickle	 cell	 disease	 and	 erythema	 infectiosum	 in	
children	(2,	3).	It	was	officially	recognized	as	a	member	of	the	Parvoviridae	family	in	1985	
(4).	 It	 is	 the	 only	 member	 of	 the	 Parvoviridae	 family	 to	 be	 a	 human	 pathogen	 with	 a	
widespread	trasmission	and	association	to	an	ample	range	of	clinical	manifestations.		
	
1.2.	TAXONOMY	
The	Parvoviridae	family	is	divided	in	two	subfamilies,	Parvovirinae	and	Densovirinae,	based	
on	the	ability	to	infect	vertebrate	or	invertebrate,	respectively.	Parvovirinae	are	subdivided	
into	8	genera,	according	to	their	transcription	maps,	the	nature	of	terminal	repeats	and	the	
ability	to	replicate	either	autonomously	or	with	helper	virus,	like	Dependovirus	genus.	B19V	
infects	 only	 humans,	 does	 not	 require	 a	 virus	 helper	 to	 replicate	 and	 replicates	
preferentially	 in	 erythroid	 progenitors	 cells.	 Thus,	 B19V	 is	 classified	 as	 a	member	 of	 the	
Erythroparvovirus	genus	and	the	correct	species	name	is	now	Primate	erythroparvovirus	1	
(5).	
	
1.3.	MORFOLOGY	
Initial	 biochemical	 characterization	 confirmed	 that	 B19V	 virion	 has	 properties	 typical	 of	
parvoviruses,	with	 a	 composition	of	 two	 structural	 properties,	VP1	and	VP2.	VP1	protein	
accounts	 for	 about	 5%	of	 the	 virion	mass,	while	 95%	of	 viral	 capsid	 is	 composed	of	 VP2	
protein,	which	lacks	the	first	226	amino	acids	present	at	the	N-terminal	of	VP1	(VP1	unique,	
VP1u)	(6).	
7	
	
Structural	 data	 have	 been	 obtained	 mainly	 by	 means	 of	 cryoelectron	 microscopy	 and	
crystallographic	X-ray	diffraction	studies	with	VP2	protein	empty	capsids,	at	the	beginning,	
and	more	recently	also	with	native	virions	containing	or	not	DNA.		
The	 non-enveloped	 viral	 particles	 are	 20-25	 nm	 in	 diameter	 and	 exhibit	 icosahedral	
symmetry.	 The	 small	 viral	 capsid	 is	 composed	 of	 60	 capsomers.	 The	 VP	 common	 region	
constitutes	the	core	structure	formed	by	eight-stranded	β-barrel	connected	by	large	loops	
projecting	 on	 the	 outer	 surface.	 Similar	 to	 other	 parvoviruses,	 a	 cylindrical	 structure	 is	
present	at	the	5-fold	axis,	forming	a	gated	channel	connecting	interior	and	outer	surface	of	
the	virion.	On	the	other	hand,	surface	of	B19V	is	significantly	different	from	those	of	other	
parvoviruses	by	lacking	prominent	spikes	on	the	3-fold	axis	involved	in	host	recognition	and	
antigenicity	(7-10).	
	
	
Figure	1:	Structure	of	Parvovirus	B19	(10).	
	
Comparison	 of	 wild-type	 B19V	 virions	 with	 recombinant	 particles	 consisting	 of	 only	 VP2	
protein	 showed	structural	differences	near	 the	5-fold	axis.	The	VP2	N-terminal	peptide	 is	
positioned	between	neighbouring	VP	subunits	of	wild-type	B19V	virions	and	is	exposed	to	
the	 surface	 adjacent	 to	 the	 5-fold	 β-cylinder.	 The	 position	 of	 VP1u	 region	 could	 not	 be	
identified	in	the	icosahedrally	averaged	maps	of	B19V	capsid,	possibly	because	the	VP1u	is	
disordered	or	because	of	the	low	copy	number	of	molecules	per	capsid.		
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Two	possibilities	are	proposed.	VP1u	could	always	appear	on	the	surface	of	the	capsid	and	
its	 epitopes	 could	 be	 recognized	 by	 the	 immune	 system,	 or	 it	 is	 also	 possible	 that	 the	
protein	 is	 located	 internal	 to	the	capsid,	proximal	 to	the	cylinder	at	 the	5-fold	axis,	being	
exposed	when	virions	are	damaged	or	during	interaction	with	target	cells	(11).	
	
1.4.	GENOME	
After	B19V	discovery	and	its	association	to	erythrocyte	aplasia	and	erythema	infectiosum,	
its	genome	was	characterized.	A	linear	single-stranded	DNA	molecule	of	either	positive	or	
negative	polarity	was	found	to	be	encapsidated	in	the	viral	capsid.	It	was	capable	of	priming	
synthesis	of	 its	 complementary	 strain	 in	vitro.	These	properties	enabled	 the	classification	
within	 the	 Parvoviridae	 family	 (12).	 Viral	 genome	 is	 5596	 nucleotides	 in	 length	 with	 a	
unique	internal	region	of	4830	nucleotides,	flanked	by	two	inverted	terminal	repeats	of	383	
nucleotides	each	(ITRs)	that	form	an	imperfect	palindrome	(Figure	1)	(13).	
	
	
	
Figure	2:	Schematic	diagram	of	B19V	genome.	Identical	ITRs	are	present	at	each	end	of	the	genome	and	form	
terminal	loop	structures	(45).	
	
	
As	 a	 result	 of	 the	 occurrence	 of	 sequence	 asymmetries	 within	 the	 palindrome,	 each	
terminal	region	can	be	present	in	either	one	of	two	alternative	sequences,	creating	termini	
in	two	inverted	complementary	sequence	orientations,	usually	referred	to	as	flip/flop.	The	
result	 of	 the	 relative	 possible	 combinations	 is	 the	 existence	 of	 four	 different	 genome	
isomers	(14).	The	presence	of	self-complementary	sequences	in	the	terminal	regions	allows	
the	formation	of	terminal	loop	and	stem	structures	(15).	
Two	large	open	reading	frames	are	present	(Figure	3):	the	left	half	of	the	genome	encodes	
for	the	non-structural	protein	NS,	while	the	right	one	codes	for	the	capsid	proteins	VP1	and	
VP2.	 Other	 minor	 open	 reading	 frames	 are	 present,	 coding	 for	 smaller	 non-structural	
proteins	(11	kDa,	9	kDa,	7.5	kDa).		
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Figure	3:	B19V	genome	organization	and	map	of	 the	whole	set	of	viral	 transcripts.	Top:	Open	reading	 frames	
identified	in	the	positive	strand	of	the	genome.	Center:	distribution	of	regulatory	signals;	P6,	promoter;	D1,	D2,	
splice	 donor	 sites;	 A1-1/2,	 A2-2/2,	 splice	 acceptor	 sites;	 pAp1,	 pAp2,	 pAd,	 cleavage-polyadenylation	 sites.	
Bottom:	 viral	 mRNA	 species;	 black	 lines	 indicate	 the	 exon	 composition	 and	 light	 boxes	 indicate	 the	 ORFs	
contained	within	mRNAs.	
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2.	EVOLUTION	
	
The	 species	 B19V	 is	 now	 formally	 subdivided	 into	 three	 genotypes	 (16):	 the	 genotype	 1,	
which	includes	prototype	strain	B19V,	the	variant	genotype	2,	including	the	Lali	and	the	A6	
strains	(17,	18),	and	the	variant	genotype	3,	containing	the	V9	strain	(19).	At	the	nucleotide	
level,	 the	 genetic	 distance	 between	 clusters	 is	 5-10%;	 while	 the	 genetic	 distance	 within	
clusters	is	generally	lower	for	genotype	1,	normally	less	than	2%,	and	higher	for	genotype	2	
and	3,	in	the	range	of	3-10%	(14).	
The	constant	insertion	of	new	sequences	into	the	database,	leads	further	subdivisions	into	
subtypes.	 Therefore,	 genotype	 1	 can	 be	 subdivided	 into	 two	 subgroups,	 referred	 as	
genotype	1a	and	1b	(20),	and	genotype	3	contains	two	subgenotypes,	3a	and	3b	(21).		
No	correlation	between	specific	clinical	symptoms	and	B19V	sequence	has	been	observed.	
All	 three	 genotypes	 showed	 similar	 functional	 characteristics,	 in	 term	 of	 infectivity	 of	
permissive	cell	lines,	mRNA	production	and	expression	and	transcription	efficiencies	of	the	
p6	promoter	(22).	
The	global	distribution	of	each	genotype	 is	not	uniform	and	depends	on	geographic	area,	
population	and	sample	type	(23-25).	Overall,	genotype	1	is	the	major	circulating	genotype	
with	a	worldwide	distribution	(26);	the	genotype	2	is	rare	but	found	in	different	geographic	
areas	(27,	28);	the	genotype	3	is	the	prevalent	variant	circulating	in	western	Africa	(21).	
A	massive	study	has	been	conducted	in	Finland,	by	collecting	523	solid	tissue	samples	(skin,	
synovium,	 tonsil	 and	 liver),	 and	 1640	 sera	 from	 patients	with	 various	 clinical	 symptoms.	
Regarding	 the	 tissue	 specificity,	 genotype	 1	 DNA	 was	 found	 in	 all	 tissue	 types,	 with	
detection	rates	varying	from	16%	in	tonsils	to	35%	in	synovia.	Genotype	2	has	a	universal	
distribution	too,	albeit	at	a	 lower	frequency,	while	genotype	3	was	absent	from	all	of	the	
tissues	 studied.	Grouping	samples	according	 to	 the	birth	date	of	donors,	genotype	1	was	
found	 almost	 uniformly	 in	 all	 individuals	 (except	 small	 children),	 while	 genotype	 2	 was	
strictly	 confined	 to	 the	 elders.	 Thus,	 data	 suggested	 that	 the	 new	 variant	 2	 of	 B19V	
circulated	earlier	in	respect	to	the	prototype	1.	Results	indicated	that	genotypes	1	and	2	co-
circulated	in	Northern	Europe	until	1950s	at	a	similar	frequency,	with	genoprevalence	rates	
of	 22%	 and	 28%,	 respectively.	 Then,	 genotype	 1	 became	 prevalent	 and	 genotype	 2	
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disappeared	 in	 1960s-1970s	 (present	 in	 3%	 among	 those	 born	 in	 1960s	 and	 in	 a	 single	
individual	born	 in	1970s),	and	remained	absent	thereafter	 (only	genotype	1	was	found	at	
low	 frequency	 in	 children	born	during	 the	1990s).	Moreover,	 B19V	DNA	was	detected	 in	
17%	of	sera	collected	during	1983-1997,	all	corresponding	to	genotype	1.	
This	 study	 confirmed	 that	 erythrovirus	 DNA	 persistence	 in	 human	 tissue	 is	 lifelong	 and	
could	represent	an	 important	source	of	 information,	called	Bioportfolio.	The	maintenance	
of	 the	 Bioportfolio	 could	 involve	 a	 dynamic	 interplay	 between	 viral	 replication	 and	 the	
immune	surveillance	of	the	host	and	it	provides,	at	epidemiological	and	phylogenetic	level,	
a	database	for	analysis	of	the	occurrence	and	circulation	of	viruses	and	their	variants	(29).	
The	pattern	of	evolution	of	B19V	is	still	under	 investigation.	By	 inferring	the	phylogenetic	
history	 and	 evolutionary	 dynamics	 of	 temporally	 sampled,	 a	 high	 rate	 of	 evolutionary	
change,	at	approximately	104	nucleotide	substitutions/site/year,	was	observed.	This	rate	is	
within	 the	 range	 seen	 in	 RNA	 viruses	 and	 is	 so	 similar	 to	 those	 estimated	 for	 other	
parvoviruses,	suggesting	that	high	mutation	rates	may	be	characteristic	of	all	autonomous	
parvoviruses	(30).	
This	 high	 rate	 of	 mutation	 was	 confirmed	 in	 a	 study	 comparing	 the	 rates	 of	 sequence	
change	 in	 exogenous	 virus	 populations	 with	 those	 in	 persistently	 infected	 individuals,	
analysing	 large	 genotype	 1	 VP1/VP2	 sequence	 data	 sets	 of	 plasma-	 and	 tissue-	 derived	
variants	of	B19V	virus	with	known	sample	dates.	By	using	linear	regression	and	likelihood-
based	 methods,	 plasma-derived	 B19V	 showed	 a	 substitution	 rate	 of	 4×104	 and	 a	
synonymous	 substitution	 rate	of	18×104	per	 site	per	 year.	 The	 last	 common	ancestor	 for	
genotype	1	was	predicted	to	exist	around	1956	to	1959,	fitting	well	with	previous	analyses	
described	 above.	 In	 contrast,	 the	 evolution	 of	 B19V	 amplified	 from	 tissue	 samples	 was	
consistent	 with	 slow	 or	 absent	 sequence	 change	 during	 persistence.	 However,	 paired	
samples	 from	 acute	 infection	 and	 after	 a	 period	 of	 persistence	 were	 not	 available	 to	
directly	investigate	the	sequence	change,	and	this	study	had	to	rely	on	estimates	of	times	
of	 infection,	 supposing	 primary	 infections	 at	 the	 age	 of	 9	 and	 no	 subsequent	 sequence	
change	during	persistence	(31).	
Recently,	the	B19V	genomic	prevalence	was	determined	in	DNA	extracts	of	 long	bones	of	
106	anonymous	World	War	II	Finnish	casualties.	B19V	DNA	was	found	in	45%	of	long	bone	
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samples	 and	 was	 exclusively	 of	 genotype	 2	 and	 3,	 thus	 confirming	 the	 hypothesis	 that	
prototype	 1	 virus	 emerged	 after	 World	 War	 II.	 The	 detection	 of	 genotype	 3	 was	 in	
discrepancy	 with	 previous	 studies	 that	 revealed	 an	 absence	 of	 this	 variant	 in	 the	 North	
Europe	with	predominance	in	Africa.	Thus,	analysis	of	mitochondrial	DNA	of	the	respective	
positive	 two	 soldiers	 suggested	 that	 they	 are	 not	 of	 Finnish	 origin.	 The	 rate	 of	 B19V	
sequence	change	was	calculated,	using	the	assumption	of	primary	infection	at	the	age	of	9	
and	 no	 sequence	 change	 after	 infection,	 as	 in	 the	 previous	 cited	work.	 The	 change	 rate	
estimated	was	approximately	2×104	substitutions/site/year	for	the	combined	NS/VP	region,	
which	 is	 was	 lower	 than	 previous	 analyses	 based	 on	 the	 whole	 VP1,	 a	 genome	 region	
showing	substantially	greater	variability	than	the	conserved	NS	and	VP	regions	targeted	in	
this	study.	The	time	to	most	recent	common	ancestor	of	all	three	genotypes	was	estimated	
as	1833,	1868	for	genotypes	2	and	1917	for	genotype	3	(32).	
	
The	 underlying	 high	 mutation	 frequency	 found	 for	 B19V	 may	 lead	 to	 rapid	 adaptive	
changes,	more	commonly	ascribed	to	RNA	virus	populations,	and	to	the	formation	of	viral	
quasi-species.	 Determining	 what	 epidemiological	 or	 biological	 factors	 led	 to	 such	 a	
complete	 and	 geographically	 extensive	 population	 replacement	 over	 a	 short	 period	 is	
central	to	understanding	the	nature	of	parvovirus	evolution.	Moreover,	understanding	viral	
evolutionary	 dynamics	 may	 be	 crucial	 for	 better	 monitoring	 and	 predicting	 the	
epidemiological	trajectory	of	clinically	relevant	viruses.	
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3.	VIRAL	LIFE	CYCLE	
	
The	life	cycle	of	B19V	includes	binding	of	the	virus	to	host	cell	receptors,	internalization	and	
translocation	 of	 the	 genome	 to	 the	 host	 nucleus,	 DNA	 replication,	 RNA	 transcription,	
protein	production	and	finally	assembly	and	release	of	mature	virions.	
	
	
Figure	4:	Principal	steps	of	B19V	life	cycle.	
	
3.1.	VIRUS	BINDING/UPTAKE	
Globoside	 (erythrocyte	P	 antigen)	was	 identified	 as	 the	primary	 receptor	 for	B19V.	B19V	
was	 initially	shown	to	agglutinate	human	red	cells	(33).	Thus,	by	using	hemmaglutination,	
B19V	was	found	to	bind	the	glycolipid	globoside.	Purified	globoside	blocked	the	binding	of	
B19V	to	erythroid	cells	and	late	erythroid	colony-forming	units	(CFU-E)	were	protected,	in	a	
colony	formation	assay,	from	the	cytopatic	effect	of	B19V	in	presence	of	purified	globoside,	
as	well	as	by	using	monoclonal	antibody	against	globoside	(34).	Moreover,	persons	with	the	
p	phenotype	whose	erythrocytes	do	not	express	globoside	are	naturally	resistant	to	B19V	
infection	(35).	
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Coreceptors	like	α5β1	integrins	and	Ku80	were	proposed,	although	their	role	in	virus	entry	
needs	further	investigation.		
The	phenotype	shift	of	erythroleukemia	cell	line	K562	from	non-adherent	to	adherent	cells	
that	 is	 α5β1	 integrin-mediated,	 renders	 the	 cells	 susceptible	 to	 B19V	 infection.	 α5β1	
integrin	coreceptor	function	 in	 induced	K562	cells	could	be	enhanced	either	by	stabilizing	
the	 high	 affinity	 conformation	 of	 β1	 integrins	 or	 by	 inducing	 β1	 integrin	 clustering,	
suggesting	that	β1	integrin-mediated	signaling	might	be	important	for	B19V	internalization.	
In	addition,	virus	 internalization	 into	purified	human	erythroid	progenitor	cells	 (EPCs)	can	
be	completely	inhibited	by	antibodies	blocking	β1	integrin	function	(36).	
	
	
Figure	5:	Proposed	model	of	B19V	entry	into	erythroid	cells.	Mature	human	red	blood	
cells	 allow	 virus	 binding	 but	 not	 internalization	 (A),	 whereas	 virus	 uptake	 occurs	 in	
erythroid	progenitor	cells	expressing	both	globoside	and	α5β1	integrin	(B).		
	
The	expression	of	a	constitutively	active	mutant	of	the	small	GTPase	Rap1	render	K562	cells	
permissive	to	B19V	infection	and	this	effect	is	mediated	through	functional	recruitment	of	
β1	 integrin	 coreceptors,	 as	demonstrated	by	 the	 complete	block	of	 transduction	with	β1	
integrin	 antibodies.	 The	 active	 actin	 polymerization	 played	 a	 critical	 role	 in	 β1	 integrin	
coreceptor	recruitment	because	the	effect	 is	abolished	also	by	inhibition	of	de	novo	actin	
polymerization	with	cytochalasin	D.	Furthermore,	pharmacological	 induction	of	Rap1	GTP	
significantly	increased	B19V-mediated	gene	transfer	into	human	erythroid	progenitor	cells	
in	vitro,	suggesting	that	these	cells	possess	the	cytoskeleton	organization	capacity	for	the	
efficient	recruitment	of	β1	integrins	(37).	
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Although	originally	described	as	a	nuclear	protein,	Ku80	was	 found	on	 the	cell	 surface	of	
different	 cell	 types.	 A	 study	 aimed	 to	 investigate	 its	 role	 in	 B19V	 interaction	 showed	 a	
marked	increase	in	B19V	binding	in	Ku80-transfected	HeLa	cells	that	was	inhibited	by	using	
antibody	 recognizing	 the	 N-terminus	 of	 the	 Ku80,	 suggesting	 that	 B19V	 interacts	 with	
specific	 sites	 of	 Ku80	 on	 the	 cell	 surface.	 Moreover,	 reduction	 of	 Ku80	 expression	 in	
KU812Ep6	cells	by	short	interfering	RNA	resulted	in	the	marked	inhibition	of	B19V	binding	
(38).	However,	the	possible	role	of	Ku80	in	the	B19V	life	cycle	needs	to	be	confirmed.	
	
Cryo-electron	microscopy	studies	of	empty	B19V	capsid	complexed	with	globoside	showed	
that	the	receptor	bound	into	the	depression	of	3-fold	axis	of	the	virion	(39).	
However,	 a	 successive	 study,	 attained	 much	 higher	 resolution,	 more	 powerful	
computational	 resources	 and	 a	 greater	 number	 of	 particles,	 failed	 to	 confirm	 the	 earlier	
observation,	 but	 neither	 specific	 complexes	 nor	 specific	 interaction	 of	 B19V	 with	
reconstituted	plasma	membrane	could	be	detected.	It	is	thought	that	globoside	alone	does	
not	interact	directly	with	B19V,	but	rather	it	may	function	in	complex	with	other	molecules	
(40).	
	
The	interaction	of	B19V	with	globoside	receptor	was	investigated	in	more	detail.		
Results	 showed	 that	 the	 binding	 of	 B19V	 to	 the	 cellular	 receptor	 globoside	 induced	
conformational	changes	in	the	capsid	leading	to	the	accessibility	of	the	N-terminal	region	of	
VP1	(VP1u)	to	antibodies.	However,	 the	question	remains	whether	VP1u	 is	not	accessible	
because	it	is	buried	within	the	capsid	or	because	it	is	already	external	but	not	accessible	to	
antibodies	due	to	a	particular	inaccessible	conformation.	
VP1u	 exposure	 did	 not	 facilitate	 the	 externalization	 of	 the	 viral	 genome	 in	 response	 to	
increasing	 temperatures,	 but	 on	 the	 contrary,	 receptor-bound	 capsids	 were	 remarkably	
more	 resistant	 than	 native	 or	 detached	 capsids.	 It	 is	 proposed	 that	 B19V	 capsids	 would	
become	 more	 resistant	 when	 needed	 but	 then	 become	 flexible	 again	 upon	 receptor	
dissociation	 and	 endosomal	 escape	 to	 facilitate	 uncoating.	 These	 receptor-induced	
conformational	 changes	 are	 necessary	 for	 subsequent	 virus	 internalization:	 VP2-only	
capsids,	 lacking	 VP1u,	 were	 unable	 to	 be	 internalized	 and	 virus	 internalization	 was	
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hampered	when	 an	 antibody	 recognizing	 an	 epitope	 in	 the	N-terminal	 part	 of	 VP1u	was	
added	 during	 binding.	 However,	 only	 a	 small	 proportion	 of	 cell-bound	 viruses	 were	
internalized,	while	the	majority	became	detached	from	the	receptor,	probably	because	the	
interaction	of	B19V	with	 isolated	globoside	 is	highly	unstable	due	 to	 the	 lack	of	 required	
stabilizing	 coreceptors.	 When	 added	 to	 uninfected	 cells,	 the	 receptor-detached	 virus	
showed	superior	cell	binding	capacity	and	infectivity	than	native	virus.	The	model	proposed	
is	 a	 complex	 internalization	 mechanism:	 B19V	 binds	 to	 globoside	 and	 this	 interaction	
triggers	 conformational	 changes	 that	 lead	 the	 exposure	 of	 N-terminal	 part	 of	 VP1u	 that	
could	now	interact	with	the	coreceptors.	When	this	is	not	possible,	the	virus	detaches	from	
cell	 surface	 and	 the	 scheme	 is	 repeated	 until	 the	 second	 interaction	 is	 possible	 with	
subsequent	internalization.	The	mechanism	of	detachement-reattachment	would	enhance	
the	 probability	 of	 productive	 infection	 by	 minimizing	 the	 consequences	 of	 abortive	
attachments	(41).	
Recent	 studies	 focused	more	 on	 the	 role	 of	 VP1u	 in	 the	 early	 phases	 of	 B19V	 infection,	
using	 recombinant	 full-length	 or	 truncated	 versions	 of	 VP1u.	 The	 first	 evidence	was	 that	
while	native	virus	and	virus-like	particles	of	VP	proteins	(VLPs)	were	internalized	in	UT7/Epo	
cells,	 no	 detectable	 signal	was	 observed	 in	 cells	 incubated	with	 VP2-only	 particles.	 Since	
VP1u	is	the	only	region	lacking	in	VP2-only	capsids,	this	result	suggested	that	the	presence	
of	VP1u	 as	 a	 component	 of	 the	 capsid	 is	 required	 for	 internalization.	 Recombinant	VP1u	
alone	 is	 internalized	efficiently	 in	UT7/Epo	 cells,	 similar	 to	native	B19V,	while	N-terminal	
truncations	 totally	 abolished	 the	 internalization.	 The	 presence	 of	 an	 antibody	 directed	
against	 the	N-terminal	 part	 of	VP1	 inhibited	 internalization	of	 both	N-ter-VP1u	 construct	
and	 native	 virus,	 suggesting	 N-terminal	 part	 of	 VP1u	 is	 the	 region	 responsible	 for	 virus	
uptake	(42).		
Further	studies	using	site-directed	mutagenesis	confirmed	that	VP1-N-ter	region	represents	
the	receptor-binding	domain	required	for	B19V	uptake	and	identified	a	cluster	of	important	
amino	acids	playing	a	critical	role.	The	tertiary	structure	prediction	of	the	receptor-binding	
domain	 and	 experimental	 data	 showed	 a	 tertiary	 assembly	 of	 three	 α-helices	 and	 a	
conserved	 hydrophobic	 pocket,	 which	 might	 represent	 the	 receptor	 binding	 site	 (43).	
Overall,	this	finding	may	propose	a	multi-steps	mechanism	of	virus	uptake:	the	binding	of	
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B19V	 to	 the	 globoside	 receptor	 may	 lead	 to	 conformational	 changes	 that	 allow	 the	
exposure	 of	 a	 critical	 domain	 in	 the	VP1u	 region,	which	 could	 interact	with	 coreceptors,	
stabilizing	the	interaction	and	favouring	the	viral	uptake.	
	
The	early	steps	of	B19V	infection	were	deeply	 investigated	 in	UT7/Epo	cells.	B19V	and	its	
receptor	 globoside	 were	 found	 to	 associate	 with	 lipid	 rafts,	 predominantly	 of	 the	
noncaveolar	type.	Pharmacological	disruption	of	the	lipid	rafts	inhibited	infection	when	the	
drug	was	added	prior	to	virus	attachment	but	not	after	virus	uptake,	indicating	that	plasma	
membrane	rafts	are	important	for	the	infectious	entry/trafficking	of	B19V	and	not	for	later	
steps.	 The	 virus	 is	 internalized	 by	 clathrin-dependent	 endocytosis	 and	 spreads	 rapidly	
throughout	 the	endocytic	pathway,	 reaching	 the	 lysosomal	 compartment	within	minutes,	
where	 a	 substantial	 proportion	 is	 degraded.	 B19V	 did	 not	 permeabilize	 the	 endocytic	
vesicles,	 indicating	 a	 mechanism	 of	 endosomal	 escape	 without	 apparent	 membrane	
damage.	 Bafilomycin	 A1	 and	NH4Cl,	which	 raise	 endosomal	 pH,	 blocked	 the	 infection	 by	
preventing	 endosomal	 escape,	 resulting	 in	 a	 massive	 accumulation	 of	 capsids	 in	 the	
lysosomes.	 In	 contrast,	 in	 the	 presence	 of	 chloroquine,	 the	 transfer	 of	 incoming	 viruses	
from	late	endosomes	to	lysosomes	was	prevented,	the	viral	DNA	was	not	degraded	and	the	
infection	 was	 boosted.	 B19V	 would	 require	 acidification	 to	 facilitate	 the	 process	 of	
endosomal	 escape,	 probably	 with	 the	 involvement	 of	 the	 phospholipase	 activity	 of	 VP1.	
Viral	capsids	and	viral	DNA	were	not	detected	inside	the	nucleus	because	of	an	inefficient	
import.	However,	in	chloroquine-treated	cells,	B19V	DNA	was	efficiently	imported	into	the	
nucleus	 and	 it	was	not	 associated	with	 capsids,	which	 remained	extranuclear.	Moreover,	
since	 the	 number	 of	 intact	 capsids	 decreased	 significantly	while	 the	 viral	 DNA	 remained	
stable	in	the	nucleus,	it	is	plausible	that	uncoating	takes	place	prior	to	the	DNA	import	into	
the	nucleus	(44).		
How	 B19V	 escapes	 from	 endosomes	 and	 the	 pathway	 involved	 in	 the	 nuclear	 import	 of	
viral	DNA	need	to	be	elucidated.	
	
3.2.	GENOME	REPLICATION	
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Once	 the	 viral	 genome	 is	 exposed	 within	 the	 nucleus,	 replication	 of	 viral	 genome	 and	
transcription	of	messengers	 require	cellular	machinery.	Conversion	of	 the	ssDNA	genome	
into	a	dsDNA	is	the	first	step	and	a	possible	determinant	of	infection	restriction.	A	hairpin-
primed	 model	 of	 DNA	 replication	 is	 proposed	 (Figure	 4).	 ITRs	 present	 at	 each	 end	 of	
genome	 contain	 complementary	 sequence	 allowing	 the	 formation	 of	 double-stranded	
terminal	 hairpin	 structures	 that	 function	 as	 priming	 sites	 for	 cellular	 DNA	 polymerase	 to	
synthesize	the	complementary	strand	on	the	parental	genome.	Transcription	of	the	dsDNA	
is	necessary	 for	production	of	viral	proteins	essential	 for	genome	replication.	NS	protein,	
with	 endonuclease	 and	 helicase	 activity,	 binds	 the	 replication	 origin	 (Ori),	 nicks	 the	 so-
called	 terminal	 resolution	 site	 to	 form	a	novel	 3’-OH	 for	 starting	DNA	 synthesis.	 ITRs	 are	
than	repaired	and	a	duplex	replication	 intermediate	 is	formed.	The	helicase	activity	of	NS	
protein	is	required	for	strand	displacement	leading	reinitiation	of	the	process.	The	rolling-
hairpin	dependent	replication	proceeds	with	cycle	of	nicking	and	release	of	ssDNA	that	 is	
finally	packaged	into	the	capsid	(45,	46).	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	6:	Rolling-hairpin	model	for	B9V	replication	(46).		
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Replicative	 intermediates	 of	 B19V	 have	 not	 been	 thoroughly	 characterized.	 ssDNA,	
monomeric	dsDNA	and	dimeric	dsDNA	forms	were	detected	in	permissive	cells	(47,	48).	
By	using	the	293	cell	transfection	system,	a	B19V	DNA	replication	origin	has	been	identified	
(45).	The	minimum	origin	of	B19V	DNA	replication	is	only	67	nucleotides	(nucleotide	5214	
to	5280),	and	covers	a	NS-terminal	resolution	site	and	four	repeated	NS-binding	elements	
(NSBEs).	B19V-NS	specifically	binds	to	the	NSBE1-NSBE2	region	in	an	in	vitro	binding	assay,	
while	NSBE3	and	NSBE4	may	provide	binding	sites	for	potential	cellular	factors	(49),	which	
should	assemble	a	nucleoprotein	complex	involving	cellular	factors	to	separate	the	dsDNA	
and	enable	NS	protein	to	nick	the	top	strand	at	the	terminal	resolution	site.		
	
3.3.	GENOME	EXPRESSION		
The	double-stranded	intermediate	is	a	transcriptional	active	template.	A	unique	functional	
promoter,	 p6,	 directs	 transcription	 from	 the	 left	 to	 the	 right	 of	 the	 genome	 (50,	 51).	 A	
fragment	 upstream	 of	 the	 promoter	 containing	 two	 GC-box	 motifs	 was	 identified.	
Mutations	of	this	GC-box	reduce	in	vitro	transcription	from	the	p6	promoter,	suggesting	the	
GC-box	motif	is	a	controlling	sequence	for	in	vitro	transcription	(52).	Strong	activity	of	the	
p6	promoter	was	measured	even	in	non-permissive	cell	lines	(53).	To	determine	promoter	
activity	and	to	characterize	regulatory	elements,	sequences	spanning	the	total	p6	promoter	
and	subfragments	of	them	were	 introduced	 into	a	eukaryotic	expression	vector	upstream	
of	 the	 luciferase	 gene.	 Several	 cis-acting	 elements	were	 identified	 for	 the	 transactivating	
activity	of	NS	proteins	and	for	recognition	of	transcription	factors	(54).	
P6	 promoter	 controls	 the	 synthesis	 of	 at	 least	 nine	 transcripts.	 The	 set	 of	 mature	
transcripts	originates	by	a	combination	of	co-	and	post-	 transcriptional	events	due	to	 the	
presence	of	 two	splicing	donor	sites	 (D1	and	D2),	each	followed	by	two	alternative	splice	
acceptor	 sites	 (A1-1/2	 and	 A2-1/2),	 and	 of	 two	 transcriptional	 termination	 sites	 in	 the	
middle	and	at	the	right	of	the	genome	(pAp	and	pAd)	(55).	All	viral	mRNAs	share	a	common	
sequence	 of	 60	 nucleotides	 at	 their	 5’-end,	 then,	 one	 class	 of	 mRNA	 is	 not	 spliced	 and	
terminates	 in	 the	middle	 of	 the	 genome,	 containing	 the	 ORF	 coding	 for	 the	 NS	 protein,	
while	all	other	classes	undergo	single	or	double	splicing,	terminating	either	in	the	middle	or	
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at	 the	 right	 end	of	 the	 genome,	 containing	ORF	 coding	 for	 viral	 capsid	 proteins	 or	 other	
small	proteins	(56).	
Precise	mapping	of	splicing	junctions	and	cleavage-polyadenylation	sites	was	first	obtained	
by	cloning	and	sequencing	of	cDNA	libraries	obtained	from	infected	erythroid	cells	(57).	All	
the	spliced	B19V	mRNA	transcripts	contain	the	60	nt	long	5’	leader	sequence	spliced	from	
the	D1	splice	site	to	the	central	exon,	which	spans	the	A1-1/A1-2	to	D2	splice	site.	Further	
splicing	at	the	D2	donor	site	is	a	central	step	in	the	control	of	B19V	pre-mRNA	processing,	
depending	on	the	balanced	recognition	of	cis-elements	at	A1-1/A1-2	or	D2	splice	sites	(58).	
A	 second	 key	 factor	 in	 the	 mapping	 of	 viral	 mRNAs	 is	 the	 frequency	 of	 cleavage-
polyadenylation	events	at	the	centre	or	right	end	sites	present	in	the	genome.	Cleavage	at	
pAp1	will	generate	the	most	abundant	classes	of	viral	mRNAs,	cleavage	at	pAp2	will	occur	
at	 tenfold	 lower	 frequency	 and	 generate	 alternative	 mRNAs	 potentially	 including	 an	
additional	 small	 ORF	 for	 a	 9	 kDa	 protein,	 while	 read-through	 will	 generate	 mRNAs	
extending	 into	 the	 capsid	 coding	 region	and	 coding	 for	VP1	protein.	 Competitive	 splicing	
from	D2	to	A2-1	or	A2-2	sites	will	regulate	the	production	of	mRNAs	coding	for	VP2	or	11	
kDa	proteins,	respectively.	All	of	these	events	appear	to	be	coordinated	and	in	relation	to	
the	replicative	process	involving	the	DNA	template	(59-61).	
A	first	model	of	B19V	genome	expression	was	obtained	in	infected	UT7/Epo-S1	cells.	RNA	
transcription	appeared	as	an	early	event	following	infection,	with	viral	RNA	detected	about	
6	hours	after	infection	(hpi)	and	with	an	earlier	appearance	of	non	structural	protein	RNA	
(6	hpi)	compared	to	capsid	protein	RNA	(24	hpi).	Viral	replication,	in	contrast,	did	not	start	
before	16	hpi,	suggesting	an	‘early	and	late	model’	of	gene	expression	(62).	
A	more	precise	reevaluation	of	the	expression	profile	of	B19V	genome	by	using	quantitative	
Real	 Time-PCR	 array	 proposed	 to	 considering	 B19V	 genome	 as	 a	 single	 replicative	 and	
transcriptional	 unit,	 characterized	 by	 two-state	 expression	 profile,	 either	 silent	 and	 non-
replicating	 or	 transcriptionally	 active	 and	 replicating.	 Viral	 RNA	was	 detected	 at	 6	 hpi	 in	
permissive	 cells,	 its	 increase	preceded	 that	 of	 viral	DNA	and	utilization	of	 the	processing	
signals	is	relatively	constant	throughout	the	viral	infection	cycle	(63,	64).	Overall,	such	data	
indicate	 that	 the	 genome	 of	 B19V	 can	 be	 considered	 as	 a	 single	 functional	 unit,	 whose	
expression	 profile	 can	 be	 clearly	 differentiated	 depending	 on	 the	 degree	 of	 intracellular	
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restriction.	In	non-permissive	cellular	environments,	the	viral	genome	can	be	present	but	is	
silent,	 while	 in	 permissive	 cellular	 environments,	 the	 genome	 is	 active	 and	 both	 full	
transcription	and	replication	of	the	viral	genome	occur,	resulting	in	a	productive	replicative	
cycle.	 The	 generation	 of	 a	 full	 complement	 of	 viral	 mRNAs	 appears	 to	 occur	 and	 be	
maintained	 before	 the	 onset	 of	 template	 replication,	 thus	 contrasting	 the	 previous	
distinction	between	early	and	late	events	(14).	
	
3.4.	PROTEOME	
The	proteome	potentially	encoded	by	B19V	appears	to	be	limited	(56,	65-68).	A	total	of	six	
ORFs	are	present	on	the	genome.	In	the	left	half	of	the	genome,	unspliced	mRNAs	contain	a	
major	ORF	in	frame	1,	coding	for	NS	protein.	In	the	right	half	of	the	genome,	single-spliced	
mRNAs	 contain	 a	 major	 ORF	 in	 frame	 2	 encoding	 for	 VP1,	 and	 double-spliced	 mRNAs	
contain	 a	 portion	of	 the	 same	ORF	 encoding	 for	VP2.	As	 both	 capsid	 proteins	 are	 coded	
from	the	same	ORF	in	frame	2,	the	two	structural	proteins	differ	only	for	the	so-called	VP1	
unique	region	(VP1u).	Two	ORFs	in	frame	3	are	present	in	the	middle	and	right	end	of	the	
genome	and	have	 the	potential	 to	 code	 for	a	9	 kDa	and	11	kDa	proteins,	 respectively.	A	
small	 additional	 ORF,	 positioned	 in	 frame	 2	 ahead	 of	 the	 ORF	 for	 VP	 proteins,	 has	 the	
potential	to	code	for	7.5	kDa	protein.	However,	the	RNA	complement	is	only	indicative	of	
the	 potential	 viral	 proteome.	 A	 deep	 analysis	 for	 characterization	 of	 the	 whole	 viral	
proteome,	 definition	 of	 post	 translational	modifications	 of	 viral	 proteins,	 investigation	 of	
the	dynamics	and	 interactions	of	viral	proteins	produced	 in	 infected	cells,	and	the	role	of	
the	minor	proteins,	is	still	lacking.	
	
3.4.1	NS	protein	
The	NS	protein	(74	kDa)	is	composed	of	671	aa.	It	is	produced	early	in	infected	cells	and	it	
possesses	a	DNA-binding	domain,	endonuclease,	helicase	and	transactivating	activities.	It	is	
essential	for	viral	replication	promoting	terminal	resolution	and	strand	unwinding	on	DNA	
replicative	 intermediates,	necessary	 for	priming	of	strand	displacement	synthesis	 (45).	NS	
protein	transactivates	its	own	promoter	promoting	viral	replication	and	transcription	(69),	
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but	it	is	able	to	transactivate	other	promoters	in	heterologous	system,	such	as	IL-6	and	TNF-
α	promoters	in	NS-transduced	K562	and	U937	cells,	respectively	(70,71).		
All	their	activities	may	explain	its	cytoxicicity	(72)	that	was	abolished	when	the	nucleoside	
triphosphate-binding	motif	was	mutated	 (73).	 NS	 protein	 expression	 in	 erythroid	 lineage	
cells	induces	DNA	fragmentation	and	apoptosis,	activating	a	caspase-3	dependent	pathway.	
Caspase	3,	6,	and	8	 inhibitors	 repressed	B19V-	and	NS-	 induced	apoptosis.	Since	Fas-FasL	
interaction	seemed	not	involved,	the	cells	were	sensitized	to	TNF-α-induced	apoptosis	(74).	
Sensitivity	to	TNF-α	was	not	due	to	upregulation	of	TNF-receptor	or	TNF-α	expression,	thus	
NS	 protein	 might	 modulate	 TNF-receptor	 signaling	 by	 direct	 interaction	 with	 certain	
components	of	the	signaling	pathway	downstream	of	TNF-receptor	(75).	
	
3.4.2.	VP	proteins	
Two	capsid	proteins	 form	the	capsid	shell,	VP1	of	781	aa	(86	kDa)	and	VP2	of	554	aa	(61	
kDa).	 The	 two	 proteins	 are	 identical	 except	 for	 a	 sequence	 of	 227	 aa	 present	 at	 the	 N-
terminus	of	the	VP1	protein,	which	constitutes	the	VP1u	region	with	phospholipase	activity	
(76).	Both	proteins	accumulated	through	the	course	of	infection	and	are	transported	to	the	
nucleus	 where	 virion	 assembly	 may	 occur.	 The	 relative	 abundance	 of	 the	 two	 proteins	
depends	 in	 part	 on	 the	 relative	 abundance	 of	 their	 mRNAs	 and	 in	 part	 on	 different	
efficiencies	of	translation.	A	non	consensus	basic	motif	in	the	C-terminal	region	of	VP1/VP2	
mediates	transport	of	capsid	proteins	to	the	nucleus,	where	capsid	assembly	and	genome	
packaging	may	occur	(77).		
VP	proteins	 can	be	 express	 in	mammalian	 and	 insected	 cells.	 The	baculovirus	 expression	
system	is	the	most	diffuse	method	for	heterologous	expression	of	VP	proteins.	While	VP2	
protein	alone	can	self-assemble	without	viral	DNA	to	form	virus-like	particles	(VLP)	that	are	
similar	to	native	virions,	VP1	protein	alone	does	not	(78-81).	
VP2	protein	was	shown	to	interact	directly	with	B19V	receptor,	an	event	that	favours	the	
exposure	of	VP1u	 region.	The	main	neutralizing	epitopes	of	B19V	are	 in	 the	VP1u	 region	
and	 the	 phospholipase	 A2	 (PLA2)	 activity	 is	 required	 for	 viral	 infectivity.	 Mutations	 of	
critical	amino	acids	strongly	reduce	both	PLA2	activity	and,	proportionally,	viral	infectivity,	
but	cell	surface	attachment,	entry,	and	endocytosis	are	not	affected.	PLA2	activity	could	be	
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critical	 for	 efficient	 transfer	 of	 the	 viral	 genome	 from	 late	 endosomes/lysosomes	 to	 the	
nucleus	to	initiate	replication	(76,	82).	
	
3.4.3.	Small	proteins	
The	B19V	genome	encodes	for	at	 least	three	small	proteins.	Two	of	these	are	 in	frame	3,	
the	9	kDa	and	11	kDa	proteins,	and	one	in	frame	2,	the	7.5	kDa	protein.	The	11	kDa	protein	
is	the	best	characterized.	It	translated	from	the	small,	double	spliced	mRNA	cleaved	at	the	
pAd	 site.	 It	 is	 a	 proline-rich	 protein	 presenting	 SH3	 binding	 sites	 and	with	 cytoplasmatic	
localization.	 It	 is	 essential	 in	 maintaining	 infectivity,	 probably	 involved	 in	 post-
transcriptional	events	necessary	to	have	a	correct	balance	of	capsid	proteins	and	in	altering	
the	 cellular	 environment	 to	 promote	 viral	 replication	 and	 maturation.	 Interaction	 with	
some	 cellular	 factors,	 such	 as	 receptors-binding	 protein	 2,	 has	 been	 demonstrated	 (83).	
11kDa	protein	induced	apoptosis	in	infected	primary	erythroid	progenitor	cells,	by	caspase-
10	pathway	 (84).	7.5	 kDa	protein	expression	was	discovered	by	 in	 vitro	mutagenesis	 and	
was	also	observed	in	COS-7	cells	transfected	with	a	plasmid	containing	the	B19V	genome	as	
well	as	in	human	peripheral	mononucleocytes	infected	with	B19V,	by	immunoprecipitation	
of	cell	 lysates	with	polyclonal	antibodies	raised	against	a	synthetic	peptide	corresponding	
to	a	portion	of	the	predicted	protein	sequence.	(68).	It	was	not	associated	to	any	function	
right	now.	
The	expression	of	the	predicted	9	kDa	protein	has	not	been	actually	traced	in	infected	cell,	
thus	the	exact	function	of	its	corresponding	small	mRNAs	is	not	elucidated.	
	
3.5.	LATE	EVENTS	
The	 last	 phases	 of	 B19V	 life	 cycle	 are	 poorly	 characterized.	 After	 translation	 in	 the	
cytoplasm,	 viral	 proteins	 are	 transported	back	 to	 the	nucleus	where	 the	assembly	of	 the	
virions	 into	 large	 inclusion	 bodies	 occurs.	 New	 progenies	 escape	 from	 infected	 cells	
presumably	after	cell	 lysis,	as	supported	by	 the	pronounced	cytopathic	effect	seen	 in	 the	
bone	marrow	cells.		
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4.	TROPISM	
	
4.1.	CELLULAR	RECEPTORS	
B19V	infection	is	restricted	by	the	narrow	tropism	of	the	virus.	In	vivo,	the	main	target	cells	
are	 erythroid	 progenitor	 cells	 from	 bone	 marrow	 (85).	 B19V	 was	 first	 propagated	 in	
suspension	 cultures	 of	 human	 erythroid	 bone	 marrow,	 stimulated	 with	 erythropoietin,	
from	patients	with	B19V	infection	(47,	48).	Virus	inoculation	in	vitro	reduced	the	number	of	
erythroid	 cells	 and	 alters	 the	 morphology,	 as	 demonstrated	 by	 the	 presence	 of	
characteristic	giant	erythrocells.		
B19V	purified	from	viremic	sera	inhibited	bone	marrow-derived	erythroid	cells	in	a	colony	
formation	 assay	 and	 the	 virus	 was	 detectable	 in	 infected	 EPCs.	 The	 susceptibility	 of	
hematopoietic	stem	cells	to	B19V	was	assessed	by	the	 inhibition	of	colony	formation	and	
the	target	cells	were	identified	in	the	limited	lineage	from	BFU-E	to	erythroblasts	(86).	
Erythroid	progenitors	cells	susceptible	to	B19V	can	be	obtained	also	from	peripheral	blood,	
foetal	 liver	and	umbilical	cord	blood	(87-89).	Anyway,	due	to	 its	strictly	tropism,	only	few	
cell	lines	support	B19V	infection,	including	erythroid	leukemic	cell	lines,	KU812Ep6	and	JK-
11,	and	human	megakaryocytic	cell	lines,	UT7/Epo	and	UT7/Epo-S1	(90,	91).	UT7/Epo-S1	is	
the	most	sensitive	and	widely	used	cell	 line	 for	 in	vitro	studies,	although	 it	shows	 limited	
ability	to	support	viral	infection	and	low	viral	yield.		
The	 lacking	 of	 adaptation	 to	 growth	 in	 vitro	 cell	 cultures	 have	 impaired	 a	 thorough	
understanding	of	viral	life	cycle	and	limiting	the	source	of	virus	to	sera	of	viremic	patients.	
Recently,	 new	 advances	 in	 developing	 erythroid	 culture	 systems	 starting	 from	peripheral	
blood	 hematopoietic	 stem	 cells	 provided	 a	 more	 suitable	 model	 system	 to	 study	 B19V	
replicative	cycle	in	primary	target	cells	(91,	92).		
The	cellular	factors	influencing	B19V	permissiveness	are	not	yet	identified	and	are	a	major	
filed	of	interest	to	understand	the	pathogenic	potential	of	B19V.		
Many	 factors	 contribute	 to	 the	 strictly	 tropism	of	B19V.	 The	 first	 determinant	of	 cellular	
sensitivity	 is	 the	expression	of	globoside.	However,	globoside	 is	expressed	on	several	 cell	
type,	not	only	of	 the	erythroid	 lineage,	 such	as	megagaryocytes	 and	 in	 some	endothelial	
cells,	and	these	cells	are	not	permissive	to	B19V	infection.	Thus,	the	presence	of	globoside	
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by	itself	is	not	sufficient	to	explain	the	narrow	tropism	and	the	role	of	coreceptors	in	virus	
entry	need	further	investigation	(94).		
As	described,	the	VP1u	domain	plays	a	critical	role	in	the	viral	uptake	by	direct	interaction	
with	cellular	surface.	Recently,	this	property	of	VP1u	region	was	exploited	to	develop	a	cell	
specific	targeting	system.	B19V-VP1u	was	conjugated	to	NeutrAvidin	as	a	loading	platform	
for	 biotinylated	 cargo.	 Using	 a	 biotinylated	 fluorescent	 dye	 as	 a	 reporter	 molecule,	 the	
VP1u−NeutrAvidin	appeared	as	a	unique	marker	for	intermediate	erythroid	differentiation	
stages,	around	the	proerythroblastic/early	basophilic	stage,	and	specifically	detected	early	
erythroid	 precursors	 or	 erythroleukemic	 cells	 in	 heterogeneous	 cell	 populations	 from	
different	 tissues.	 Thus,	 this	 system	 could	 represent	 a	 reliable	marker	 for	 targeting	 B19V	
susceptible	 cells	 and	 the	 possibility	 of	 a	 yet	 unknown	 cellular	 receptor	 exclusively	
expressed	during	the	intermediate	erythroid	differentiation	could	be	intriguing	(95).	
Since	B19V	DNA	can	also	be	detected	 in	additional	cell	 types,	such	as	endothelial	cells	of	
the	myocardium,	 alternative	mechanism	 of	 infection	 are	 supposed.	 B19V	 bound	 primary	
endothelial	cells	at	a	similar	level	as	that	of	UT7/Epo-S1	cells,	but	internalization	of	the	virus	
was	 strongly	 reduced.	 This	 deficiency	 in	 internalization	 was	 significantly	 enhanced	 by	
preincubation	 of	 the	 virus	 with	 anti	 B19V-antibodies.	 Antibody-dependent	 enhancement	
(ADE)	 was	 mediated	 by	 the	 direct	 interaction	 of	 B19V-antibodies	 complex	 with	 the	
complement	 factor	 C1q	 and	 its	 receptor	 CD93	 on	 the	 cell	 surface.	 This	 alternative	
mechanism	of	virus	uptake	could	play	a	role	in	the	pathogenicity	of	cardiac	B19V	infection	
(96).	
	
4.2.	ERYTHROPOIETIN	DEPENDENCE	
Another	 key	 factor	 shared	 by	 all	 the	 megakaryocyte-erythroid	 lineage	 cells	 productively	
infected	by	B19V	 is	 the	need	of	erythropoietin	 (Epo)	 for	growth	 (47,	90).	 Epo	 is	not	only	
necessary	 for	 cell	 growth	 but	 also	 to	 activate	 the	 signal	 cascade	 downstream	 of	 Epo	
receptor	 (EpoR)	 that	 achieves	 a	 productive	 viral	 replication.	 EPCs	 culture	 in	 fact	 did	 not	
support	 B19V	 replication	 in	 the	 absence	 of	 Epo,	 although	 virus	 entered	 the	 cells.	 The	
EpoR/Janus	 kinase	 2	 (Jak2)	 pathway	 played	 a	 direct	 role	 in	 supporting	 replication	 of	 the	
B19V	genome,	 involving	 the	signal	 transducer	and	activator	of	 transcription	5A	 (STAT5A),	
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mitogen-activated	 protein	 kinase	 (ERK/MAPK)	 kinase	 (MEK)	 and	 phosphatidylinositol-3	
kinase	(PI3K)	(97).	
	
4.3.	HYPOXIA	
Hypoxia	 also	 promotes	 viral	 replication.	 EPCs	 cultured	 in	 hypoxic	 condition	 showed	 a	
significantly	increase	of	B19V	expression	and	replication	compared	to	EPCs	cultured	under	
normoxia.	 The	 low	 oxygen	 tension	 levels	 measured	 in	 bone	 marrow	 and	 during	 foetal	
development	 could	 contribute	 to	 B19V	 replication	 in	 sensitive	 cells	 in	 vivo	 (98).	 Hypoxia	
promoted	 replication	 of	 B19V	 genome	within	 the	 nucleus,	 regulating	 Epo/EpoR	 receptor	
signaling	 trough	 a	 STAT5A	 and	 MEK/ERK	 signaling,	 rather	 than	 the	 canonical	 PHD/HIFa	
pathway.	 The	 simultaneous	 up-regulation	 of	 STAT5A	 signaling	 and	 down-regulation	 of	
MEK/ERK	signaling	boosted	the	 level	of	B19V	 infection	 in	EPCs	under	normoxia	 to	 that	 in	
cells	 under	 hypoxia.	 The	 MEK/ERK	 pathway	 is	 therefore	 a	 negative	 regulator	 of	 B19V	
infection	in	EPCs.	The	B19V	small	11	kDa	protein	has	been	shown	to	interact	with	Grb2,	a	
crucial	 adaptor	 for	 the	 activation	 of	 MEK/ERK	 signaling,	 which	 is	 activated	 by	
phosphorylation	of	EpoR.	These	findings	may	lead	to	suppose	that	11	kDa	protein	interacts	
with	Grb2	 to	 inhibit	MEK/ERK	 signaling,	 thereby	 facilitating	 B19V	DNA	 replication	 during	
infection	(99).	
	
4.4.	MACROMOLECULAR	SYNTHESIS	
Conversion	 of	 the	 incoming	 parental	 ssDNA	 into	 a	 dsDNA	 is	 the	 first	 step	 in	 the	
macromolecular	 synthesis	 and	 a	 possible	Achilles’	 heel	 for	 a	 productive	 replicative	 cycle.	
Non-permissive	 cells	 may	 be	 not	 able	 to	 support	 the	 synthesis	 of	 the	 complementary	
strand,	although	they	can	be	susceptible	to	viral	entry.	For	example,	HepG2	hepatocellular	
carcinoma	 cells	 cannot	 support	 B19	 virus	 replication,	 although	 viral	 DNA	 was	 detected	
within	cells,	but	neither	genome	replication	nor	transcription	and	protein	expression	were	
measured	(100).	
Cell	permissiveness	could	depend	also	on	the	ability	to	express	the	full	set	of	viral	mRNA,	
either	at	transcriptional	and	translation	level.	In	permissive	cells,	mRNAs	splicing	of	mRNAs	
at	the	second	intron	lead	to	generation	of	sufficient	amounts	of	VP2	transcript,	permitting	
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virus	 assembly.	 A	 blockage	 in	 the	 production	 of	 full-length	 transcripts	 at	 the	 internal	
polyadenilation	site	is	associated	with	the	limited	permissiveness	to	B19V	infection	because	
of	the	relative	absence	of	VP	proteins	(101).	Replication	of	the	viral	genome	on	the	contrary	
promotes	read-through	of	pAp	and	the	polyadenilation	of	transcripts	at	the	distal	site	pAd,	
leading	 to	 generation	 of	 full-length	 transcripts	 that	 encode	 for	 essential	 proteins	 (61).	
Moreover,	the	expression	profile	shifted	preferentially	on	the	left	half	of	the	genome	lead	
to	a	mainly	production	of	NS	and	7.5	kDa	proteins,	and	a	consequent	abortive	infection	and	
cell	death	due	to	its	cytotoxic	and	apoptosis-inducing	properties.		
	
4.5.	CELL	CYCLE	ARREST	
B19V	induces	cell	cycle	arrest	and	apoptosis	(102).	In	infected	UT7/Epo-S1	cells,	more	than	
60%	 of	 the	 cells	 showed	 the	 4N	 karyotype	 at	 48	 hpi,	 indicating	 an	 accumulation	 of	 the	
G2/M-phase	cell	population.	The	cell	cycle	progression	is	critically	regulated	by	sequential	
activation	of	cyclin-dependent	kinases	(cdks).	Cyclins	A	and	B	are	involved	in	regulation	of	
the	S	and	G2/M	phases	of	the	cell	cycle.	Expression	of	cyclin	A	becomes	detectable	near	the	
G1/S	transition	and	peaks	in	the	S	phase,	and	interacts	with	both	cdk2	and	cdc2	to	ensure	
completion	of	DNA	replication	before	entering	into	mitosis.	Cyclin	B	is	synthesized	through	
the	S	and	G2	phases	and	associates	with	cdc2	 to	become	an	 inactive	complex,	called	 the	
pre-mitosis-promoting	factor	(MPF).	Translocation	of	active	MPF	containing	cyclin	B1	from	
the	 cytoplasm	 into	 the	 nucleus	 is	 indispensable	 for	 cell	 cycle	 entry	 into	 the	M	phase.	 In	
B19V-infected	 UT7/Epo-S1	 cells,	 cyclin	 B1	 accumulated	 in	 the	 cytoplasm	 but	 not	 in	 the	
nucleus	at	24	hpi	without	an	up-regulation	of	 its	mRNA.	These	observations	 suggest	 that	
MPF	 is	 activated	 in	 the	 cytoplasm	 of	 B19V-infected	 cells,	 but	 cannot	 translocate	 to	 the	
nucleus,	thus	resulting	 in	suppression	of	cell	cycle	transition	from	G2	phase	 into	M	phase	
(103).	
In	the	presence	of	a	mitotic	inhibitor,	B19V	infection	induced	not	only	G2	arrest	but	also	G1	
arrest.	UV-irradiated	B19V,	 inactivating	the	expression	of	NS,	still	harboured	the	ability	to	
induce	G2	arrest	but	not	G1	arrest.	Furthermore,	treatment	with	caffeine,	a	G2	checkpoint	
inhibitor,	 abrogated	 the	 B19V-induced	 G2	 arrest	 despite	 expression	 of	 NS.	 These	 results	
suggested	 that	 the	 B19V-induced	 G2	 arrest	 is	 not	 mediated	 by	 NS	 expression	 (104).	
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Furthermore,	 NS	 expression	 significantly	 increased	 p21/WAF1	 expression,	 a	 cyclin-
dependent	kinase	inhibitor	that	induces	G1	arrest.	Thus,	G1	arrest	mediated	by	NS	may	be	
a	prerequisite	for	the	apoptotic	damage	of	erythroid	progenitor	cells	upon	B19V	infection	
(105).		
Primary	 EPCs,	 B19V	 infected	 or	 NS	 transduced,	 displayed	 G2	 arrest	 mediated	 by	 NS-
dependent	 enhancement	 of	 nuclear	 import	 of	 E2F4/E2F5	 as	 well	 as	 repression	 of	
E2F4/E2F5	target	genes	and	deregulation	of	a	variety	of	transcription	factors	important	for	
cell	cycle	control	and	differentiation.	NS-dependent	E2F4	and	E2F5	nuclear	translocation	is	
likely	an	early	event	and	 initiate	G2	arrest,	allowing	B19V	 to	deregulate	host	cell	 cycle	 in	
order	 to	 create	 a	 favourable	 environment	 for	 its	 replication.	 Infected	 EPCs	 showed	 also	
time-dependent	 increase	 of	 E2F7,	 E2F8,	 p53,	 and	 p21	 as	 well	 as	 the	 activation	 of	 p53,	
known	 to	 be	 induced	 in	 response	 to	 DNA	 damage.	 Thus,	 the	 proposed	 model	 is	 that	
interaction	 of	 NS	 with	 E2F4	 or	 E2F5	 induces	 exclusive	 redistribution	 of	 these	 repressive	
E2Fs	 to	 nucleus,	 leading	 to	 stable	 G2	 arrest	 and	 eventually	 impairing	 erythroid	
differentiation	 by	 downregulation	 of	 E2F	 target	 genes.	 Subsequently,	 activation	 of	 G2-
related	 transcription	 factors	 and/or	DNA	 repair	 proteins	 enhances	 viral	 transcription	 and	
DNA	 replication.	 As	 B19V	 infection	 progresses,	 viral	 replication	 activates	 p53	 signal	
transduction	and	upregulates	E2F7	and	E2F8	in	the	context	of	the	DNA	damage	response,	
blocking	 cell	 cycle	 progression.	 In	 this	 way,	 virus	 production	 would	 be	 maximized	 while	
simultaneously	abrogating	the	cell	differentiation	machinery	(106).	
A	more	careful	examination	of	B19V	infected	EPCs	using	5-bromo-2’-deoxyuri-	dine	(BrdU)	
pulse-labeling	and	DAPI	staining,	which	precisely	establishes	the	cell	cycle	pattern	based	on	
both	cellular	DNA	replication	and	nuclear	DNA	content,	was	performed.	Although	both	NS	
protein	 transduction	 and	 infection	 immediately	 arrested	 cells	 at	 a	 status	 of	 4N	 DNA	
content,	 B19V-infected	 4N	 cells	 still	 incorporated	 BrdU,	 indicating	 active	 DNA	 synthesis.	
Moreover,	 several	 S	 phase	 regulators	were	 abundantly	 expressed	 and	 colocalized	within	
the	 B19V	 replication	 centers.	 Taken	 together,	 the	 results	 confirmed	 that	 B19V	 infection	
triggers	 late	 S	 phase	 arrest,	 which	 presumably	 provides	 cellular	 S	 phase	 factors	 for	 viral	
DNA	 replication.	 It	 is	 possible	 that	 B19V-DNA	 replication	 induced	DNA	 damage	 response	
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that	cause	cell	arrest	at	S	phase,	while	NS	alone	arrests	cells	at	a	status	G2/M	and	that	the	
compromising	of	these	two	arrest	blocks	the	infected	cells	at	late	S	phase	(107).		
	
4.6.	DNA	DAMAGE	RESPONSE	
Several	 studies	 have	 shown	 that	 parvovirus	 infection	 induces	 a	 DNA	 damage	 response	
(DDR)	 that	 plays	 an	 important	 role	 in	 viral	 DNA	 replication.	 DDR	 is	 triggered	 by	 damage	
DNA	 structures,	 such	 as	 ssDNA	 breaks,	 dsDNA	 breaks	 and	 stalled	 replication	 forks.	 In	
particular,	B19V	infection	induced	a	broad	range	of	DDRs	by	triggering	phosphorylation	of	
all	 the	 upstream	 kinases	 of	 each	 of	 three	 repair	 pathways:	 ATM	 (ataxia-telangiectasi	
mutated),	 ATR	 (ATM	 and	 Rad3	 related),	 and	 DNA-PKcs	 (DNA-dependent	 protein	 kinase	
catalytic	 subunit).	 Inhibition	 of	 kinase	 phosphorylation,	 through	 treatment	 with	 either	
kinase-specific	inhibitors	or	kinase-specific	shRNAs,	revealed	that	only	signaling	via	the	ATR-
Chk1	pathway	is	critical	to	B19V	replication,	while	DNA-PK	signaling	contributed	to	a	lesser	
extent	 and	 ATM	 signaling	 was	 not	 influent.	 The	 replication	 of	 B19V	 DNA	 following	 the	
rolling-hairpin	 model	 involves	 steps	 that	 could	 activate	 a	 DDR,	 such	 as	 formation	 of	
replication	origin	complex,	nicking	at	the	terminal	resolution	site	or	unwinding.	It	is	possible	
that	ATR	recognizes	the	nicked	site	within	the	terminal	sequence	of	the	genome	and	that	
the	 ssDNA	 binding	 protein	 RPA32	 is	 recruited	 to	 the	 displaced	 ssDNA,	 which	 mimics	 a	
stalled	 replication	 fork.	 However,	 knockdown	 of	 ATM,	 ATR	 and	 DNA-PKcs	 did	 not	 affect	
B19V	 infection-induced	 G2/M	 arrest,	 suggesting	 that	 B19V	 infection	 causes	 G2/M	 arrest	
through	a	DDR-independent	cell	cycle	checkpoint	(108).	
Preventing	replication	of	the	B19V	dsDNA	genome	by	mutating	the	endonuclease	domain	
or	 helicase-A	 motif	 within	 NS	 protein,	 which	 prohibits	 the	 DDR,	 did	 not	 reduce	 the	
percentage	 of	 cells	 arrested	 at	 G2/M.	 Therefore,	 B19V	 utilizes	 the	mechanism	 of	 a	 DDR	
only	to	promote	viral	DNA	replication,	and	the	NS-induced	G2/M	arrest	 is	dispensable	for	
viral	DNA	replication	(109).	
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5.	PATHOGENESIS	
	
5.1.	EXPERIMENTAL	INFECTION	
The	kinetics	of	B19V	 infection	has	been	studied	 in	two	set	of	experiments	 involving	adult	
healthy	volunteers	(110).	Subjects	inoculated	with	108	virus	particles	showed	viremia	after	
6	 days	 reaching	 a	 peak	 of	 1011	 virus	 particles/ml	 after	 8-9	 days.	 Viral	 DNA	was	 found	 in	
throat	 swabs	 during	 viremia	 but	 not	 in	 urine	 or	 faeces.	 Viremia	 disappeared	 with	 the	
activation	of	 immune	response.	On	days	6-8,	 the	 first	phase	of	 illness	occurred	with	viral	
infection-related	symptoms	such	as	headache,	myalgia,	chills	and	pyrex,	typically	correlated	
to	cytokine	release,	even	if	production	of	α-interferon	was	not	detected.	This	first	episode	
of	 illness	coincided	with	viremia	and	the	detection	of	circulating	IgM	(Figure	7).	The	bone	
marrow	examination	 showed	an	 almost	 complete	 loss	 of	 erythroid	precursors	 at	 day	 10,	
and	the	number	of	BFU-E	and	CFU-E	in	peripheral	blood	was	decreased.	A	second	phase	of	
clinical	 illness	 could	be	 recognized	on	days	15-17,	when	 IgM	 levels	were	highest	 and	 IgG	
production	started,	with	symptoms	typical	of	B19V	infection,	such	as	maculopapular	rash,	
arthralgia	and	in	some	cases	arthritis.	The	illness	was	short-lived,	with	the	rash	fading	after	
2/3	days,	while	the	joint	symptoms	persisted.	In	this	period,	viremia	was	absent.	
	
Figure	7:	Clinical	course	following	B19V	infection	(126).	
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5.2.	CLINICAL	MANIFESTATIONS	
B19V	 is	 spread	 by	 respiratory	 route.	 The	 mechanisms	 of	 virus	 transmission	 from	 the	
oropharyngeal	 mucosa	 to	 the	 target	 cells	 are	 unknown:	 a	 first	 cycle	 of	 virus	 replication	
could	occur	in	tonsils	and	the	lymphoid	vessels	could	be	involved	in	spreading	infection,	or	
the	virus	can	gain	access	to	vessels	by	transcytosis	through	respiratory	epithelia.	
When	 the	 virus	 reaches	 the	 bone	marrow,	 it	 can	 infect	 erythroid	 progenitors	 cells.	 The	
cytopathic	 effect	 on	 infected	 cells	 is	 manifested	 as	 giant	 pronormoblasts	 with	 large	
eosinophilic	 nuclear	 inclusion	 bodies	 and	 cytoplasmatic	 vacuolization	 (Figure	 8).	 The	
consequently	block	of	erythropoiesis	derives	from	the	capability	of	the	virus	to	induce	cell-
cycle	arrest,	to	inhibit	the	formation	of	bone	marrow	derived	erythroid	colonies	at	the	BFU-
E	and	CFU-E	stages,	and	eventually	to	cause	apoptosis	of	infected	cells.	However,	the	block	
in	erythropoiesis	 is	temporary	because	the	more	undifferentiated	precursors	are	resistant	
to	B19V	and	infection	can	be	resolved	with	a	neutralizing	immune	response.	The	productive	
infection	 in	 the	 bone	 marrow	 allows	 virus	 release	 in	 the	 blood,	 starting	 a	 secondary	
viremia,	that	can	reach	high	levels	(1012	virus/ml),	and	leading	the	systemic	distribution	of	
the	virus	(14).	
	
	
Figure	8:	Giant	pronormoblast	with	typical	‘dog-ear’	projections	(126).	
	
In	normal	subjects,	production	of	neutralizing	antibodies	contributes	to	the	rapid	clearance	
of	 infection,	usually	within	3-4	months	 (111,	112).	The	decrease	of	haemoglobin	 levels	 is	
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only	 transient	 and	 the	 destruction	 of	 reticulocytes	 has	 minimal	 clinical	 effect,	 as	
erythrocytes	 have	 long	 life	 spans.	 Approximately	 25%	 of	 infected	 individuals	 will	 be	
completely	asymptomatic	during	their	infection,	while	50%	will	have	only	non-specific	flu-
like	 symptoms	 of	 malaise,	 muscle	 pain,	 and	 fever.	 The	 two	 classical	 late	 clinical	
manifestations	 in	 immunocompetent	hosts	 are	erythema	 infectiosum,	 typical	of	 children,	
and	arthropathies,	typical	of	adults.		
	
5.2.1.	ERYTHEMA	INFECTIOSUM	
The	first	association	of	B19V	with	erythema	infectiosum	is	dated	1983,	when	the	discovery	
of	specific	B19V-IgM	in	the	serum	of	involved	patients	confirmed	the	etiology	of	the	disease	
(113).	 Erythema	 infectiosum,	also	 known	as	 fifth	disease,	 appears	 approximately	18	days	
after	infection	and	is	characterized	by	slapped	cheek	rash	and	relative	circumoral	pallor.	A	
second	 stage	 eruption,	 with	 erythematous	 maculopapular	 exanthema	 on	 the	 trunk	 and	
limbs,	 often	 appears	 1	 to	 4	 days	 later.	 Prodromal	 symptoms	 often	 may	 include	 fever,	
coryza,	 headache,	 and	 nausea.	 The	 rash	 is	 characterized	 by	 pink	 maculae	 that	 usually	
undergo	a	 central	 fading.	 It	may	be	 transient	or	 recurrent	and	variations	of	 intensity	 can	
depend	on	environmental	factors,	such	as	light	exposure	and	heat.		
	
	
Figure	9:	Erythema	infectiosum	with	rash	and	slapped	cheeks.	
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5.2.2.	ARTHROPATIES	
Arthralgia	and	arthritis	are	the	most	common	manifestations	in	adults.	The	first	evidences	
of	 the	 link	 between	 arthropaties	 and	 B19V	 are	 dated	 back	 to	 1985	 (114).	 In	 children,	
arthritis	can	accompany	erythema	infectiosum	at	 low	frequencies	(10%	or	 less),	while	the	
incidence	 in	adults	 is	approximately	60%	 in	 females	and	30%	 in	males.	Typical	 symptoms	
are	 acute	 peripheral	 polyarthritis,	 usually	 symmetric,	 affecting	mainly	 the	 small	 joints	 of	
hands,	feet	and	keens	(115,	116).	Joint	symptoms	usually	resolve	in	three	weeks,	although	
in	 some	 cases,	 arthropathy	 may	 become	 chronic	 and	 about	 one	 half	 of	 patients	 whose	
sympotms	 become	 chronic	 meet	 the	 criteria	 of	 American	 Rheumatoid	 Association	 for	 a	
diagnosis	of	rheumatoid	arthritis	(117).		
The	 involvement	 of	 B19V	 in	 the	 development	 of	 rheumatic	 diseases	 is	 subject	 of	
continuous	 investigations.	Since	 the	occurrence	of	arthralgia	coincides	with	 the	detection	
of	circulating	IgM	and	IgG	direct	against	the	viral	capsid	proteins,	it	is	possible	that	immune	
complexes	deposited	in	the	synovial	fluid	are	involved	in	the	pathogenesis	of	B19V-related	
arthropaties.		
A	 variety	 of	 autoimmune	disease,	 rather	 than	 arthopaties,	 has	 been	 associated	 to	 B19V,	
such	as	systemic	lupus	erytematosus,	Kawasaki	disease,	vasculitis	and	others.	Some	clinical	
features	of	both	acute	and	chronic	B19	infection	are	very	similar	to	those	of	autoimmune	
diseases,	 leading	 the	 researchers	 to	 investigate	 the	 role	 of	 autoimmunity	 in	 the	
pathogenesis	 of	 B19V	 (118).	 The	 production	 of	 autoantibodies	 against	 proteinase	 3	 and	
myeloperoxidase	 and	 the	 detection	 of	 antinuclear	 antibodies	 have	 been	 reported	 in	 the	
course	of	B19V	infection.	
The	 production	 of	 antiphospholipid	 antibodies	 in	 patients	 with	 rheumatic	 disease	 was	
associated	with	persistent	B19V	infection.	This	link	is	supported	not	only	by	the	presence	of	
autoantibodies	but	also	by	the	similarity	in	the	clinical	symptoms	present	in	B19V-infected	
patients	 and	 in	 subjects	 with	 the	 antiphospholipid	 syndrome.	 A	 possible	 mechanism	
involved	in	the	production	of	this	kind	of	antibodies	may	be	the	phospholipase	A2	activity	
of	VP1u	region.	The	enzymatic	activity	of	VP1u	can	 induce	the	production	of	 leukotrienes	
and	prostaglandins,	which	contribute	to	the	inflammatory	process,	and	of	unusual	cleavage	
products	 from	 cellular	 phospholipid	 factors	 that	 may	 activate	 the	 antiphospholipid	
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antibodies	 response.	 This	 is	 a	 possible	 explanation	 for	 the	 formation	 of	 autoantibodies	
together	with	the	classic	molecular	mimicry	mechanism.	It	has	been	shown	in	fact	that	VP1-
specific	IgG	react	specifically	with	human	keratin,	collagen	type	II,	single-stranded	DNA	and	
cardiolipin	(119).	
The	 NS	 protein	 may	 be	 involved	 too	 in	 the	 autoimmune	 phenomena.	 It	 has	 a	
transactivating	 domain	 that	 can	 work	 on	 the	 viral	 p6	 promoter	 as	 well	 as	 on	 cellular	
promoters,	 like	 those	 controlling	 the	 expression	 of	 TNF-α	 and	 IL-6.	 The	 costant	 stimulus	
derived	from	these	proinflammatory	cytokines	during	persistent	B19	infection	may	result	in	
the	induction	of	autoimmune	reactions	(120).	
B19V	DNA	may	be	found	in	inflamed	joints	and	in	synovial	membranes	(122).	However,	its	
presence	 is	 not	 a	 sufficient	 marker	 since	 it	 was	 found	 also	 in	 control	 samples	 without	
chronic	arthritis.	The	mechanism	by	which	the	virus	can	persist	in	the	synovial	membrane	is	
unknown:	 synovial	 membrane	 cells	 are	 not	 permissive	 to	 B19V,	 although	 globoside	 is	
expressed	 on	 the	 human	 synovium	 (123).	 However,	 it	 was	 demonstrated	 that	 normal	
human	 synovial	 fibroblast	 treated	 in	 vitro	 with	 B19V	 positive	 serum	 show	 an	 invasive	
phenotype	that	means	an	increased	ability	to	degrade	reconstituted	cartilage	matrix	(124).	
	
In	subjects	with	alterations	in	the	erythropoiesis	process	or	defects	in	the	immune	system,	
infection	becomes	manifest	as	pure	red-cell	aplasia	and	anemia.	
	
5.2.3.	TRANSIENT	APLASTIC	CRISIS	
In	 patients	 with	 haematological	 disorders	 with	 improved	 red	 cell	 turnover,	 including	
increased	red	blood	cells	destruction	(sickle	cell	disease,	hereditary	spherocytosis,	chronic	
autoimmune	 anemia)	 or	 decreased	 red	 blood	 cells	 production	 (iron	 deficiency	 anemia,	
thalassemia),	B19V	infection	can	lead	to	the	classical	aplastic	crisis	(125).	The	arrest	of	the	
production	of	erythrocytes	and	the	reduced	lifespan	of	red	cells	 lead	to	a	marked	drop	in	
haemoglobin.	 Usually,	 aplastic	 crisis	 presents	 with	 anaemia,	 weakness,	 dyspnoea,	 and	
confusion,	rarely	with	congestive	heart	failure	and	in	the	most	severe	cases	bone	marrow	
necrosis.	 In	 some	 cases,	 concurrent	 thrombocytopenia,	 neutropenia	 or	 pancytopenia	 is	
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found.	 The	 aplastic	 crisis	 is	 typically	 self-limited	 as	 the	 activation	 of	 a	 specific	 immune	
response	clears	the	infection	and	red	cell	production	returns	to	baseline.	(126)	
	
5.2.4.	PURE	RED	CELL	APLASIA	
In	immunocompromised	patients,	where	the	immune	system	fails	to	clear	B19V	infection,	
anaemia	can	become	chronic	and	persistent	or	recurrent	viremia	can	be	detected.	This	can	
lead	to	hypoplasia	or	aplasia	of	the	erythroid	cells	and	precursors,	reduction	of	peripheral	
reticulocytes	 and	 a	 severe	 acute	 or	 chronic	 anaemia,	which	 can	 be	 life-threatening.	 This	
condition	 includes	 situations	 of	 congenital	 or	 acquired	 immunodeficiencies,	 such	 as	 HIV-
infection,	 of	malignancies,	 such	 as	 acute	 lymphatic	 leukaemia,	 acute	 or	 chronic	myeloid	
leukaemia,	 of	 bone	 marrow	 or	 solid	 organ	 transplantation,	 and	 of	 chemotherapy	
treatment.	 In	 immunocompromised	 patients	 B19V	 infection	 generally	 does	 not	manifest	
with	the	classic	rash	or	joint	symptoms,	may	be	due	to	the	inadequate	immune	response,	
but	clinical	hallmarks	are	fatigue	and	pallor	(127-131).	
	
5.2.5.	MATERNAL	INFECTION	
In	 case	 of	maternal	 infection,	 B19V	 can	 cross	 the	 placental	 barrier	 and	 infect	 the	 fetus,	
leading	 to	 asymptomatic	 infection	 or	 adverse	 outcomes,	 such	 as	 fetal	 anemia,	 hydrops	
fetalis	or	 fetal	death	 (132).	The	 risk	of	 fetal	 infection	and	 tissue	damage	 is	greater	 in	 the	
second	 trimester.	 This	 can	 be	 linked	 to	 the	 expression	 of	 globoside	 on	 the	 placental	
trophoblast	that	is	higher	in	the	first	and	second	trimester	but	decrease	with	gestional	age	
(133,	 134).	 The	 change	 in	 the	 expression	 level	 of	 globoside	 can	 therefore	 reflect	 the	
frequency	 of	 intrauterine	 infection.	Moreover,	 the	 site	 of	 erythrocyte	 production	 during	
early	development	is	the	fetal	liver	and,	because	of	the	boosted	demand	from	the	growing	
fetus,	there	is	an	increase	in	red	blood	cell	mass	and	a	reduction	of	red	cell	life	span.	These	
factors	make	the	fetus	particularly	vulnerable	at	deficiencies	in	the	erythropoiesis	process.	
Trophoblasts	are	not	permissive	to	the	virus	but	they	may	promote	its	transcytosis	to	the	
fetal	 circulation	 (135).	 When	 the	 virus	 is	 in	 fetal	 circulation,	 it	 can	 infect	 erythroid	
progenitor	 cells.	 The	 consequent	 block	 of	 fetal	 erythropoiesis	 and	 red	 cell	 precursors	
destruction	 may	 lead	 to	 severe	 anemia,	 fetal	 death	 and	 non-immune	 hydrops	 fetalis.	
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Hydrops	 fetalis	 is	 caused	by	 functional	 failure	of	 the	 liver	and	 is	 characterized	by	anemia	
(hemoglobin	 levels	 of	 2	 g/dL	 or	 lower),	 hypoalbuminemia,	 peripheral	 oedema	 and	
congestive	heart	 failure	that	can	be	 lethal	 (136).	Cardiac	 failure	can	also	be	associated	to	
fetal	myocarditis	as	a	consequence	of	direct	infection	of	fetal	cardiomyocytes	(137,	138).	
The	outcome	of	fetal	infection	is	influenced	by	several	factors.	First,	the	immune	status	of	
the	mother	is	crucial	since	the	presence	of	specific	IgG	is	protective	for	the	fetus.	A	second	
aspect	 is	 the	gestational	age:	as	described	above,	 the	 rate	of	 intrauterine	 transmission	 is	
higher	 in	 the	 first	 two	 trimesters.	 The	 consequences	 for	 the	 fetus	 also	 depend	 on	 its	
development	stage.	The	risk	of	fetal	 loss	 is	higher	when	infections	occurring	in	the	earlier	
stages,	when	the	rate	of	hematopoiesis	 increases	and	the	fetus	is	more	vulnerable	to	low	
hematocrit	due	 to	high	 tissue	oxygen	demand.	Furthermore,	hydrops	 is	most	common	 in	
the	central	part	of	pregnancy,	while	the	incidence	of	B19V-related	fetal	loss	is	lower	in	the	
third	 trimester	 (139).	 Finally,	 congenital	 infections	 have	 been	 occasionally	 associated	 to	
neonatal	anemia	or	abnormalities,	but	the	number	of	case	reports	is	too	low	to	support	a	
link	between	B19V	infection	during	pregnancy	and	fetal	malformations	(140).	
	
The	 spectrum	 of	 clinical	 manifestations	 associated	 to	 B19V	 infection	 is	 in	 constant	
expansion.	
	
5.2.6.	CARDIOMYOPATHIES	
In	the	recent	years,	a	major	concern	aspect	is	the	cardiac	tropism	of	B19V.	
The	presence	of	B19V	has	been	revealed	in	endomyocardial	tissue	and	in	the	nuclei	of	fetal	
myocytes	(141).	Its	association	with	myocarditis	was	proposed	in	both	children	and	adults	
(142-144).	Infection	of	myocardial	endothelial	cells	activates	inflammatory	responses	in	the	
cardiac	tissue	that,	together	with	endothelial	dysfunction,	 induces	cardiac	cell	 injury.	At	a	
second	 level,	 the	 specific	 cellular	 immune	 response	 is	 able	 to	 recognize	 and	 destruct	
infected	 cells.	 Moreover,	 the	 immunological	 cross-reaction	 to	 epitopes	 shared	 between	
viral	antigens	and	myocardial	cellular	antigens	may	promote	an	autoimmune	response	that	
enhances	the	inflammatory	process.	(145)	
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A	 recent	 in	 vitro	 study	 suggests	 that	 the	 phospholipase	 activity	 of	 B19V-VP1	 can	 cause	
inflammatory	cardiomyopathy	and	endothelial	cell	dysfunction	through	downregulation	of	
Na+/K+	 ATPase.	 This	 induce	 a	 wide	 range	 of	 cellular	 effects,	 such	 as	 loss	 of	 ionic	
equilibrium,	 hyperpolarization	 or	 depolarization	 of	 cell	 membrane,	 effects	 on	 the	
expression	 of	 different	 genes,	 that	 promote	 cell	 death,	 shrinkage	 or	 swelling	 (146).	 The	
molecular	 mechanisms	 responsible	 for	 the	 reactivation	 of	 latent	 B19V	 infection,	 the	
influence	 of	 immune	 response	 in	 chronic	 myocarditis,	 and	 immune-independent	 viral	
pathogenesis	in	non-inflamed	hearts	need	more	investigations	to	be	clarified.		
However,	 considering	 the	 rare	 occurrence	 of	 myocarditis	 in	 respect	 of	 the	 widespread	
circulation	 of	 B19V,	 it	 is	 possible	 that	 the	 virus	 is	 only	mildly	 cardiotropic	 or	 that	 other	
unknown	factors	are	needed	in	order	to	manifest	clinical	disease.	
	
5.2.7.	OTHER	ASSOCIATIONS	
The	presence	of	B19V	was	detected	in	cases	of	encephalopathy,	meningitis	and	neurologic	
amyotrophy,	 but	 they	 are	 very	 few	 cases	 and	 the	 mechanism	 for	 the	 neurological	
symptoms	 is	 unknown.	 Elevated	 levels	 of	 liver	 transaminases	 are	 common	 during	 B19V	
infection	and	the	virus	was	associated	to	fulminant	hepatitis.	Other	associations	have	been	
reported	with	necrotinzing	vasculitis,	Kawasaki’s	disease	and	a	variety	of	complications,	but	
all	these	associations	need	more	investigation	to	be	supported	(126).	
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6.	EPIDEMIOLOGY	
B19V	 infection	 occurs	 wordwide.	 Data	 accumulated	 in	 the	 years	 report	 values	 differing	
widely	 in	 dependence	 of	 the	 sensitivity	 of	 the	 methodologies	 used,	 the	 epidemiological	
context,	the	tissue	type	and	the	geographic	area.	
The	seroprevalence	increases	with	age	from	2%	to	10%	in	children	under	5	years	old,	to	40-
60%	in	adults	and	up	to	85%	in	the	elderly	population.	During	outbreaks,	the	rates	increase	
at	70%	in	children	aged	5	to	15	years	and	20%	in	subjects	older	than	15	years.	
The	peak	 incidence	of	 infection	 shows	 seasonal	 variation,	occurring	mainly	 in	 late	winter	
and	early	summer	with	epidemic	peaks	every	3	to	4	years.	(14)	
	
Transmission	of	B19V	occurs	mainly	 via	 the	 respiratory	 route.	Although	B19V	 infection	 is	
not	 primarily	 associated	with	 respiratory	 symptoms,	 viral	 DNA	 is	 detected	 in	 respiratory	
secretions	during	viremia.		
The	 virus	 can	 be	 transmitted	 transplacentally	 to	 the	 fetus.	 Approximately	 30%-40%	 of	
pregnant	women	lack	measurable	B19V-specific	IgG	and	are	therefore	susceptible	to	B19V	
infection.	 However,	 the	 incidence	 of	 primary	 infection	 during	 pregnancy	 has	 been	
estimated	 at	 1%	 to	 5%,	 and	 subsequent	 transplacental	 transmission	 is	 25%-50%,	but	 the	
risk	of	fetal	loss	is	estimated	to	be	quite	low,	lower	than	10%	(14,	147,	148).	
	
The	 presence	 of	 B19V	 in	 blood	 during	 the	 viremic	 phase	 of	 infection	 poses	 a	 risk	 of	
iatrogenic	transmission	of	the	virus	via	blood	and	blood	components,	 in	particular	packed	
red	 cells	 from	 blood	 collected	 during	 the	 short	 pre-seroconversion	 viremic	 phase.	 B19V	
viremia	 frequency	 in	 blood	 products	 ranged	 between	 1.3%	 and	 0.006%	 according	 to	 the	
sensitivity	of	molecular	assays	used	and	seasonal	epidemiologic	circumstances	(149,	150).	
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7.	IMMUNITY	RESPONSE	
	
7.1.	INNATE	IMMUNITY	
The	role	of	 innate	immunity	during	B19V	infection	has	not	been	investigated	in	detail	but	
most	studies	have	focused	on	the	adaptive	immune	response.	
Like	other	viruses,	B19V-PAMPs	may	be	recognized	by	cellular	PRRs,	the	viral	components	
acting	 as	 PAMPs	 are	 still	 unknown.	 B19V	 has	 been	 associated	 with	 various	 Toll-like	
receptors	 (TLRs),	 such	as	TLR-4,	 -5,	 -7	and	 -9	 (151).	A	work	 investigated	 the	 role	of	CpG-
ODN	 2006	 in	 the	 inhibition	 of	 erythroid	 progenitor	 cells	 showed	 that	 this	 TLR-9	 ligand	
affects	 hematopoiesis	 by	 a	 selective	 inhibition	 of	 growth	 and	 development	 of	 human	
erythroid	 progenitor	 cells.	 It	 probably	 acts	 as	 a	 siDNA	 for	 the	 erythropoietin	 receptor	
(EpoR),	 resulting	 in	 down-regulation	 of	 EpoR	 expression,	 inhibition	 of	 EpoR	 mRNA	
expression	and	decrease	of	Epo	binding	(154).	A	possible	same	mechanism	can	be	shared	
by	 B19V,	 whose	 genome	 has	 a	 ssDNA	 consensus	 sequence	 that	 could	 be	 potentially	
involved	in	the	inhibition	of	erythroid	progenitor	cells.		
A	recent	study	investigated	the	effect	of	B19V	on	the	expression	of	defensins	and	TLRs.	The	
authors	 reported	 a	 significantly	 increased	 expression	 of	 defensins	 and	 TLR-9	 on	 COS-7	
epithelial	cells	after	transfection	with	a	vector	expressing	NS	protein,	but	to	a	 less	extent	
after	transfection	with	a	vector	expressing	VP2	protein.	Moreover,	they	also	suggested	that	
the	cytotoxicity	of	viral	NS	protein	might	play	a	crucial	role	 in	eliciting	TLRs	and	defensins	
expression	since	no	significant	variations	were	observed	 in	COS-7	cells	 transfected	with	a	
vector	expressing	 the	mutant	 form	of	NS	protein	without	 the	cytotoxicity.	These	 findings	
provide	a	clue	in	understanding	the	role	of	innate	immunity	in	B19V	infection	(151).	
	
7.2.	SPECIFIC	IMMUNITY	
7.2.1	Humoral	response	
Specific	 IgM	 and	 IgG	 antibodies	 are	 produced	 in	 naturally	 and	 experimentally	 infected	
individuals	 and	 are	 supposed	 to	 be	 able	 to	 progressively	 clear	 the	 infection.	 IgM	 are	
produced	 first,	 10-12	 days	 post	 infection,	 and	 usually	 persist	 for	 3-6	 months.	 IgG	 are	
detectable	 two	weeks	 after	 infection	 and	 are	 assumed	 to	 be	 long-lasting	 and	 protective	
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against	 secondary	 infections.	 IgA	 can	 also	 be	 detected	 and	 probably	 plays	 a	 role	 in	
protection	against	infection	by	the	natural	nasopharyngeal	route.		
Several	neutralizing	epitopes	have	been	mapped	in	the	VP1u	region	and	are	mainly	linear,	
while	epitopes	located	in	the	common	region	of	capsid	proteins	are	mainly	conformational.	
However,	linear	epitopes	in	the	VP1u	region	and	in	VP1-VP2	junction	regions	seem	to	elicit	
a	more	 efficient	 immune	 response	 than	 epitopes	 of	 VP2	 region	 (152-157).	 It	was	 shown	
that,	although	VP2	region	contains	neutralizing	domains,	empty	capsids	composed	only	of	
this	 protein	 are	 similarly	 antigenic	 but	 fail	 to	 induce	 high	 titer	 neutralizing	 antisera,	
compared	 to	 empty	 capsids	 composed	 of	 VP1-VP2	 that	 elicit	 a	 stronger	 neutralizing	
antibodies	 response.	This	evidence	could	be	 in	contrast	with	 the	presence	of	neutralizing	
epitopes	in	the	VP2	region	and,	anymore,	convalescent	phase	sera	from	patients	exposed	
to	B19V	show	activity	confined	to	the	common	region	of	VP2.	The	data	suggest	that	VP1	is	
important	to	enhance	the	antigenicity	of	neutralizing	regions,	promoting	the	mature	capsid	
conformation	(158-159).	
A	 work	 aimed	 to	 examine	 the	 specific	 immune	 response	 against	 B19V	 showed	 that	 the	
humoral	 response	 in	 recently	B19V	 infected	children	 is	dominated	by	antibodies	directed	
against	 conformational	 epitopes	 on	 VP1	 and	 VP2	 and	 against	 linear	 epitopes	 on	 VP1u	
region,	 while	 linear	 epitopes	 present	 on	 VP2	 are	 poorly	 immunogenic.	 In	 long-term	
convalescent	patients,	antibodies	against	conformational	epitopes	of	VP1	and	VP2	persist,	
while	immunoreactivity	against	linear	epitopes	on	VP1	is	lost.	This	probably	depends	on	the	
induction	 of	 B-cell	 memory	 that	 is	 maintained	 by	 the	 persistence	 of	 conformational	
antigens	on	specialized	follicular	dendritic	cells	(160).	
	
Humoral	immune	response	against	NS	poteins	is	poor	investigated.		
Three	antigenic	 regions	on	 the	B19V	NS	protein	were	 identified	 in	healthy	subjects	when	
using	 linear	 peptides	mapping	 the	NS	 sequence.	 The	 frequencies	 of	 reactivity	 against	NS	
proteins	were	 found	 similar	between	healthy	and	persistent	 infected	people,	except	 that	
the	 latter	 group	 showed	 a	 lower	 reactivity	 to	 the	 C-terminal	 end	 of	 VP1/VP2	 (161).	
However,	 in	 previous	 studies,	 aimed	 to	 investigate	 a	 possible	 different	 reactivity	 among	
patients	with	 acute	 or	 past	 B19V	 infection,	 it	 has	 been	 supposed	 that	NS-antibodies	 are	
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most	often	present	in	patients	with	chronic	infection,	especially	in	B19V-related	arthritis.	A	
possible	explanation	is	the	prolonged	antigenic	stimulation	in	persistence	infection.	Usually,	
during	 replication	 in	 erythroid	 progenitor	 cells,	 only	 few	 amounts	 of	 NS	 protein	 are	
produced,	maybe	insufficient	to	stimulate	antibodies	production;	that	 is	why	the	majority	
of	 sera	 from	 infected	 people	 are	 negative	 for	 NS-specific	 antibodies.	 In	 a	 persistence	
infection,	 on	 the	 contrary,	 non-permissive	 cells	 could	 be	 infected	 and	 NS	 protein	 is	
preferentially	expressed.	The	NS	cytotoxicity	causes	cell	death	and	release	of	large	amounts	
of	protein	that	may	induce	a	specific	immune	response.	NS	antibodies	are	not	likely	to	be	
protective,	 since	 the	 virus	 can	 persist	 in	 the	 serum	 despite	 the	 presence	 of	 NS-specific	
immunoglobulins	(162).	
	
7.2.2.	Cellular	response	
The	cellular	immune	response	is	harder	to	study.		
T-cell	reactivity	to	B19V	infection	was	first	shown	by	measuring	the	proliferation	responses	
of	PBMC	after	in	vitro	stimulation	by	recombinant	B19V	proteins.	The	results	indicated	that	
T	cells	of	subjects	with	preexisting	B19V	immunity	show	HLA	II-restricted	responses	against	
B19V	capsid	proteins	(163).		
T	 cell	 reactivity	 after	 stimulation	 with	 the	 VP1/2	 capsid	 antigen	 was	 than	 confirmed	 in	
patients	with	recent	or	remote	B19V	infection	and	not	only	in	patients	with	arthropathy,	as	
previous	 described.	 Even	 if	 the	 recently	 infected	 patients	 generally	 had	 stronger	 B19V	
reactivity	than	the	remotely	ones,	some	of	the	strongest	responders	are	remotely	infected	
patients	 that	 show	 specific	 responses	 comparable	 to	 the	 highest	 values	 seen	 among	 the	
recently	 infected	patients.	 Their	 strong	VP1/2-specific	 reactivity	 is	most	 readily	explained	
by	a	good	general	ability	to	maintain	T	cell	memory	to	recall	antigens.	Moreover,	HLA	class	
II-restricted	CD4+	cells	are	responsible	for	T-cell	reactivity,	as	depletion	of	CD4+	T-cells	from	
PBMC	abrogate	T-cell	 responses	as	well	as	the	blocking	by	HLA	class	 II-specific	antibodies	
(164).	
A	 first	 approach,	 using	 a	 peptide	 library	 designed	 to	 cover	 the	 entire	 NS	 sequence,	was	
used	 to	 identify	 B19V-epitopes	 for	 CD8+	 lymphocyte	 cells-mediated	 immunity.	 Following	
PBMC	 stimulation	 with	 peptides	 and	 by	 measuring	 the	 cytolitic	 activity	 of	 CD8+	 T-cells	
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against	 autologus	 B-cell	 lines,	 a	 single	 HLA-B35-restricted	 epitope	 was	 identified.	 It	 was	
strongly	 immunogenic	 in	 B19V-seropositive	 donors,	 able	 to	 stimulate	 CD8+	 T-lymphocyte	
cells	that	showed	rapid	expansion	in	vitro,	cytolysis	and	rapid	effector	function	ex	vivo.	The	
strong	 T-cell	 responses	 may	 result	 from	 a	 continuous	 or	 intermittent	 exposure	 to	 viral	
antigen,	which	may	be	endogenously	presented	or	easily	reexposed	due	to	the	high	levels	
of	virus	in	the	population	(165).	
A	 more	 extensive	 assessment	 of	 the	 specificity	 and	 kinetics	 of	 the	 acute	 CD8+	 T-cell	
responses	was	studied	with	210	peptides	synthesized	to	cover	the	sequence	of	NS	protein,	
VP1u	region	and	VP2	protein.	The	peptides	were	used	 to	 test	 in	vitro	cytotoxicity	and	ex	
vivo	stimulation	assays	and	to	estimate	HLA	restrictions.	Novel	CD8+	T-cell	epitopes	were	
identified,	 nine	 in	 the	 NS	 protein	 and	 one	 in	 the	 VP2	 protein,	 while	 no	 responses	 were	
observed	 to	 the	 VP1u	 region.	 Seropositive	 healthy	 patients	 with	 symptomatic	 B19V	
infection	 rapidly	 develop	 cellular	 immune	 responses	 with	 multiple	 specificities.	 The	
responses	 are	 maintained	 at	 high	 levels	 for	 months,	 sometimes	 more	 than	 two	 years,	
maybe	 as	 the	 result	 of	 continuous	 antigenic	 stimulation.	 At	 the	 opposite,	 subjects	 with	
B19V	persistence	showed	higher	reactivity	to	the	structural	proteins,	whereas	responses	to	
the	 NS	 protein	 were	 of	 lower	 magnitude.	 The	 immunological	 discrepancies	 between	
healthy	and	persistently	infected	individuals	may	reflect	both	failed	immunity	and	antigenic	
exhaustion	(166).	
The	 importance	of	CD8+	T-cells	was	confirmed	by	studying	the	number	and	phenotype	of	
B19V-specific	 CD8+	 T-cell	 responses,	 during	 and	 after	 adult	 infection,	 using	 HLA-peptide	
multimeric	complexes.	Results	 indicated	a	continued	 increase	 in	magnitude	of	CD8+	T-cell	
responses	 during	 acute	 B19V	 infection,	 sustained	 even	 at	 later	 time	 points,	 long	 after	
resolution	 of	 clinical	 symptoms	 and	 control	 of	 viremia.	 T-cells	 possessed	 strong	 effector	
function	and	 intact	proliferative	activity.	B19V-specific	 cytotoxic	T-lymphocytes	were	also	
detectable	in	healthy	individual	with	remote	infection,	tested	many	years	after	infection,	at	
low	 frequencies	 but	with	mature	 phenotype.	 Thus,	 data	 suggest	 that	 the	 acute	 infection	
induce	 persistent	 activated	 CD8+	 T-cell	 responses,	 possibly	 due	 to	 low-level	 antigen	
exposure	after	the	resolution	of	acute	viremia.	Since	the	most	active	CD8+	T-cell	responses	
were	seen	when	clinical	symptoms	had	resolved,	these	T	cell	responses	are	not	likely	to	be	
43	
	
directly	 volved	 in	 the	 acute	 phase,	 but	 they	 ultimately	may	 contribute	 to	 the	 long-term	
control	of	infection	and	viral	clearance	(167).	
	
The	 involvement	 of	 T-helper	 cells	 in	 the	 immune	 response	 to	 B19V	 infection	 was	 also	
investigated.	As	describe	previously,	first	evidence	was	the	strong	proliferation	of	CD4+	T-
cells,	when	stimulated	with	VP1/VP2	capsids,	of	both	recently	and	remotely	infected	adults	
(164).	 The	 role	 of	 T-helper	 cells	 was	 explored	 by	 using	 recombinant	 VLPs	 composed	 of	
VP1/VP2	proteins	or	VP2	protein	alone.	The	ability	of	VLPs	to	stimulate	PBMC	to	proliferate	
and	secrete	IF-γ	and	IL-10	was	determined	in	recently	and	remotely	infected	individuals.	In	
general,	B19V-specific	 IFN-γ	 responses	were	stronger	 than	 IL-10	 responses	 in	both	 recent	
and	 remote	 infection.	 VP1/VP2	 capsids	 and	 VP2	 capsids	 elicited	 similar	 T-helper	 cell	
proliferation	 and	 IL-10	 responses,	while	 the	 IFN-γ	 response	was	 higher	with	 VP2	 capsids	
than	with	VP1/VP2	capsids.	Thus,	epitopes	on	VP2	protein	are	important	to	elicit	T-helper	
cell	 responses	 for	 activation	 of	 B19V-specific	 B-cells	 in	 remotely	 infected	 subjects.	 On	
contrast,	 whereas	 VP1u-specific	 IFN-γ	 responses	 were	 very	 strong	 among	 the	 recently	
infected	 subjects,	 the	 VP1u-specific	 IFN-γ	 and	 IL-	 10	 responses	 were	 absent	 among	 the	
remotely	 infected	subjects.	This	finding	is	 in	contrast	with	the	documented	persistence	of	
VP1u-specific	IgG	during	late	convalescence	(168,	169).	
The	peptide	 library	approach	was	used	also	 to	 investigate	 the	magnitude	and	breadth	of	
the	 CD4+	 T-cell	 response	 to	 the	 capsid	 proteins	 in	 acutely	 infected	 individuals	 with	
arthropathy	 and	 in	 remotely	 infected	 individuals.	 Both	 groups	 maked	 broad	 CD4+	
responses,	 but	 whereas	 responses	 following	 acute	 infection	 were	 detectable	 ex	 vivo,	
responses	 in	 remotely	 infected	 individuals	 were	 detected	 only	 after	 culture.	 Several	 VP-
peptide	pools	were	identified	in	CD4+	T-cell	responses	of	acutely	infected	individuals,	while	
a	 single	 dominant	 epitope	 in	 the	 VP	 common	 region	 was	 evident	 in	 remotely	 infected	
people.	 Phenotypic	 analysis	 of	 B19V-specific	 CD4+	 cells	 suggests	 that	 they	 are	 mainly	
“central”	 memory,	 thus	 following	 a	 different	 evolution,	 after	 acute	 infection	 resolution,	
compared	to	CD8+	T-cells.	 Indeed,	CD8+	T-cell	responses	showed	an	 increase	 in	frequency	
and	 the	acquisition	of	 a	mature	phenotype,	 as	well	 as	maintaining	activation,	over	many	
months	after	acute	disease.	Overall,	the	exact	role	of	B19V-specific	CD4+	T-cells	upon	acute	
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infection	is	unknown.	Hypothetically,	B19V-specific	CD4+	T-cells	recognizing	persisting	B19	
or	 cross-reactive	 self-antigens	 could	 play	 a	 role	 in	 both	 viral	 elimination	 and	 the	
pathogenesis	 of	 autoimmune	 disease,	 while	 CD8+	 T-cell	 responses	 would	 limit	 viral	
replication	and,	in	turn,	reduce	CD4+	T-cell	activation	and	control	viral	persistence	(170).	
	
7.2.3.	Cytokine	Expression	
The	 proinflammatory	 and	 T	 helper	 Th1/Th2	 cytokine	 responses	 during	 acute	 B19V	were	
characterized.	 In	 addition	 to	 proinflammatory	 cytokines	 IL-1β,	 TNF-α,	 IL-6	 and	 IL-8,	
elevated	levels	of	the	Th1	type	of	cytokines	IL-2,	IL-12	and	IL-15	were	evident	at	time	of	the	
initial	 peak	 of	 B19V	 viral	 load	 in	 a	 few	 patients	 during	 acute	 infection.	 This	 pattern	was	
sustained	during	the	follow-up	period.	In	contrast,	cytokines	associated	with	a	Th2	type	of	
immune	 response,	 IL-4,	 IL-5	 and	 IL-10,	 as	 well	 IFN-γ	 response	 remained	 low	 during	 the	
observation	 time.	 Thus,	 the	 continuous	 viremia	 in	 the	 acutely	 infected	 patients	 may	 be	
associated	with	an	aberrant	 cytokine	profile	with	a	 selective	 IFN-γ	deficiency	despite	Th1	
cytokine	 induction.	 On	 the	 other	 hand,	 persistently	 infected	 patients	 did	 not	 exhibit	 an	
apparent	 imbalance	 of	 their	 cytokine	 pattern	 except	 for	 an	 elevated	 IFN-γ	 response,	 but	
this	cannot	explain	the	persistence	status	of	the	virus	(171).	
	
7.3.	AUTOIMMUNITY	
B19V	was	 associated	 to	 a	 variety	 of	 autoimmune	 diseases	 and	 the	 relationship	 between	
B19V	 and	 autoimmunity	 is	 constantly	 investigated.	 The	 production	 of	 autoantibodies	
against	proteinase	3	and	myeloperoxidase	and	the	detection	of	antinuclear	antibodies	have	
been	reported	in	the	course	of	B19V	infection.		
The	 production	 of	 antiphospholipid	 antibodies	 in	 patients	 with	 rheumatic	 disease	 was	
associated	with	persistent	B19V	infection.	This	link	is	supported	not	only	by	the	presence	of	
autoantibodies	but	also	by	the	similarity	in	the	clinical	symptoms	present	in	B19V	infected	
patients	 and	 in	 subjects	 with	 the	 antiphospholipid	 syndrome.	 A	 possible	 mechanism	
involved	in	the	production	of	this	kind	of	antibodies	may	be	the	phospholipase	A2	activity	
of	VP1u	region.	The	enzymatic	activity	of	VP1u	can	 induce	the	production	of	 leukotrienes	
and	prostaglandins,	which	contribute	to	the	inflammatory	process,	and	of	unusual	cleavage	
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products	 from	 cellular	 phospholipid	 factors	 that	 may	 activate	 the	 antiphospholipid	
antibodies	 response.	 This	 is	 a	 possible	 explanation	 for	 the	 formation	 of	 autoantibodies	
together	with	the	classic	molecular	mimicry	mechanism.	It	has	been	shown	in	fact	that	VP1-
specific	IgG	react	specifically	with	human	keratin,	collagen	type	II,	single-stranded	DNA	and	
cardiolipin	(119).	
The	 production	 of	 antiviral	 antibodies	 with	 autoantigen	 binding	 properties	 has	 been	
previously	 demonstrated	 in	 chronic	 parvovirus	 B19	 infection.	 IgG	 antibodies	 directed	
against	 VP	 proteins	 were	 purified	 from	 the	 sera	 of	 patients	 with	 persistent	 parvovirus	
infection,	using	a	synthetic	immunodominant	VP	peptide.	Such	anti-viral	peptide	antibodies	
reacted	 specifically	 with	 human	 keratin,	 collagen	 type	 II,	 single-stranded	 DNA,	 and	
cardiolipin.	 The	main	 reactivity	was	against	 keratin	and	 collagen	 type	 II,	 and	 there	was	a	
correlation	 between	 the	 clinical	 manifestations	 and	 the	 autoantigen	 specificity:	
immunoglobulins	 from	 patients	 with	 arthritis	 reacted	 preferentially	 with	 collagen	 II,	
whereas	 immunoglobulins	 from	 patients	 with	 skin	 rashes	 reacted	 preferentially	 with	
keratin.	When	mices	were	 immunized	with	 the	 viral	 peptide,	 antibodies	 able	 to	bind	 the	
viral	 peptide	 and	 to	 cross-react	 with	 different	 autoantigens,	 including	 keratin,	 collage	 II,	
ssDNA	and	cardiolipin,	were	detected	 in	those	that	developed	a	strong	antiviral	 response	
(172,	173).	
The	 NS	 protein	 may	 be	 involved	 too	 in	 the	 autoimmune	 phenomena.	 It	 has	 a	
transactivating	 domain	 that	 can	 work	 on	 the	 viral	 p6	 promoter	 as	 well	 as	 on	 cellular	
promoters,	 like	 those	 controlling	 the	 expression	 of	 TNF-α	 and	 IL-6.	 The	 costant	 stimulus	
derived	from	these	proinflammatory	cytokines	during	persistent	B19V	infection	may	result	
in	the	induction	of	autoimmune	reactions	(118,	120).	
NS	protein	 is	 known	 to	 induce	 apoptosis	 and	host	DNA	damage	 as	well	 as	 form	NS-DNA	
adducts	in	non-permissive	cells.	It	has	been	proposed	that	B19V	induction	of	autoimmunity	
may	occur	when	T	cells	specific	for	NS	protein	are	stimulated	during	a	reoccurrence	of	B19V	
infection	 or	 reactivation	 of	 NS	 expression.	 Specific	 Th	 cells	 would	 then	 provide	 second	
signal	 to	anergized	autoantigen	specific	B-lymphocytes.	Apoptotic	bodies	 (ApoBods)	were	
detected	 in	 HepG2	 cells,	 a	 non-permissive	 system	 to	 B19V	 infection,	 transduced	 with	
recombinant	baculovirus	to	express	NS	protein.	ApoBods	usually	contain	only	self-antigens	
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that	typically	do	not	cause	inflammatory	or	immune	responses,	but	impaired	clearance	of	
apoptotic	 cells	 has	 been	 proposed	 to	 cause	 autoimmunity	 by	 increasing	 the	 quantity	 of	
ApoBods	 and	 expanding	 the	 diversity	 of	 self-antigens	 presented	 to	 the	 immune	 system.	
Characterization	of	 the	purified	ApoBods	 formed	 in	 the	 trasnduced	HepG2	 cells	 revealed	
that	 they	contained	modified	host	 cell	DNA	as	well	 as	nucleosomal	 self-antigens,	 such	as	
Smith,	ApoH,	histone	H4	and	phosphatidylserine,	which	are	associated	with	autoimmunity.	
In	 addition,	 when	 purified	 ApoBods	 were	 added	 to	 dTHP-1	 cells,	 a	 differentiated	
macrophage	 cell	 line,	 recognition	 and	 uptake	 occurred,	 suggesting	 that	 ApoBods	 could	
expose	a	repertoire	of	self-antigens	to	the	immune	system.	Thus,	uptake	of	ApoBods,	with	
B19V	NS	 protein-DNA	 adducts	 and	 nucleosomal	 and	 lysosomal	 antigens	within	 them,	 by	
anergic	 B	 lymphocytes	 would	 allow	 presentation	 of	 NS	 peptides	 to	 NS-specific	 T	 helper	
cells,	 thereby	breaking	 tolerance.	Reaction	 to	 self-	 and	non	 self-	 antigens	by	professional	
antigen	 presenting	 cells	 (APCs)	 and	 lymphocytes	would	 elicit	 tissue	 damage	 that	 in	 turn	
accelerates	autoimmune	disease	(173).	
The	 idea	 that	 CD4+	 T-cells	may	 have	 direct	 cytolytic	 activity	 is	 emerging.	 One	 cell-killing	
mechanism	 involves	 the	 granule	 exocytosis	 pathway,	 which	 employs	 perforin	 and	
granzymes	to	induce	cell	death.	This	enzymatic	activity	is	thought	to	potentially	contribute	
to	autoimmunity	by	creating	novel	autoimmune	epitopes	from	self-proteins.	The	cytolytic	
potential	 of	 B19V-specific	 T	 cells	 was	 explored	 by	 stimulating	 PBMC	 from	 seropositive	
healthy	 subjects	 with	 recombinant	 VP2-VLPs.	 Results	 indicated	 a	 strong	 correlation	
between	B19V-induced	perforin	and	granzyme	secretion.	Depletion	of	CD4+	or	CD8	+	T-cells	
from	PBMC	and	the	HLA	restriction	assays	showed	that	the	responses	were	largely	confined	
to	CD4+	T-cells.	Intracellular	cytokine	staining	confirmed	that	granzymes	and	perforin	were	
co-expressed	 in	 the	 same	B19V-specific	CD4+	 T-cells	 that	produced	also	 IFN-γ.	Moreover,	
these	CD4+	T-cells	were	directly	cytotoxic	in	a	lactate	dehydrogenase	release	assay.	Finally,	
they	 showed	expression	of	 the	natural	 killer	 cell	 surface	marker	CD56,	 together	with	 the	
CD4	 marker.	 CD4+/CD56+	 T-cells	 have	 proved	 to	 be	 important	 in	 autoimmune	 diseases.	
CD4+	 T-cells	 secreting	 granzymes	may	potentially	 contribute	 to	 control	 B19V	by	 guarding	
against	 reactivation	 in	 cases	 where	 viral	 helper	 function	 is	 provide	 by	 other	 pathogens	
(175).	
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8.	DIAGNOSIS	
	
The	 lack	of	adaptation	to	 in	vitro	cell	cultures	 implies	that	virus	 isolation	methods	cannot	
be	used	 in	diagnostics.	 The	presence	of	 giant	pronormoblasts	 in	a	bone	marrow	aspirate	
could	be	indicative	of	B19V	infection	but	is	not	diagnostic.	
Numerous	techniques	are	now	available	for	the	diagnosis	of	B19V	infection	based	on	direct	
methods,	 searching	 the	 presence	 of	 viral	 genome	 or	 proteins,	 or	 indirect,	 detecting	 a	
specific	immune	response.	Plasma	and	serum	specimens	are	suitable	for	both	viral	DNA	and	
antibodies	detection.	Bone	marrow	aspirates	or	bioptic	 samples	can	also	be	used.	During	
B19V	infection	in	pregnancy,	analysis	of	the	amniotic	fluid	can	reveal	the	presence	of	viral	
DNA,	while	fetal	or	placental	tissues	are	analysed	in	case	of	fetal	death	(176,	177).	
B19V	 genome	 can	 be	 detected	 in	 peripheral	 blood,	 bone	 marrow	 or	 tissues	 by	 direct	
hybridization	 (178-180)	 or	 nucleic	 acid	 amplification.	 	 Although	 direct	 hybridization	 is	
sensitive	enough	to	detect	viral	DNA	in	acute	infections,	lower	viremia	will	be	missed	due	
to	 its	 detection	 limit.	 Thanks	 to	 the	 constant	 advances	 in	 the	 development	 of	molecular	
analytic	techniques,	real-time	quantitative	PCR	assays	are	nowadays	the	standard	analytical	
method	for	B19V	molecular	detection.	These	more	sensitive	techniques	allow	the	detection	
of	all	B19V	genotypes,	a	calibrated	quantification	of	viral	target	and	can	be	challenged	by	
international	proficiency	panels	using	international	standard	(181-184).	
In	situ	hybridization	 techniques	can	be	useful,	 in	association	with	PCR,	 for	 the	analysis	of	
bioptic	sample	for	the	direct	identification	of	infected	cells.		
Detection	 of	 B19V	 specific	 antibodies	 is	 the	 most	 common	 laboratory	 test	 for	 B19V	
infection	 and	 correct	 interpretation	 of	 results	 is	 helpful	 to	 define	 active,	 recent	 or	 past	
infection.		
Viral	capsids	purified	 from	serum	of	viremic	patients	were	 initially	used	 in	 immunological	
tests	 (185).	Afterwards,	 recombinant	expression	systems	allowed	 the	production	of	B19V	
antigens	 suitable	 for	 antibody	 tests.	 Currently,	 most	 antigens	 are	 produced	 by	 the	
baculovirus	 expression	 system	 to	 obtain	 capsid	 proteins	 as	 VLPs	 with	 antigenic	
configuration	correlated	with	that	of	native	virus	(186).		
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Acute	 B19V	 infection	 is	 usually	 diagnosed	 by	 detection	 of	 specific	 IgM	 antibodies.	 B19V-
specific	 IgM	 are	 generally	 found	 within	 7-10	 days	 after	 viral	 exposure	 and	 remain	
detectable	for	approximately	2-6	months.	Therefore,	the	presence	of	IgM,	especially	at	low	
titers,	 is	not	necessary	a	conclusive	proof	of	 recent	 infection.	Acute	 infection	can	also	be	
diagnosed	 retrospectively	 by	 checking	 serum	 samples	 collected	 in	 the	 acute	 and	
convalescent	phase	(approximately	four	to	six	weeks	later)	to	measure	a	fourfold	or	greater	
increment	of	B19V-specific	IgG	titer/avidity.	IgG	antibodies	usually	appear	and	begin	to	rise	
approximately	two	weeks	following	infection	and	then	persist	for	life.		
Unlike	nucleic	acids	amplification	 technics,	 serological	 tests	do	not	appear	 to	 suffer	 from	
recognition	 issues	 between	 genotypes	 1,	 2,	 and	 3	 as	 the	 level	 of	 divergence	 among	 the	
strains	 at	 the	 amino	acid	 level	 is	 significantly	 less	 than	 that	 seen	at	 the	nucleotide	 level.	
Several	B19V-specific	IgM	or	IgG	enzyme	immunoassays	(EIAs)	are	commercially	available.	
The	different	kits	vary	in	their	antigen	composition:	some	contain	recombinant	VP2	alone,	
while	 others	 consist	 of	 a	 combination	 of	 VP1	 and	 VP2	 antigens.	 Kits	 containing	
conformational	B19	antigens	have	 improved	performance	over	kits	 containing	only	 linear	
B19	antigens,	since	IgG	directed	against	conformational	epitopes	are	maintained	long	term	
(126).	
Since	 B19V	 infection	 can	 follow	 different	 courses,	 depending	 on	 the	 balance	 between	
active	 viral	 replication	 and	 physiological	 and	 immune	 status	 of	 the	 subject,	 a	
multiparametric	approach	is	necessary	to	define	a	clinically	significant	diagnosis.	
In	immunocompetent	hosts	with	the	classic	rash	of	erythema	infectiosum,	the	presumptive	
diagnosis	 can	 be	 made	 on	 the	 clinical	 manifestations	 alone	 and	 diagnostic	 tests	 are	
generally	not	essential	to	clinical	care.	Confirmation	of	the	viral	etiology	became	important	
when	 the	 result	 would	 affect	management	 decisions,	 as	 in	 atypical	 presentations	 of	 the	
infection	 or	 in	 patients	 with	 new-onset	 arthropathy	 of	 unclear	 cause.	 In	 these	 cases,	
serologic	tests	can	confirm	the	diagnosis	of	acute	B19V	by	revealing	B19V-specific	IgM.	
Detection	of	viral	DNA	by	PCR	is	generally	not	useful	for	the	diagnosis	of	acute	infection	in	
immunocompetent	 hosts	 without	 aplasia	 since	 viremia	 generally	 falls	 down	 when	
symptoms	arise.	Furthermore,	low	levels	of	B19V	DNA	may	persist	in	serum	or	tissues,	even	
in	healthy	patients;	so,	viral	DNA	detection	does	not	necessarily	indicate	acute	infection.		
49	
	
In	 patients	with	 hematological	 disorders	 or	 defects	 in	 the	 immune	 system,	who	 present	
with	 anemia,	 the	diagnosis	of	B19V	 infection	may	 rely	on	 the	detection	of	B19V	DNA	by	
PCR.	 In	 immunocompetent	 patients	 with	 transient	 aplastic	 crisis,	 serology	 can	 also	 be	
useful	to	support	the	diagnosis,	even	if	the	absence	of	IgM	antibodies	does	not	exclude	the	
possibility	 of	 B19V	 infection;	 on	 the	 contrary,	 it	 is	 not	 useful	 in	 immunocompromised	
patients	unable	to	develop	sufficient	antibody	levels.	
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9.	THERAPEUTIC	OPTIONS	
	
Usually,	 B19V	 infection	 in	 healthy	 subject	 does	 not	 require	 specific	 therapy.	 Infection	 is	
often	asymptomatic	and	the	immune	response	is	able	to	clear	it.	Erythema	infectiosum	is	a	
self-limited	and	mild	illness	that	not	requires	treatment.	However,	an	intervention	could	be	
relevant	 in	patients	with	hematological	disorders	or	deficits	 in	the	 immune	system	and	in	
infected	pregnant	women	because	of	the	risk	of	fetal	death.	
Currently,	no	specific	antiviral	drug	is	available	against	B19V;	treatment,	when	required,	is	
limited	to	ameliorate	the	symptomatology.	
In	 patients	 with	 transient	 aplastic	 crisis,	 anemia	 is	 treated	 with	 transfusion	 until	 the	
immune	 response	 clear	 the	 infection	 and	 red	 cells	 production	 resumes	 (187),	while	 non-
steroid	anti-inflammatory	drugs	can	be	helpful	in	case	of	arthritis	and	arthralgia.		
	
9.1.	INTRAUTERIN	BLOOD	TRANSFUSION	
Intrauterine	blood	 transfusion	of	packed	 red	 cells,	 into	 the	umbilical	 vein,	 is	 indicated	 to	
prevent	 fetal	 lost	 in	 case	 of	 severe	 anemia.	 The	 optimal	 period	 for	 the	 treatment	 is	
between	18	and	35	weeks	of	gestation	because	before	18	weeks	 it	 is	 technically	difficult	
due	 to	 the	 small	 size	 of	 the	 relevant	 anatomic	 structures,	 while	 after	 35	 weeks	 it	 is	
considered	 riskier	 than	 postnatal	 transfusion	 therapy.	 Ultrasound	 and	 Doppler,	 used	 to	
detect	 signs	 of	 anemia	 and	 cardiac	 failure,	 are	 supportive	 for	 the	 optimal	 fetus	
management.	Several	case	studies	reported	an	enhancement	in	the	rate	of	fetal	survival.	In	
a	large	study	of	the	Society	of	Perinatal	Obstetricians,	the	incidence	of	fetal	death	was	6%	
of	cases	of	B19V-related	hydrops	treated	with	transfusion,	while	30%	of	fetus	with	hydrops	
that	did	not	receive	transfusion	died	in	utero.	There	is	only	one	study	indicating	that	30%	of	
24	 hydropic	 fetus,	 who	 were	 transfused,	 died	 and	 30%	 of	 the	 survivors	 had	 delayed	
psychomotor	development	(188,	189).	
	
9.2.	IVIG	THERAPY	
In	 immunocompromised	 patients,	 the	 lack	 of	 an	 efficient	 immune	 response	 can	 lead	 to	
persistent	and	chronic	infection.	Effective	therapy	of	persistent	infection	consists	of	passive	
51	
	
immunization	 by	 infusion	 of	 immunoglobulin	 (IVIG).	 IVIG	 are	 therapeutic	 preparations	 of	
normal	 human	 IgG	obtained	 from	 large	pools	 of	 donors	 and	 contain	 a	wide	 spectrum	of	
antimicrobic	 specificities,	 including	 high	 levels	 of	 B19V-neutralizing	 antibodies,	 as	 the	
majority	of	the	adult	population	has	been	exposed	to	the	virus.		
In	 a	 retrospective	 study	 of	 10	 patients	 with	 pure	 red	 cell	 aplasia	 associated	 with	 B19V	
infection,	 IVIG	 therapy	appeared	 to	be	effective	 in	9	of	 the	10	 subjects.	Normal	 levels	of	
hemoglobin	 were	 completely	 restored	 after	 one	 year.	 Treatment	 failed	 with	 low	 doses	
suggesting	the	use	of	at	least	2	g/Kg	of	IVIG	per	course.	The	data	are	in	agreement	with	the	
literature	 that	 indicates	 a	 complete	 remission	 of	 B19V-associated	 pure	 red	 cell	 aplasia	
(PRCA)	in	93%	of	cases.	However,	relapse	occurs	in	37%	of	the	responders	within	a	mean	of	
4.3	months.	 IVIG	 are	 not	 able	 to	 completely	 clear	 the	 infection,	 so	 additional	 courses	 of	
IVIG	 treatment	 are	 required.	 Interstingly,	 in	 patients	 with	 severe	 immunodeficiencies,	
especially	 with	 HIV	 infection,	 the	 prognosis	 is	 worse	 than	 in	 other	 situations.	 Usually,	
clearance	of	infection	occurs	when	a	specific	antiviral	immune	response	becomes	effective.	
If	 the	 immunodeficiency	 improves,	 chronic	 infection	may	 resolve,	 as	 examples,	 with	 the	
starting	of	antiretroviral	 therapy	 in	patients	with	HIV	 infection	or	after	discontinuation	of	
immunosuppressive	therapy	in	post-transplant.	Concerning	the	tolerance	of	the	treatment,	
10%	of	patients	showed	adverse	side	effects	(190).	
In	conclusion,	IVIG	therapy	seems	to	be	effective	for	the	treatment	of	PRCA	associated	to	
B19V	infection	in	immunocompromised	patients.	However,	therapy	with	IVIG	preparations	
is	 still	 empirical	 since	 no	 clinical	 trials	 have	 been	 carried	 out	 to	 define	 an	 optimal	
therapeutic	scheme	for	their	administrations.	Therefore,	additional	studies	are	needed	to	
define	an	optimal	dose	as	well	as	risk	factors	of	PCRA	relapse	(191-193).	
	
9.3.	VACCINE	
The	 development	 of	 a	 vaccine	 for	 B19V	 could	 be	 questionable.	 Infection	 is	 often	
asymptomatic	or	causes	a	self-limited,	wild	illness	or	could	be	chronic,	so	a	vaccine	might	
be	 of	 doubtful	 utility.	 However,	 a	 vaccine	 might	 be	 a	 benefit	 for	 some	 categories	 of	
patients,	such	as	subjects	with	hematological	disorders,	to	prevent	aplastic	crisis,	and	B19V	
seronegative	women	of	childbearing	age,	to	prevent	pregnancy	complications.	B19V	capsid	
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proteins	can	be	expressed	in	eukaryotic	systems,	were	they	self-assemble	in	VLPs	that	are	
antigenically	similar	to	native	virions.	Two	previous	study	reported	a	double-blind,	phase	1	
trial	to	evaluate	a	recombinant	human	B19V	vaccine	composed	of	VP1	and	VP2	expressed	
in	insect	cells	by	a	recombinant	baculovirus	system.	
In	the	first	study,	the	vaccine	was	composed	of	25%	of	VP1	and	of	75%	of	VP2.	It	was	given	
to	24	B19V-seronegative	adults	in	a	series	of	three	doses	over	six	months.	The	vaccine	was	
found	 to	 be	 safe,	 well	 tolerated	 and	 highly	 immunogenic.	 All	 received	 subjects	
seroconverted	after	at	least	two	doses	and	all	volunteers	developed	neutralizing	antibodies	
with	a	peak	titer	after	three	immunizations	and	the	high	titer	is	conserved	for	at	least	one	
year.	However,	 a	phase	 I/II	 trial	 of	 a	National	 Institute	of	Allergy	and	 Infectious	Diseases	
(NIAID)	initiated	to	assess	the	safety	and	immunogenicity	of	the	recombinant	vaccine	was	
suspended	due	to	vaccine-associated	adverse	events	(194).	
In	 the	 second	 study,	 the	 vaccine	 was	 composed	 of	 22.6%	 of	 VP1	 and	 77.4%	 of	 VP2.	 89	
healthy	 seronegative	 adults	 were	 enrolled	 to	 evaluate	 two	 distinct	 doses	 and	 with	 or	
without	the	MF59	adjuvant.	The	trial	was	halted	after	immunization	of	43	subjects	because	
of	 unusual	 skin	 manifestations	 (erythematous,	 indurated	 lesion,	 systemic	 rash)	 in	 two	
vaccine-	and	one	placebo-	recipients.	No	clear	cause	was	established,	although	it	is	possible	
due	to	insect	cell	contaminants	or	to	the	phospholypase	A2	activity	(PLA2)	of	the	VP1u	that	
can	 modulate	 the	 release	 of	 arachidonic	 acid	 and	 precursors	 of	 potent	 inflammatory	
mediators	(195).	
A	recent	study	was	aimed	to	investigate	a	new	B19V	vaccine	candidate	designed	to	avoid	
potential	causes	of	 reactogenicity.	The	previous	vaccine	was	based	on	the	co-infection	of	
insect	 cells	 with	 two	 recombinant	 baculoviruses,	 one	 expressed	 VP1	 and	 one	 VP2.	 This	
approach	might	 lead	to	different	ratios	of	the	two	proteins	because	not	every	 insect	cells	
can	 be	 infected	 by	 the	 same	 ratio	 of	 the	 two	 viruses.	 In	 this	 recent	 work,	 VLPs	 were	
expressed	 in	 S.cerevisiae	 using	 a	 single	 bicistronic	 plasmid	 expressimg	 VP1	 and	 VP2	 in	 a	
fixed	 ratio.	 The	 high	 homogeneity	 of	 VLPs	 led	 to	 an	 efficient	 purification.	Moreover,	 the	
PLA2	 activity	 was	 suppressed	 by	 a	 point	 mutation	 to	 eliminate	 a	 possible	 cause	 of	
reactogenicity.	 The	 vaccine,	 administered	 with	 the	 adjuvant	MF59,	 was	 immunogenic	 in	
mice	(196).	
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9.4.	SCREENING	OF	BLOOD	PRODUCTS	
Good	 practices	 for	 reducing	 B19V	 transmission	 remain	 the	 best	 measure	 to	 prevent	
infection.	 Screening	 of	 blood	 products	 is	 the	 aspect	 of	major	 concern.	 The	 absence	 of	
symptoms	 during	 the	 high-titer	 viremic	 phase,	 the	 possible	 occurrence	 of	 low-titer	
chronic	 infection,	as	well	as	the	slow	clearance	of	virus	from	bloodstream,	underlie	the	
care	 for	 the	 risk	of	B19V	 transmission	 through	 contaminated	blood	or	blood	products.	
Moreover,	 the	 small	 size	 of	 B19V	 virion	 and	 the	 lack	 of	 a	 lipid	 envelope	 make	 B19V	
extremely	resistant	to	physical	inactivation.		
The	 range	 of	 incidence	 of	 B19V	 antibodies	 or	 DNA	 in	 blood	 derivatives	 is	 very	 large	
according	to	the	reports	carried	out	in	the	last	twenty	years,	although	results	can	be	the	
very	different	depending	on	the	epidemiological	settings,	the	sensitivity	of	the	methods	
used	and	the	seasonal	variations	in	B19V	trasmission.	Several	reports	of	B19V	trasmission	
by	 pooled	 plasma	 components	 are	 present,	 but	 transmission	 due	 to	 single-donor	
components	is	rare	(197).	
Observations	in	healthy	volunteers	suggest	that	a	high	threshold	level	of	viral	DNA	of	107	
International	 Units	 per	 ml	 is	 required	 in	 order	 to	 transmit	 B19V	 infection	 after	
administration	of	blood.	Furthermore,	the	presence	of	neutralizing	activity	in	the	donor	
pools	may	interfere	with	infectivity	and	the	existence	of	previous	immunity	in	recipients	
will	be	protective.	Therefore,	considering	the	high	seroprevalence	rate	in	the	population	
and	the	 low	frequencies	of	high-titer	viremic	blood	units,	the	risk	of	acquiring	 infection	
by	exposure	to	single	blood	or	blood	components	unit	is	low.	Systematic	donor	screening	
is	therefore	unjustified,	although	B19V-free	donation	could	be	indicated	in	patients	with	
hematological	disorders,	immunodeficiencies	and	pregnant	women.	Greater	attention	is	
focus	 on	 blood	 products	 that	 are	 manufactured	 from	 large	 pool	 of	 donation,	 with	 a	
consequent	 increased	 probability	 of	 contamination	 by	 high-titer	 viremic	 units.	
Postmarketing	studies	of	plasma	manufactured	by	VITEX,	revealed	the	presence	of	B19V	
antibodies	or	B19V	DNA.	Plasma	with	high	titer	of	B19V	DNA	was	given	to	19	recipients,	
of	whom	18	seroconverted	after	3	months,	with	also	viral	replication	in	14	cases.	So,	the	
antibodies	 present	 in	 the	 pooled	 plasma	 were	 not	 protective.	 On	 the	 contrary,	 58	
patients	who	received	plasma	with	low	B1V	DNA	titer	remain	seronegative	and	no	viral	
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DNA	was	detected.	This	evidence	led	the	Food	and	Drug	Administration	to	set	the	limit	of	
104	genome	copies/ml	of	B19V	DNA	for	the	manufacturing	pools	of	plasma.	Similarly,	the	
European	Farmacopoeia	imposed	a	threshold	level	of	104	IU/ml	in	immunoglobulins	and	
pooled	 plasma.	 Of	 note,	 B19V	 transmission	 by	 pooled	 plasma	 products	 was	 almost	
always	demonstrated	by	recipient	seroconversion	without	clinical	manifestations,	while	
B19V-related	disease	associated	to	transmission	by	contaminated	plasma	is	less	frequent	
(198-201).		
In	 conclusion,	 sensitive	 molecular	 assays	 for	 screening	 and	 the	 viral	 decontamination	
during	 the	 manufacturing	 plasma	 process	 increased	 the	 safety	 of	 blood	 products,	
minimizing	the	risk	of	transmission.	
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10.	AIM	OF	THE	STUDY	
Parvovirus	B19	(B19V)	is	the	main	human	pathogenic	virus	of	the	Parvoviridae	family.	It	can	
cause	 clinical	 complications	 in	 particular	 situations,	 such	 as	 persistent	 anemia	 in	
immunosuppressed	 patients,	 transient	 aplastic	 crisis	 in	 subjects	 with	 haematological	
disorders,	 and	 hydrops	 fetalis	 and	 congenital	 anemia	 during	 maternal	 infection.	 Viral	
replication	 and	productive	 infection	 are	 restricted	by	 the	narrow	 tropism	of	 the	 virus.	 In	
nature,	B19V	replicates	preferentially	in	human	erythroid	progenitors	cells	of	bone	marrow,	
although	 restricted	 infection	 of	 other	 tissue	 has	 been	 reported.	 The	 restricted	 tropism	
results	 from	 combinations	 of	 several	 factors.	 First,	 virus	 attachment	 is	 mediated	 by	
globoside	receptors	expressed	on	cell	surface	and	by	coreceptors.	However,	the	presence	
of	 receptors	 and	 corecptors	 is	 not	 sufficient	 to	 achieve	 a	 productive	 infection,	 but	
intracellular	events	are	likely	to	affect	the	outcome	of	B19V	infection.	The	strictly	tropism	
has	 impaired	a	deep	understanding	of	virus	dynamics	and	 life	cycle.	Only	 few	cell	 lines	 in	
fact	can	support	B19V	replication,	although	to	a	limited	extent.	Recently,	new	advances	in	
generation	and	differentiation	of	human	progenitors	cells	(EPCs)	in	vitro	allow	the	study	of	
viral	 characteristics	 in	 a	highly	permissive	environment	mimicking	 the	 in	 vivo	 infection	 in	
bone	marrow.	EPCs	can	be	obtained	from	peripheral	blood	by	culture	in	medium	containing	
erythropoietic	growth	and	differentiation	factors.	This	culture	system	not	only	provides	an	
effective	permissive	cell	population	but	consents	also	the	study	of	 the	changes	 in	cellular	
expression	patterns	that	occur	during	erythroid	differentiation	regulating	viral	replication.	
A	 first	 aim	 of	 the	 present	 study	was	 the	 characterization	 of	 B19V	 dynamics,	 in	 terms	 of	
distribution	 of	 productively	 infected	 cells,	 macromolecular	 synthesis	 and	 production	 of	
infectious	 virus,	 in	 dependence	 on	 the	 differentiation	 stage	 of	 EPCs	 obtained	 from	
peripheral	blood.	A	window	of	permissiveness	to	a	productive	infection	of	B19V	was	found	
and	 was	 constituted	 by	 a	 heterogeneous	 population	 of	 differentiating	 cells,	 around	 the	
pronormoblast	phase,	consenting	an	efficient	viral	 replication,	a	mature	mRNAs	synthesis	
and	 production	 of	 infectious	 virus.	 All	 these	 characteristics	 describe	 a	 model	 system	
suitable	 for	 studying	 virus-cells	 interaction,	 understanding	 viral	 pathogenesis	 and	
researching	compounds	with	potential	antiviral	activity.	
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PBMC-derived	EPCs	constitute	a	reference	system	representing,	in	vitro,	the	primary	target	
cells	 of	 natural	 infection	 in	 vivo	 and	 a	 permissive	 cellular	 system	 suited	 to	 assess	 the	
inhibitory	 effect	 of	 potential	 antiviral	 drugs	 on	 B19V	 replication.	 Nowadays,	 no	 specific	
antiviral	drugs	active	against	B19V	are	present	and	current	treatments	are	effective	only	to	
ameliorate	symptoms.	Although	B19V	 infection	 is	usually	asymptomatic	or	causes	a	mild,	
self-limited	 illness,	 a	 specific	 antiviral	 treatment	 would	 be	 useful	 in	 the	 acute	 phase	 of	
aplastic	crisis,	 in	 immunocompromised	patients	not	able	to	mount	 immune	responses	 for	
infection	 clearance,	 and	 in	 maternal	 infections	 with	 the	 risk	 of	 fetal	 loss.	 Current	
treatments	 include	 blood	 transfusion,	 to	 overcome	 acute	 or	 chronic	 anemia,	 and	
intravenous	 immunoglobulins	 (IVIG)	 administration	 for	 neutralizing	 infection	 in	
immunocompromised	 patients.	 IVIG	 therapy	 however	 has	 some	 limitations,	 considering	
that	 virus	 clearance	 become	 effective	 when	 a	 mature	 immune	 response	 develops,	 and	
treatment	 cycles	 are	 empirical	 since	 no	 clinical	 trials	 are	 available	 to	 define	 an	 optimal	
therapeutic	scheme.	
Strategies	 for	 discovery	 and	 development	 of	 antiviral	 compounds	 include	 rational	 drug	
design,	 which	 is	 focused	 on	 identifying	 molecules	 that	 specifically	 target	 known	 viral	
components,	 and	 testing	 of	 compounds	 with	 known	 biological	 activity.	 The	 second	
approach	was	thus	used	in	the	present	work	in	order	to	investigate	the	potential	inhibitory	
activity	of	Cidofovir	on	B19V.	Cidofovir	 is	a	monophosphate	nucleotide	analogue	that	has	
shown	activity	against	all	not	 retrotranscribing	dsDNA	viruses.	A	 second	aim	of	 this	work	
was	 then	 the	 investigation	 of	 inhibitory	 activity	 of	 Cidofovir	 on	 B19V	 replication	 in	 the	
model	system	constituted	by	differentiating	EPCs	isolated	from	peripheral	blood.	
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11.	B19V	REPLICATION	AND	EXPRESSION	IN	ERYTHROID	
PROGENITORS	CELLS	
	
11.1.	Cells	
Erythroid	 progenitor	 cells	 (EPCs)	 were	 generated	 in	 vitro	 from	 peripheral	 blood	
mononuclear	cells	(PBMC)	obtained	from	the	leukocyte-enriched	buffy	coats	of	anonymous	
blood	donors.	PBMC	were	isolated	using	centrifugation	in	Ficoll-Paque	Plus	(GE	Healthcare	
Bio-Sciences	 AB)	 and	 cultured	 in	 IMDM	 medium	 containing	 erythropoietic	 growth	 and	
differentiation	factors.	In	particular,	IMDM	was	supplemented	with:	
• serum	 substitute	 BIT	 9500	 (StemCell	 Technologies),	 diluted	 1:5	 for	 a	 final	
concentration	 of	 10	 mg/ml	 bovine	 serum	 albumin,	 10	 mg/ml	 recombinant	 human	
(rhu)	insulin,	and	200	mg/ml	iron-saturated	human	transferrin,		
• 900	ng/ml	ferrous	sulphate	(Sigma),		
• 90	ng/ml	ferric	nitrate	(Sigma),	
• 1	mM	hydrocortisone	(Sigma),		
• 3	IU/ml	rhu	erythropoietin	(NeoRecormon,	Roche),		
• 5	ng/ml	rhu	IL-3	(Life	Technologies),	
• 20	ng/ml	rhu	stem	cell	factor	(Life	Technologies).		
Cells	 were	maintained	 at	 37°C	 in	 5%	 CO2,	 at	 an	 initial	 density	 of	 2-3x10
6	 cells/mL,	 then	
splitted	at	day	4±1	and	maintained	at	a	density	of	0.5-1.0x106	cells/mL	 for	up	 to	20	days	
post-isolation.	
	
11.2.	Flow	Cytometry	Analysis	
During	cell	growth	and	differentiation,	in	vitro	cultured	EPCs	were	characterized	using	flow	
cytometry	 (FACSCalibur,	 Becton	 Dickinson).	 Aliquots	 of	 5x105	 EPCs	 were	 stained	 with	
antibodies	specific	for	erythroid	differentiation	markers	(CD36,	CD71,	CD235a)	and	known	
B19V	 receptors	 (globoside,	 α5β1	 integrin).	 CD36	 and	 CD71	 expression	was	 evaluated	 by	
phycoerythrin	(PE)-labeled	monoclonal	antibodies	(BD	Biosciences).	CD235a,	α5β1	integrin	
and	 globoside	 expression	 was	 evaluated	 by	 monoclonal	 mouse	 anti-CD235a	 (BD	
Biosciences),	monoclonal	mouse	anti-α5β1	(Immunological	Sciences)	and	polyclonal	rabbit	
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anti-globoside	 (Matreya),	 followed	 by	 anti-mouse-Alexa	 488	 (Life	 Technologies)	 or	 anti-
rabbit-FITC	 (DakoCytomation)	 antibody,	 respectively.	 Aliquots	 of	 cells	were	 collected	 and	
analyzed	 every	 three	 days	 during	 in	 vitro	 culture,	 up	 to	 18	 days.	 Antibody	 binding	 was	
performed	 incubating	 samples	 at	 4°C	 for	 30	minutes	 (min)	 and	washing	 twice	 in	 PBS	 to	
remove	unbound	antibody.	Cells	were	finally	resuspended	in	500	μl	of	PBS	and	analyzed.	
For	 each	 experimental	 series	 and	 each	marker	 analyzed,	 negative	 controls	were	 used	 to	
define	 the	percentage	of	positive	cells.	 In	case	of	direct	staining,	a	corresponding	sample	
were	 treated	equally	but	without	adding	 the	conjugated	antibody,	while	 in	case	of	direct	
staining	 only	 the	 secondary	 antibody	 was	 added	 in	 the	 control	 sample.	 The	 control	
histogram	was	subtracted	from	the	sample	histogram	and	the	percentage	of	positive	cells	
was	calculated	as	number	of	events	in	the	resulting	subtracted	histogram	in	comparison	to	
the	 total	 events	 of	 sample	 histrogram.	 Data	 were	 analyzed	 using	 the	 Cell	 Quest	 Pro	
Software	(Becton	Dickinson).	
	
11.3.	Virus	and	Infection	
A	 B19V	 viremic	 serum	 sample,	 identified	 in	 our	 laboratory	 in	 the	 course	 of	 routine	
diagnostic	analysis	and	available	for	research	purposes	according	to	Italian	privacy	law,	was	
used	 as	 source	 of	 virus	 for	 the	 infection	 experiments.	 The	 viremic	 serum	 contained	 1012	
B19V	genome	copies	(geq)/mL,	and	resulted	negative	by	routine	diagnostic	assays	to	other	
viruses.	
Viremic	sample,	appropriately	diluted	in	PBS,	was	added	to	a	define	number	of	cells,	at	the	
density	of	107	cells/mL,	 in	order	to	obtain	a	multiplicity	of	 infection	(moi)	of	103	geq/cell.	
Following	adsorption	for	2	hours	(h)	at	37°C,	the	inoculum	virus	was	washed	twice	in	PBS	
and	 the	 cells	 were	 incubated	 at	 37°C	 in	 complete	medium	 at	 an	 initial	 density	 of	 5x105	
cells/ml,	for	a	time	course	of	infection	of	48	h.	
	
11.4.	Infectivity	assay	
Equivalent	aliquots	of	supernatants	separated	from	the	respective	fraction	of	infected	cells	
at	each	time	point	and	day	series	were	processed	for	nucleic	acid	purification	and	analysis	
of	viral	DNA.	
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100	μl	of	supernantants	collected	at	12	hpi	and	48	hpi	from	cells	 infected	at	the	different	
days	of	culture,	were	then	used	to	 infect	1x106	cells	of	a	new	in	vitro	culture	at	day	9±1.	
Following	absorption	 for	2	hpi	 at	 37°C,	 cells	were	washed,	 then,	 an	aliquot	of	 cells	were	
stored	and	an	equivalent	aliquot	were	resuspended	in	complete	medium	for	48	h.	Samples	
collected	at	2	hpi	and	48	hpi	for	each	infection	were	processed	for	nucleic	acids	purification	
and	analysis	of	viral	DNA	amount	by	qPCR	assay.	
	
11.5.	Flow-FISH	Assay	
To	 detect	 viral	 nucleic	 acids	 by	 flow-FISH	 assay,	 1x106	 cells	 were	 collected	 at	 the	
appropriate	time	points	post-infection.	Cells	were	fixed	in	300	μl	of	PBS-paraformaldehyde	
0.5%	at	4°C	overnight	and	permeabilized	in	200	μl	of	PBS	containing	0.2%	saponin	at	room	
temperature	 (RT)	 for	 45	min.	 Finally,	 cells	 were	 resuspended	 in	 50	 μl	 of	 a	 hybridization	
solution	containing	2×	SSC,	70%	 formamide,	250	g/ml	DNA	calf	 thymus	and	10%	Dextran	
sulfate.	 A	 digoxigenin-labeled	 DNA	 probe	 mixture	 specific	 for	 B19V	 nucleic	 acids	 was	
generated	by	the	random	priming	method	on	a	cloned	full-length	genomic	DNA	template,	
according	 to	 the	manufacturer’s	 instructions	 (Dig-High	Prime,	 Roche).	 The	probe	mixture	
was	denatured	at	95°C	for	5	min,	then	added	at	2	μg/mL	to	the	cell	suspension,	previously	
heated	at	70°C	for	5	min.	Hybridization	reaction	was	performed	at	70°C	for	5	min	and	37°C	
overnight.	Following	hybridization,	cells	were	washed	with	1×	Stringent	Wash	(Zytovision)	
at	RT	for	15	min,	then	at	55	°C	for	5	min	and	again	at	RT	for	5	min.	For	the	detection	of	the	
hybrids,	 the	 cell	 suspension	was	 incubated	 for	 1	 h	with	 a	 FITC-conjugate	 antidigoxigenin	
antibody	(Roche)	diluted	1:20	in	100	μl	of	PBS-BSA	1%.	Finally,	cells	were	washed	twice	in	
PBS	and	 resuspended	 in	500	μl	of	PBS	 for	cytometer	analysis.	A	parallel	aliquot	of	mock-
infected	 cells	 was	 treated	 equally	 as	 control	 sample.	 Samples	 were	 gated	 on	 the	 FSC	
(forward	 light	 scatter)	 versus	 SSC	 (side	 light	 scatter)	 plot	 to	 exclude	 cellular	 debris	 and	
50000	events	per	sample	were	collected.	The	percentage	of	positive	cells	was	calculated	on	
the	number	of	events	showing	fluorescence	intensity	greater	then	a	fixed	gate	set	in	order	
to	have	at	least	99.5%	of	mock-infected	cells	below	threshold.		
	
11.6.	Nucleic	acids	purification	
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Equal	 amounts	 of	 cell	 cultures,	 corresponding	 to	 2x105	 cells,	 were	 collected	 at	 the	
appropriate	time	points	following	infection	(hours	post-infection,	hpi),	resuspended	in	200	
μL	 of	 Buffer	ATL	 and	processed	 by	 using	 the	 EZ1	 viral	 nucleic	 acid	 kit	 on	 a	 EZ1	 platform	
(Qiagen),	 following	the	manufacturer’s	 instructions,	 in	order	to	obtain	a	total	nucleic	acid	
fraction,	containing	both	viral	DNA	and	RNA,	in	a	final	elution	volume	of	120	μL.	Volumes	of	
10	 μL	 were	 then	 used	 in	 the	 subsequent	 qPCR	 and	 qRT-PCR	 assays	 for	 the	 quantitative	
evaluation	of	target	viral	nucleic	acids.	For	quantitative	analysis	of	viral	DNA,	aliquots	of	the	
eluted	nucleic	acids	were	directly	amplified	 in	a	qPCR	assay,	while	 for	 viral	RNA	analysis,	
corresponding	aliquots	were	first	treated	with	Turbo	DNA-free	reagent	(Ambion)	and	then	
amplified	in	a	qRT-PCR	assay.		
	
11.7.	Quantitative	real-time	PCR	and	RT-PCR	
Standard	 targets	 for	 the	quantification	of	 viral	 nucleic	 acids	were	obtained	 from	plasmid	
pHR0	 that	 contains	 an	 insert	 corresponding	 to	 the	 complete	 internal	 region	 of	 B19V	
genome	 (nt.	 346-.5245)	 ().	 From	 pHR0	 plasmid,	 in	 vitro	 amplified	 DNA	 or	 in	 vitro	
transcribed	RNA	corresponding	 to	 the	viral	 insert	were	obtained,	purified,	quantified	and	
used	as	genome	equivalents	(geq)	standards.	Serial	dilutions	of	the	standard	products,	from	
101	to	108	geq/reaction,	were	amplified	to	obtain	calibration	curves	by	plotting	Cp	values	as	
a	function	of	log	of	target	copy	number.		
DNA	amplification	was	performed	by	using	QuantiTect	PCR	SybrGreen	PCR	Kit	(Qiagen).	The	
primer	 pair	 R2210-R2355,	 located	 in	 the	 central	 exon	 of	 B19V	 genome,	 was	 used	 for	
amplification	at	a	final	concentration	of	0.5	μM	in	a	total	volume	of	20	μl.	Thermal	profile	
consisted	in	15	min	at	95°C,	then	40	cycles	of	15	sec	at	95°C,	30	sec	at	55°C,	and	15	sec	at	
72°C	 and	 15	 sec	 at	 78°C	 both	 coupled	with	 signal	 acquisition.	 A	 final	melting	 curve	was	
performed,	with	 thermal	 profile	 ramping	 from	50°C	 to	 95°C	 at	 a	 12°C/min	 rate,	 coupled	
with	continuous	signal	acquisition.	
RNA	amplification	was	performed	by	using	QuantiTect	SybrGreen	RT-PCR	Kit	(Qiagen).	The	
primer	pair	R2210-R2355,	being	 located	 in	 the	central	exon,	could	amplify	both	DNA	and	
the	whole	set	of	viral	transcripts.	Thus,	it	was	used	for	quantification	also	of	the	total	RNA,	
at	a	final	concentration	of	0.5	μM	in	a	final	volume	of	20	μl.	For	each	sample,	two	parallel	
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reactions	were	performed,	either	including	(RT+)	or	omitting	(RT-)	the	reverse	transcriptase	
in	the	reaction	mix,	to	discriminate	the	residual	viral	DNA	present	after	DNase	treatment.	
DNA	contamination	was	considered	negligible	during	viral	RNA	quantification	 if	 there	 is	a	
difference	 of	 al	 least	 3	 cycles	 between	 RT+	 and	 RT-	 amplified	 sample.	 Thermal	 profile	
consisted	in	the	same	amplification	reaction	of	qPCR	with	the	addition	of	an	initial	step	of	
retrotranscription	at	30	min	at	55°C.		
To	 obtain	 a	 systematic	 functional	 analysis	 of	 B19V	 genome	 expression	 a	 PCR	 array	 was	
designed	 in	 order	 to	 specifically	 discriminate	 all	 the	 diverse	 classes	 of	 viral	 mRNA.	
Oligonucleotide	primers	were	selected	and	combined	to	define	genome	expression	profile	
on	the	basis	of	splice	definition	and	exon/intron	composition.		
Primers	 and	 primer	 combinations	 used	 in	 the	 qPCR	 and	 qRT-PCR	 assays	 are	 indicated	 in	
Table	1	and	mapped	with	respect	to	B19V	genome	in	Figure	10.	
All	oligonucleotides	were	obtained	from	MWG	Biotech.	
	
	
Table	1:	Primers	used	in	the	qPCR	and	qRT-PCR	assay.	
	
64	
	
	
Figure	10:	A	simplified	map	of	B19V	transcripts	with	the	position	of	primers	used	in	the	PCR	array.	
	
Real-time	 PCR	 and	 RT-PCR	 were	 performed	 and	 analysed	 by	 using	 the	 RotorGene	 3000	
system	 and	 the	 RotorGene	 6.0	 software.	 All	 reported	 experiments	 were	 carried	 out	 in	
duplicate	series.	Melting	curve	analysis	was	used	for	the	determination	of	the	specificity	of	
the	amplification	products.	Quantitation	of	viral	DNA	and	of	total	viral	RNA	was	obtained	by	
the	 absolute	 quantitation	 algorithm,	 converting	 quantification	 cycle	 (Cq)	 values	 to	 geq	
number	using	external	DNA	or	RNA	calibration	curves.	Relative	quantitation	of	the	different	
subsets	of	viral	 transcripts	was	obtained	by	efficiency-corrected	comparative	quantitation	
using	LinRegPCR	software,	and	subsequent	normalization	within	each	combination	set	and	
to	the	amount	of	total	viral	RNA.		
The	 program	GraphPad	 Prism	 version	 5.00	 for	Windows	 (GraphPad	 Software,	 San	 Diego	
California,	USA)	was	used	for	data	analysis.	
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12.	ANTIVIRAL	ACTIVITY	OF	CIDOFOVIR	
	
12.1.	Cidofovir	
Cidofovir	 (CDV),	 [(S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine],	was	 purchased	
from	Sigma	at	a	purity	degree	>98%.	The	drug	was	dissolved	in	H2O	to	a	final	concentration	
of	5	mg/mL	and	stored	at	20	°C.	
	
12.2.	Cells	
UT7/EpoS1	cells	were	cultured	in	IMDM	(Cambrex),	supplemented	with	10%	FCS	(Cambrex)	
and	2	U/mL	rhu	erythropoietin	(NeoRecormon,	Roche),	at	37°C	and	5%	CO2.	Cells	were	kept	
in	 culture	at	densities	of	1-2x105	 cells/mL,	and	used	 for	 infection	experiments	when	at	a	
density	of	3x105	cells/mL.	
Erythroid	progenitor	 cells	 (EPCs)	were	 generated	 and	 cultured	 as	previous	described	and	
used	for	infection	experiments	after	9	±	1	days	of	culture.	
	
12.3.	Antiviral	Assay	
For	 infection	of	both	UT7/EpoS1	and	EPCs,	5x105	cells	were	 incubated	 in	50	μl	volume	of	
PBS,	in	the	presence	of	5	μl	of	the	viremic	serum,	diluted	in	PBS	in	order	to	obtain	different	
moi,	from	104	geq/cell	to	101	geq/cell.	Following	adsorption	for	2	h	at	37°C,	the	inoculum	
virus	 was	 washed	 and	 the	 cells	 were	 incubated	 at	 37	 °C	 at	 an	 initial	 density	 of	 5x105	
cells/mL	 in	 the	 respective	 complete	 medium,	 in	 the	 absence	 of	 drug	 or	 in	 presence	 of	
different	concentrations	of	CDV	(range	0.1	μM-500	μM).	
	
12.4.	Cell	Viability	and	Proliferation	Assays	
For	cellular	assays,	UT7/EpoS1	and	EPCs	cells	were	seeded	at	the	density	of	5x104	cells/well	
in	 a	 96-well	 culture	 microplate,	 and	 volumes	 of	 100	 µl	 of	 CDV	 freshly	 diluted	 in	 the	
respective	medium	 at	 the	 different	 concentrations	were	 added.	 Cells	without	 drug	were	
seeded	too	as	reference	point	of	maximum	activity.	Cells	were	then	cultured	for	72	h,	for	
UT7/EpoS1	cells,	or	24	h,	for	EPCs.		
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The	 effects	 of	 CDV	 on	 viability	 of	 cells	 were	 monitored	 by	 the	 alamarBlue	 assay	 (Life	
Technologies).	 10	 µl	 of	 reagent	 were	 added	 to	 cells	 and	 after,	 the	 incubation	 period,	
absorbance	was	 read	 on	 a	 plate	 reader	 spectrophotometer,	 according	 to	manufacturer’s	
instruction.	 AlamarBlue	 cell	 viability	 reagent	 is	 a	 redox	 indicator	 dye	 that	 yields	 a	
fluorescent	 signal	 in	 response	 to	metabolic	 activity	 functions.	When	 cells	 are	 alive,	 they	
maintain	 a	 reducing	 environment	 within	 the	 cytosol	 of	 the	 cell.	 Upon	 entering	 cells,	
resazurin,	the	active	ingredient	of	alamarBlue	reagent,	is	reduced	to	resorufin,	a	compound	
that	 is	 red	 in	 color	 and	 highly	 fluorescent.	 Both	 absorbance	 and	 fluorescence	 can	 be	
measured.	
Evaluation	of	5-bromo-20-deoxyuridine	(BrdU)	incorporation	(Cell	proliferation	ELISA	BrdU	
Assay,	 Roche	 Diagnostics)	 into	 newly	 synthesised	 DNA	 was	 suitable	 for	 monitoring	 the	
effects	of	CVD	on	cell	proliferation.	BrdU	is	a	pyrimidine	analogue	of	thymidine,	selectively	
incorporated	into	cell	DNA	at	the	S	phase	of	the	cell	cycle.	The	assay	consists	in	multistep	of	
fixation	 of	 cells	 after	 the	 incubation	with	 BrdU,	 labeling	 of	 BrdU	 incorporated	with	 anti-
BrdU	antibody,	detection	of	the	complex	BrdU/anti-BrdU	antibody	by	a	secondary	antibody	
conjugate	 with	 peroxidase,	 and	 colour	 development	 by	 adding	 a	 colorimetric	 substrate.	
Absorbance	is	read	at	450nm	and	630nm.	
	
12.5.	Quantitative	real-time	PCR	and	RT-PCR	
Nucleic	acids	purification	and	quantitative	Real-Time	PCR	were	performed	as	described.	In	
particular,	 the	primer	pair	R2210-R2355	was	used	for	amplification	of	both	viral	DNA	and	
the	whole	set	of	viral	transcripts,	the	primer	pair	R1882-R2033	for	the	amplification	of	the	
mRNAs	coding	for	NS	protein,	and	the	primer	pair	R4883-R5014	for	the	amplification	of	the	
mRNAs	coding	for	capsid	VP1	and	VP2	proteins.		
	
12.6.	Immunofluorescence	Assay	
Aliquots	of	cell	culture	samples,	corresponding	to	0.5x105	cells,	were	centrifuged	at	4000g	
for	5	min.	Pelleted	cells	were	washed	with	PBS,	spotted	onto	glass	slides	and	fixed	with	1:1	
acetone:methanol	 for	 10	min	 at	 	 20	 °C.	 Slides	were	 then	 incubated	 at	 RT	 for	 1	 h	with	 a	
monoclonal	mouse	antibody	against	VP1	and	VP2	proteins	(MAB8293,	Chemicon),	diluted	
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1:200	 in	 PBS/BSA	 1%.	 After	 washing	 in	 PBS,	 slides	 were	 incubated	 for	 1	 h	 with	
AlexaFluor488	 anti-mouse	 secondary	 antibodies	 (Life	 Technologies),	 diluted	 1:1000	 in	
PBS/BSA	1%.	After	further	washing,	slides	were	stained	with	Evans	blue,	washed,	mounted	
and	viewed	on	a	fluorescence	microscopy	with	a	fluorescein	isothiocyanate	filter	set.	
	
12.7.	Statistical	Analysis	
Experiments	were	carried	out	in	triplicate	series,	and	for	each	quantitative	determination,	
triplicate	values	were	obtained.	Statistical	analysis	was	carried	out	by	using	the	programme	
GraphPad	Prism	version	5.00	for	Windows	(GraphPad	Software,	San	Diego	California,	USA).	
Linear	 regression	 analysis	 was	 carried	 out	 to	 correlate	 input	 moi	 values	 and	 calculated	
amounts	 of	 viral	 nucleic	 acids.	 One-way	 ANOVA	 (analysis	 of	 variance)	 followed	 by	 the	
Dunnett’	 Multiple	 comparison	 test	 was	 used	 to	 compare	 data	 obtained	 in	 different	
experimental	conditions.	EC50	and	EC90	values	for	the	different	moi	were	determined	by	
non-linear	 regression	 curve	 on	 percentage	 inhibition	 of	 viral	 activity	 for	 each	 different	
concentration	of	CDV.	
	
	
68	
	
RESULTS
69	
	
13.	B19V	AND	ERYTHROID	PROGENITORS	CELLS	
	
13.1.	EPCs	dynamics	and	differentiation	
PBMC	 isolated	 from	 peripheral	 blood	 of	 normal	 donors	 were	 grown	 in	 culture	 medium	
containing	 erythropoietic	 growth	 and	 differentiation	 factors.	 In	 these	 conditions,	 the	 cell	
population	 expanded	 and	maintained	 viability	 for	 15-20	 days.	 The	 progressive	 change	 of	
cell	population	compositition	was	monitored	by	cytofluorimetric	analysis	(Figure	11).		
	
	
Figure	11:	Phenotipic	characterization	of	differentiang	EPCS.	Each	graph	reports	the	percentage	
of	cells	positive	for	each	indicated	marker	and	the	relative	Mean	Fluorescence	Intensity.	
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During	 the	 time	of	 culture	 a	 progressively	 higher	 proportion	 of	 cells	 expressed	 erythroid	
lineage-specific	markers,	such	as	CD36,	CD71	and	CD235a,	reaching	highest	values	between	
days	 9-15,	 while	 during	 the	 last	 day	 of	 culture	 (18	 day),	 markers	 expression	 decreased.	
Concerning	B19V	 receptors,	 the	 trend	of	 globoside	 expression	 followed	 that	 of	 erythroid	
markers,	while	 the	distribution	of	α5β1	 integrin	appeared	constant.	Overall,	 these	results	
indicated	a	progressive	in	vitro	differentiation	of	isolated	PBMC	through	erythroid	lineage,	
obtaining	a	culture	system	potentially	susceptible	to	B19V	infection.	
	
13.2.	Viral	replication	in	EPCs	
Efficiency	 of	 viral	 replication	 was	 studied	 in	 dependence	 on	 the	 degree	 of	 erythroid	
differentiation.	Cells	were	 infected	with	B19V	at	3	days	 intervals	of	culture,	 from	3	 to	18	
days	post	isolation,	for	a	48	h	course	of	infection.	Equal	amounts	of	cells	were	collected	at	2	
hpi,	24	hpi	and	48	hpi	and	the	respective	amounts	of	viral	DNA	were	determined	by	qPCR.	
Viral	DNA	measured	at	2	hpi	represented	the	virus	input,	the	amount	of	virus	that	entered	
the	 cells.	 Increment	 of	 viral	 DNA	 between	 2	 hpi	 and	 24-48	 hpi	 is	 indicative	 of	 viral	
replication.	For	the	different	days	of	culture	and	each	infection	course,	the	Log	B19V	DNA	
increase	at	24	and	48	hpi	versus	2	hpi	was	calculated	as	the	mean	of	2	to	5	 independent	
experiments.	At	3	days	 cells	were	 susceptible,	but	not	permissive	 to	B19V	 replication,	 as	
indicated	by	the	detection	of	viral	DNA	at	2	hpi	but	showing	a	mean	0.5	Log	decrease	in	the	
amount	of	viral	DNA	associated	with	cells	during	the	48	h	of	infection	(Figure	12).	From	day	
6	to	day	18	cells	were	susceptible	and	became	also	permissive	to	viral	replication,	although	
to	 different	 extents.	 Viral	 replication	was	maximal	 at	 days	 6-9,	 with	 a	mean	 2.2-2.8	 Log	
increase,	while	at	days	12-18	cells	replication	occurred	at	reduced	degree,	with	a	mean	1.5-
1.6	 Log	 increase.	 Overall,	 data	 confirmed	 that	 viral	 replication	 depends	 on	 the	
differentiation	stage	of	in	vitro	cultured	erythroid	cells.	
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Figure	 12:	B19V	 replication	 in	 EPCs.	 The	 amount	of	 B19V	DNA	was	determined	by	qPCR,	
and	 the	Log	 increase	measured	between	2	hpi	and	24-48	hpi.	Columns	 indicate	 the	mean	
values	obtained	from	independent	experiments,	bars	indicate	the	standard	error	of	means.	
	
13.3.	Viral	distribution	in	EPCs	
Viral	 replication	 and	 distribution	 of	 productively	 infected	 cells	 within	 a	 differentiating	
population	 of	 EPCs	 was	 investigated	 in	 a	 selected	 representative	 experiment	 by	 parallel	
qPCR	 and	 flow-FISH	 assay.	 EPCs	 at	 different	 days	 of	 in	 vitro	 culture	 (6-18	 days)	 were	
infected	with	B19V,	and	equal	amounts	of	cells	were	collected	at	2,	24	and	48	hpi.	For	each	
sample,	qPCR	analysis	was	carried	out	to	determine	the	amount	of	viral	DNA,	and	flow-FISH	
assay	was	performed	to	determine	the	percentage	of	B19V	positive	cells	(Figure	14,	A	and	
B).	 The	overall	 trend	of	 replication	 activity	 correlated	with	 the	 trend	previous	 described.	
The	observed	increase	in	the	amount	of	viral	DNA	was	maximal	(3.4	Log)	for	cells	at	days	9,	
2.5-2.6	for	cells	at	days	6,	12,	15,	and	2.0	Log	for	cells	at	day	18.	In	accordance	with	these	
values,	 the	percentage	of	FISH	positive	cells	was	higher	 (41.4%)	at	day	9,	 lower	at	days	6	
(3.8%)	 and	 12	 (5.2%),	 and	 lowest	 at	 days	 15	 (1.6%)	 and	 18	 (1.1%).	 The	 dot-plot	 graphs	
(Figure	13)	showed	a	diffuse	pattern	of	positive	cells,	suggesting	a	continuous	distribution	
in	the	amount	of	intracellular	viral	nucleic	acids	within	the	fraction	of	FISH	positive	cells.	
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Figure	13:	B19V	replication	and	distribution	in	EPCs.	The	dot	plot	graphs	of	Flow-FISH	assay	 in	EPCs	
infected	at	day	6	and	9	are	reported.		
	
Plotting	 the	 percentage	 of	 FISH-positive	 cells	 versus	 the	 Log	 of	 viral	 DNA	 amount	 at	 the	
respective	 time	 points,	 a	 linear	 correlation	 was	 evident	 (Figure	 14,	 C).	 This	 correlation	
indicated	 that	 B19V	 replication	 was	 confined	 to	 a	 limited	 permissive	 fraction	 of	 the	
potentially	susceptible	cells	within	the	EPC	population,	not	uniquely	identified	by	any	of	the	
cell	 surface	 markers	 analyzed,	 but	 rather	 depending	 on	 the	 presence	 of	 other	 cellular	
factors	 linked	to	the	differentiation	stages.	Therefore,	the	extent	of	replication	of	virus	 in	
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differentiating	EPCs	was	mainly	the	result	of	the	extent	of	recruitment	of	permissive	cells	
within	a	heterogeneous	population	of	potentially	susceptible	cells.	
	
Figure	14:	B19V	replication	and	distribution	 in	EPCs.	 (A)	Amount	of	B19V	DNA	expressed	as	Log	
DNA	geq/104	cells.	(B)	Fraction	of	positive	cells	determined	by	the	flow-FISH	assay.	(C)	Correlation	
of	dat	obtained	by	the	two	different	assays.	X:	samples	at	2	hpi;	O:	samples	at	24	hpi;	•:	samples	at	
48	hpi.	
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13.4.	Viral	macromolecular	synthesis	in	EPCs	
To	assess	a	deep	systematic	analysis	of	the	dynamics	of	viral	macromolecular	synthesis	in	a	
selected	 representative	 experiment,	 cells	 at	 different	 days	 from	 isolation	 were	 infected	
with	B19V,	and	equal	amounts	of	cells	were	collected	at	early	(2,	6,	12	hpi)	and	late	(24,	36,	
48	hpi)	time	points	post	infection.	The	amount	of	viral	DNA	and	total	RNA	were	quantified	
by	qPCR	and	qRT-PCR,	respectively.	The	same	primer	pair	2210-2355,	being	located	in	the	
central	exon	of	genome,	was	used	to	amplify	both	viral	DNA	and	total	RNA.	The	amount	of	
viral	nucleic	acids	was	expresses	as	Log	target	copies/104	cells.	
Viral	 DNA	 kinetic	 in	 the	 selective	 experiment	 (Figure	 15,	 A)	 reflected	 the	 overall	 kinetic	
observed	 in	several	experiments	 (Figure	12).	Viral	binding/entry	seemed	 independent	cell	
differentiation	 stage,	 since	 comparable	 amounts	 of	 viral	DNA	were	measured	 at	 2	 hpi	 in	
cells	from	day	3	to	15	of	culture,	while	lower	amounts	(-0.6	Log)	were	observed	only	for	day	
18.	On	the	contrary,	the	ability	to	replicate	was	correlated	to	the	erythroid	stage	of	EPCs.	
Cells	infected	at	day	3	represented	a	non	permissive	environment	for	viral	replication	since	
a	DNA	decrease	of	1.0	Log	was	measured	between	2	hpi	to	48	hpi,	although	viral	DNA	was	
detectable	during	the	entire	time	course	of	infection.	On	the	contrary,	a	permissive	window	
for	viral	replication	ranged	from	day	6	to	day	15.	In	particular,	in	these	cells,	after	an	early	
steady	 state,	 viral	 replication	 started	 from	 12	 hpi.	 The	 highest	 increase	 in	 DNA	 amount	
occurred	between	12	hpi	and	24	hpi	(+1.6-2.0	Log),	and	further	increase	was	measured	up	
to	48	hpi	 (+0.6-1.4	Log	 from	24	 to	48	hpi).	Cells	 infected	at	day	9	 sustained	 the	maximal	
B19V	replication	activity	with	a	viral	DNA	amount	increment	of	+3.1	Log	from	2	to	48	hpi.	At	
day	18,	lower	amounts	of	B19V	DNA	were	measured	at	2	hpi	and	lower	levels	of	replication	
were	observed	with	an	overall	increment	of	+0.9	Log	from	2	to	48	hpi.		
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Figure	15:	B19V	replication	and	expression	in	a	time	course	of	 infection	in	EPCs.	 (A)	Amount	of	B19V	DNA	
expresses	as	Log	DNA	geq/104	cells.	 (B)	Amount	of	B19V	total	RNA	expresses	as	Log	RNA	target	copies/104	
cells.	
	
Parallel	 analysis	 of	 viral	 RNA	 (Figure	 15,	 B)	 demonstrated	 a	 strictly	 association	 between	
genome	replication	and	transcription,	thus	a	very	low	amount	of	viral	RNA	was	detectable	
at	 day	 3,	 while	 accumulation	 of	 viral	 RNA	 was	 observed	 at	 days	 6-15	 and	 at	 day	 18,	
although	to	a	lower	level,	accordingly	to	the	lower	amount	of	viral	DNA.	In	detail,	viral	RNA	
was	detected	starting	from	6	hpi	for	all	series,	with	similar	amounts	for	day	6-15	series	and	
lower	amount	for	day	3	and	day	18	(-2.3	Log	and	-1.6	Log	for	the	day	3	and	day	18	series,	
respectively,	compared	to	the	day	6-15	series).	Then,	after	a	slight	increase	between	6	hpi	
and	12	hpi,	no	further	increment	occurred	at	day	3,	while	for	the	other	day	series	viral	RNA	
dynamic	followed	viral	DNA	synthesis.	In	particular,	viral	transcription	boosted	from	12	hpi	
to	24	hpi	(+1.8-2.4	Log),	in	coincidence	with	the	start	of	viral	DNA	synthesis.	No	significative	
additional	 increment	occurred	between	24	 to	48	hpi,	with	 the	exception	of	day	9	where	
viral	RNA	amount	reached	the	highest	levels,	with	a	further	increse	of	1.4	Log	between	24	
hpi	and	48	hpi	for	an	overall	increment	of	>3.0	Log	from	12	to	48	hpi.	Results	indicated	that	
a	 productive	 infectious	 cycle	 rely	 on	 a	 biphasic	 macromolecular	 synthesis	 with	 an	 early	
transcription	 phase	 on	 the	 parental	 template,	 followed	 by	 late	 transcription	 on	 the	
replicating	templates.	The	reduced	transcriptional	activity	in	days	3	and	18	series	could	be	a	
result	of	a	block	in	the	second-strand	DNA	repair	synthesis,	thus	preventing	the	generation	
of	a	transcriptionally	active	template,	and	limiting	viral	genome	replication.		
The	complete	 set	of	mature	viral	mRNAs	originates	 from	the	combination	of	 splicing	and	
cleavage-polyadenylation	events	(Figure	10).	A	detailed	analysis	of	the	relative	abundance	
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of	the	different	mRNAs	classes	was	carried	out	by	using	a	set	of	selective	primers	for	qRT-
PCR	analysis	(Figure	16).		
	
Figure	 16:	 B19V	 replication	 and	 expression	 in	 a	 time	 course	 of	 infection	 in	 EPCs.The	 dynamics	 of	
accumulation	of	viarl	DNA	and	of	the	major	classes	of	viral	mRNAs	in	infected	EPCs	is	reported.	
	
The	primer	pair	R2210-R2355,	being	 located	 in	 the	central	exon,	was	used	to	amplify	 the	
whole	ensemble	of	viral	transcripts.	Usage	of	the	first	splice	donor	(D1)	and	selection	of	the	
first	 splice	acceptor	 (A1.1/2)	was	analyzed	by	 combining	primer	R0534,	positioned	 in	 the	
common	 leader	 region,	 with	 either	 primer	 R0622	 (specific	 for	 unspliced	 transcripts),	
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R2101*	(specific	for	the	proximal	first	acceptor	site	A1.1)	or	R2221*	(specific	for	the	distal	
first	 acceptor	 site	 A1.2).	 The	 primer	 pair	 R1882-R2033	 was	 used	 to	 define	 unspliced	
transcripts,	coding	for	NS	protein.	Usage	of	the	second	splice	donor	(D2)	and	selection	of	
the	 second	 splice	 acceptor	 (A2.1/2)	 was	 analyzed	 by	 combining	 primer	 R2210	 (common	
primer	 positioned	 in	 the	 central	 exon)	 with	 either	 primer	 R2377	 (specific	 for	 unspliced	
transcripts),	 R3238*	 (specific	 for	 the	 proximal	 second	 acceptor	 site	 A2.1)	 or	 R4897*	
(specific	for	the	distal	second	acceptor	site	A2.2).	Usage	of	the	proximal	and	distal	cleavage-
polyadenylation	signals	was	analyzed	by	the	primer	pairs	R2210-R2377	(upstream	of	pAp1),	
R2998-R3103	 (upstream	of	 pAp2),	 R3180-R3153	 (readthrough	 of	 pAp),	 and	 R4899-R5014	
(upstream	of	pAd).	With	the	exception	of	the	day	3	sample	series,	where	the	level	of	mRNA	
transcription	was	too	 low	to	a	comparative	analysis,	the	dynamics	of	accumulation	of	the	
different	 classes	 of	 viral	 mRNA	 in	 the	 days	 6-18	 sample	 series	 was	 similar	 and	 largely	
independent	on	the	degree	of	cellular	differentiation.	Two	pattern	of	expression	could	be	
distinguished	 as	 a	 result	 of	 a	 changing	 frequency	 of	 mRNA	 processing	 events:	 an	 early	
pattern	at	6-12	hpi	replaced	by	a	later	pattern	at	24-48	hpi	(Figure	17).	In	the	early	phase	of	
infection,	cleavage	at	the	pAp	site	occurred	at	a	frequency	of	81-92%,	while	in	later	phases	
of	 infection	 cleavage	 at	 the	 pAd	 site	 accounted	 for	 66-72%	 of	 events.	 In	 the	 processing	
events	of	intron	1,	12-19%	in	early	phases,	but	only	0.2-0.3%	in	late	phases	did	not	undergo	
splicing,	while	 in	 the	 remaining	 cases	 splicing	 occurred	 1.4-2.2	 times	more	 frequently	 at	
acceptor	 site	 1.1	 over	 1.2,	 increasingly	 at	 later	 times	 post-infection.	 In	 the	 processing	
events	of	intron	2,	97%	in	early	phases	and	34-46%	in	late	phases	did	not	undergo	splicing,	
while	in	the	remaining	cases	splicing	occurred	only	at	acceptor	site	2.1	in	early	phases,	and	
1.3-1.4	times	more	frequently	at	acceptor	site	2.1	over	2.2,	at	late	times	post-infection.	In	
summary,	 the	 relative	 abundance	of	 viral	mRNAs	 classes	 through	 the	 course	of	 infection	
clearly	distinguished	an	early	and	a	 late	pattern	of	expression	profile.	 In	 the	early	phase,	
prior	to	the	beginning	of	viral	replication,	mRNAs	were	mostly	cleaved	at	the	proximal	site,	
leading	 to	a	higher	 relative	abundance	of	small	mRNAs	and	mRNA	coding	 for	NS	protein,	
that	 is	 essential	 for	 viral	 replication.	 In	 the	 later	 phase,	 in	 coincidence	 with	 viral	 DNA	
replication,	 mRNAs	 were	 mostly	 cleaved	 at	 the	 distal	 site,	 leading	 to	 a	 higher	 relative	
abundance	 of	 mRNAs	 for	 VP1,	 VP2	 and	 11kDa	 proteins.	 The	 overall	 finding	 therefore	
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confirmed	 the	 linked	 coordination	 of	 viral	 DNA	 replication,	 viral	 RNA	 transcription,	 and	
differential	usage	of	mRNAs	processing	signals	to	achieve	a	productive	replicative	cycle	 in	
EPCs.	
	
Figure	 17:	 Transcript	 processing	 in	 a	 time	 course	 of	 infection	 in	 EPCs.	 Composite	 columns	 indicate	 the	
frequency	of	processing	events	at	intron	1,	intron	2	or	pAp/pAd	sites,	and	the	resulting	overall	composition	of	
the	 major	 classes	 of	 viral	 mRNAs.	 Cumulative	 data	 are	 averaged	 for	 each	 time	 point	 for	 the	 days	 6-18	
experimental	series.	
	
13.5.	Virus	release	and	infectivity	
In	the	same	experiment,	 the	corresponding	supernatant	of	 infected	cells	was	collected	at	
each	time	points	and	analyse	in	qPCR	to	determine	the	extracellular	release	of	virus	(Figure	
18,	A).	Results	indicated	that	accumulation	of	viral	DNA	in	the	supernatant	of	infected	cells	
was	 mainly	 proportional	 to	 viral	 DNA	 present	 within	 the	 corresponding	 cellular	 fraction	
(Figure	 15,	 A).	 In	 fact,	 in	 the	 non-permissive	 cells	 of	 day	 3	 series,	 DNA	 remained	 to	
background	values	for	the	whole	time	course.	In	the	day	6-15	series,	viral	DNA	accumulated	
starting	 from	 24	 hpi	 and	 reaching	maximum	 level	 at	 48	 hpi	 (+1.9-2.8	 Log	 increase	 over	
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background	values).	However,	this	correlation	between	extracellular	and	intracellular	B19V-
DNA	 was	 not	 observed	 for	 the	 day	 18	 cell	 series,	 where	 viral	 DNA	 in	 the	 supernatant	
remained	at	a	constant	background	level	within	the	48	hpi,	 like	day	3	cell	series,	with	the	
difference	that	a	modest	increase	in	intracellular	DNA	occurred	at	day	18	but	not	at	day	3.		
	
	
Figure	18:	Virus	release	from	EPCs	and	infectivity.	 (A)	Log	of	viral	DNA	target	copies	measured	in	100	µl	of	
supernatant	collected	from	infected	EPCs.	(B)	Infectivity	of	virus	released	from	EPCs.	The	amount	of	viral	DNA	
was	calculated	at	2	and	48	hpi	 in	supernatants-infected	EPCs.	DNA	amounts	are	reported	as	variation	bars:	
lower	limits	of	bars	are	the	amount	of	viral	DNA	detected	at	2	hpi;	upper	limits	are	the	amount	detected	at	48	
hpi.		
	
The	ability	of	collected	supernatants	to	start	a	new	infection	cycle	was	investigated	to	test	
the	 infectivity	of	 virus	 released	 from	EPCs.	Equal	 amount	of	 supernatants	obtained	at	12	
and	 48	 hpi	 from	 each	 samples	 series	 were	 used	 to	 infect	 new	 EPCs	 at	 day	 9	 of	 culture	
(Figure	 18,	 B).	 Supernatant	 collected	 at	 12	 hpi	 was	 chosen	 to	 verify	 a	 possible	 residual	
activity,	because	it	was	collected	before	viral	replication	started.	Thus,	potential	infectivity	
of	 supernatants	 from	 12	 hpi	 could	 not	 be	 ascribed	 to	 new	 viral	 progeny	 released	 from	
infected	cells.	After	infection	with	supernatants,	viral	replicative	activity	in	the	infected	cells	
was	determined	comparing	the	amount	of	viral	DNA	at	48	hpi	with	respect	to	that	at	2	hpi.	
Supernatants	obtained	at	12	hpi	showed	a	comparable	residual	 infectivity	for	each	of	the	
tested	sample	series,	leading	to	a	mean	increase	of	3.8	Log	from	2	to	48	hpi.	Supernatants	
from	48	hpi	of	day	3	and	day	18	cell	 series	 showed	similar	 infectivity	 (mean	 increase	3.5	
Log)	 to	 the	 supernatants	 collected	 at	 12	 hpi	 of	 the	 same	 day	 3	 and	 day	 18	 cell	 series,	
suggesting	that	no	viral	progeny	was	released	from	12	hpi	to	48	hpi	in	these	cells.	On	the	
80	
	
other	hand,	supernatants	obtained	at	48	hpi	 for	day	6-15	series	yielded	 infectivity	results	
coherent	with	the	amounts	of	virus	present	 in	supernatants,	with	a	mean	 increase	of	4.4	
Log	of	viral	DNA	in	infected	cells.	For	day	6-15	series,	the	difference	of	infectivity	obtained	
with	 supernatants	 of	 48	 hpi	 with	 respect	 to	 that	 obtained	 with	 supernatants	 of	 12	 hpi,	
indicating	that	for	these	day	series	production	and	release	of	new	infectious	virus	occurred.	
These	 results	 confirmed	 that	 B19V	 productive	 viral	 cycle	 is	 restricted	 to	 a	 limited	
differentiation	of	phase	of	erythroid	lineage.	
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14.	B19V	AND	CIDOFOVIR	
	
14.1.	Inhibitory	effect	of	cidofovir	in	UT7/EpoS1	
The	antiviral	activity	of	CDV	was	first	evaluated	in	a	reference	cell	line	(UT7/EpoS1),	largely	
used	 to	 study	 B19V	 pathogenesis.	 UT7/EpoS1	 cells	 were	 infected	 with	 different	
concetrations	of	B19V,	from	104	to	101	geq/cell,	and	following	absorption	phase	for	2	h	at	
37°C,	cells	were	incubated	in	the	absence	or	in	presence	of	different	concentration	of	CDV	
(range	0.1-500	µM)	for	a	total	course	of	infection	of	72	h.	
Following	the	same	experimental	outline	as	 for	EPCs,	UT7/EpoS1	cells	were	 infected	with	
B19V	 and	 cultured	 in	 the	 absence,	 as	 a	 control,	 and	 in	 the	 presence	 of	 the	 different	
concentrations	 of	 CDV.	 Viral	 replication	 was	 determined	 by	 quantification	 of	 viral	 DNA	
amount	present	in	cells	collected	at	72	hpi	(the	optimal	time	course	of	infection	for	this	cell	
line)	 and	 comparing	 it	 with	 the	 amount	 of	 viral	 DNA	 present	 at	 2	 hpi	 in	 an	 equivalent	
aliquot	of	 cells.	Calculated	amounts	of	viral	DNA	 (by	 interpolation	with	external	 standard	
curve)	 at	 2	 hpi	 and	 at	 72	 hpi	 are	 plotted	 as	 a	 function	 of	 the	 moi,	 for	 the	 different	
concentrations	of	CDV	studied	(Figure	19,	 left),	and	are	expressed	as	Log	of	target	copies	
(geq)	normalized	to	20000	cells.	Linear	regression	analysis	showed	that	the	amount	of	viral	
DNA	within	cells	 is	 correlated	with	 the	moi	used,	 for	 the	different	experimental	 samples.	
Virus	binding	and	uptake	was	proportional	to	viral	concentration	inoculated	with	a	constant	
∆Log	at	2	hpi	between	the	serial	dilutions	of	virus.	A	constant	replicative	activity	of	B19V	
was	also	evident	within	cells,	since	a	regular	variation	in	the	amount	of	viral	DNA	from	2	hpi	
to	72	hpi	was	measured	 for	 the	different	moi	 tested,	as	demonstrated	by	 the	equivalent	
slopes	for	the	2	hpi	and	72	hpi	sample	series	in	absence	of	CDV.	Eventual	shift	along	the	Y-
axis	indicated	a	lower	replicative	activity	attributable	to	inhibitory	effects	of	CDV	on	B19V	
DNA	 replication.	 CDV	 0.1	 µM	 possessed	 no	 significative	 inhibitory	 activity,	 while	
progressively	lower	increases	of	viral	DNA	were	detected	in	the	10	µM	-100	µM	range,	and	
a	complete	inhibition	of	viral	DNA	replication	was	reached	with	500	µM	CDV,	because	the	
amount	of	viral	DNA	at	72	hpi	was	lower	than	viral	DNA	detected	at	2	hpi.	The	progressively	
reduced	 replicative	 activity	 in	 presence	 of	 increasing	 CDV	 concentrations	 compared	 to	
control	sample	without	drug	indicated	that	CDV	showed	a	dose-dependent	inhibitory	effect	
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on	B19V	replication	in	infected	UT7/EpoS1	cells.	The	dose-dependent	relationship	allowed	
defining	 EC50	 and	 EC90	 values	 for	 CDV	 for	 all	 the	 different	 moi	 tested	 by	 plotting	 the	
percentage	 inhibition	 of	 replication	 as	 a	 function	 of	 CDV	 concentration	 and	 analyzing	
trough	a	non-linear	regression	function	(Figure	19,	right).	For	the	highest	moi	tested,	EC50	
value	corresponded	to	34.35	µM.	
	
	
Figure	19:	Inhibitory	activity	of	CDV	in	UT7/EpoS1	cells.	 (Left)	Calculated	amounts	of	B19V	DNA	in	infected	
cells	at	2	and	72	hpi	were	plotted	as	a	function	of	moi	for	the	different	concentrations	of	CDV	tested.	(Right)	
Normalised	response	to	CDV	in	UT7/EpoS1	cells.	EC50	and	EC90	values	can	be	derived	from	the	plot.	
	
	
Parallel	analysis	of	total	viral	RNA	synthesised	in	infected	UT7/Epo	S1	cells	was	determined	
at	 72	 hpi.	 Significative	 reduction	 in	 viral	 transcriptional	 activity	was	 appreciable	 only	 for	
high	moi	and	with	the	highest	CDV	concentration	tested	(Figure	20).	
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Figure	20:	Analysis	of	variance	 in	 the	amount	of	B19V	RNA	 in	UT7/EpoS1	cells.	Amount	of	 total	RNA	was	
measured	in	infected	cells	at	the	different	moi	and	in	presence	of	different	CDV	concentration.		
	
The	relative	abundance	of	mRNAs	coding	for	viral	proteins	followed	the	expression	profile	
previously	characterized,	with	mRNAs	coding	for	NS	proteins	in	the	range	of	1-3%	of	total	
viral	RNA,	and	mRNAs	coding	for	capsid	VP1	and	VP2	proteins	in	the	range	of	15-22%,	with	
an	 exception	 in	 presence	 of	 CDV	 500	 µM	 when	 range	 was	 reduced	 to	 5-8%,	 an	 effect	
possibly	linked	to	a	shift	in	the	expression	profile	of	B19V	due	to	the	marked	inhibition	of	
its	replicative	activity.		
By	immunofluorescence	assay,	a	proper	evaluation	of	protein	expression	could	be	possible	
only	for	the	highest	moi	of	104,	because	at	lower	moi	the	small	number	of	positive	cells	did	
not	 allow	 any	 reliable	 quantitative	 evaluation	 of	 inhibitory	 activity	 of	 CDV.	 5.0%	 of	 cells	
infected	 with	 104	 moi	 were	 positive	 for	 capsid	 proteins,	 while	 a	 decreasing	 value	 were	
observed	in	presence	on	increasing	CDV	concentrations	up	to	the	loss	of	positive	signal	in	
presence	of	CDV	500	µM.	
	
14.2.	Inhibitory	effect	of	cidofovir	in	EPCs	
To	 test	 the	 inhibitory	 effect	 of	 CDV	 on	 B19V	 replication	 in	 the	 natural	 target	 cells,	 EPCs	
differentiated	from	PBMC	were	infected	at	day	9	±	1	of	culture,	the	optimum	range	for	viral	
permissiveness	as	indicated	by	previous	characterization.	Following	the	same	experimental	
outline	as	for	UT7/EpoS1,	EPCs	were	infected	with	B19V	and	cultured	in	the	absence,	as	a	
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control,	 and	 in	 the	presence	of	 the	different	 concentrations	of	 CDV	 for	 a	 total	 course	of	
infection	of	24	h.	This	short	period	of	infection	was	chosen	because	the	highest	increase	in	
the	 amount	 of	 viral	 DNA	 occurred	 between	 12	 hpi	 and	 24	 hpi,	 as	 shown	 in	 Figure,	 thus	
considered	 optimal	 for	 assessing	 the	 viral	 activity	 in	 a	 single	 round	 of	 infection.	 Viral	
replication	was	determined	by	quantification	of	viral	DNA	amount	present	in	cells	collected	
at	24	hpi	and	comparing	it	with	the	amount	of	viral	DNA	present	at	2	hpi	in	an	equivalent	
aliquot	of	cells.	Calculated	amounts	of	viral	DNA	at	2	hpi	and	at	24	hpi	are	expressed	as	Log	
of	 target	copies	 (geq)	normalized	to	20000	cells	and	plotted	as	a	 function	of	 the	moi,	 for	
the	 different	 concentrations	 of	 CDV	 studied	 (Figure	 21).	 As	 for	 UT7/EpoS1	 cells,	 also	 for	
EPCs	the	amount	of	viral	DNA	within	cells	is	orrelated	with	the	moi	used,	both	at	2	hpi	and	
at	24	hpi,	for	the	different	moi	used.	The	slopes	for	the	2	hpi	and	24	hpi	sample	series	are	
statistically	equivalent,	indicating	a	constant	relative	biological	activity	of	B19V	in	EPCs,	as	
within	 UT7/EpoS1	 cells.	 Shift	 along	 the	 Y-axis	 indicated	 a	 lower	 replicative	 activity	
attributable	to	inhibitory	effects	of	CDV	on	B19V	DNA	replication.	A	statistically	significant	
difference	 in	 elevations	 that	 could	be	 attributed	 to	 the	 inhibitory	 effects	 of	 CDV	on	 viral	
DNA	 replication	 was	 evident	 only	 for	 the	 500	 µM	 concentration,	 while	 no	 statistically	
significant	differences	were	seen	for	CDV	0.1-100	µM.	
	
Figure	21:	Inhibitory	activity	of	CDV	in	EPCs	cells.	Calculated	amounts	of	B19V	DNA	in	 infected	
cells	at	2	and	24	hpi	were	plotted	as	a	 function	of	moi	 for	 the	different	concentrations	of	CDV	
tested.	
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Parallel	analysis	of	total	viral	RNA	synthesised	in	infected	EPCs	cells	was	determined	at	24	
hpi.	 Even	 at	 the	 highest	 concentration	 of	 CDV,	 which	 showed	 to	 reduce	 viral	 DNA	
replication,	 the	 amount	 of	 total	 viral	 RNA	 at	 24	 hpi	 was	 not	 significantly	 different	 with	
respect	 to	 control	 sample	without	 drug	 (Figure	 22).	 Regarding	 the	 relative	 abundance	of	
transcripts,	mRNAs	coding	for	NS	protein	was	in	the	range	of	1-3%	of	total	viral	RNA,	and	
mRNAs	 coding	 for	 capsid	 VP1/VP2	 proteins	 was	 in	 the	 range	 of	 35-45%,	 an	 expression	
profile	comparable	to	that	previously	determined,	without	any	significant	correlation	with	
the	concentration	of	CDV.	
	
	
Figure	22:	Analysis	of	variance	in	the	amount	of	B19V	RNA	in	EPCs	cells.	Amount	of	total	RNA	was	measured	
in	infected	cells	at	the	different	moi	and	in	presence	of	different	CDV	concentration.		
	
Expression	of	viral	capsid	proteins	was	also	investigated	by	immunofluorescence	assay.	The	
percentage	of	infected	cells	treated	with	CDV	500	µM	positive	for	capsid	protein	expression	
was	not	statistically	different	 from	cells	 incubated	 in	medium	alone	 (10.8	%	compared	to	
14.0%	 for	moi	of	104,	1.1%	compared	 to	1.8%	 for	moi	of	103).	 The	effect	on	CDV	on	cell	
viability	 and	 proliferation	 were	 analysed	 by	 alamarBlue	 and	 BrdU	 assay,	 respectively,	 in	
both	 EPCs	 and	UT7/EpoS1	 cells.	Data	 showed	 the	CDV,	 at	 any	 concentrations,	 possessed	
neither	cytotossic	nor	cytostatic	effects	on	both	cell	system	studied.	
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14.3.	CDV	activity	in	pre-incubated	EPCs	
Considering	the	slight	inhibition	observed	in	24	h-infected	EPCs	treated	with	500	µM	CDV,	
the	 inhibitory	 effect	 of	 500	 µM	 CDV	was	 investigated	 in	 EPCs	 throughout	 a	 single	 cycle	
infection	of	48	h,	and	in	EPCs	pre-incubated	for	24	h	in	medium	supplemented	with	500	µM	
CDV.	EPCs	on	day	9	±	1	of	culture	were	 infected	with	B19V	at	104	moi	and	 following	 the	
adsorption	period,	cells	were	split	and	grown	for	48	h	in	presence	of	500	µM	CDV,	and	in	
the	 absence,	 as	 control	 sample.	 Similarly,	 EPCs	 pre-incubated	 with	 500	 µM	 CDV	 were	
inoculated,	 and	 after	 2	 h	 of	 virus	 incubation,	 cultured	 for	 48	 h	 with	 a	 fresh	 medium	
containing	the	drug,	for	a	total	exposure	time	to	CDV	of	72	h.	DNA	amounts	at	48	hpi	in	the	
different	 experimental	 conditions	 were	 compared	 with	 those	 obtained	 in	 the	 control	
sample,	 and	 expressed	 as	 percentage	 of	 viral	 replication	 (Figure	 23).	 B19	 viral	 activity	 in	
EPCs	was	significantly	inhibited	by	500	µM	CDV	(72.95	±	1.81	%),	and	the	drug	exposure	of	
EPCs	before	infection	further	increased	the	inhibitory	effect	up	to	92.44	±	2.44	%.	
	
Figure	23:	Analysis	of	CDV-treated	EPCs	 in	a	 time	course	of	 infection	of	48	h.	Percentage	of	viral	
replication	is	reported	by	calculating	viral	DNA	amounts	at	2	hpi	and	48	hpi	in	EPCs	treated	with	500	
µM	CDV	after	infection	and	in	EPCs	pre-incubated	with	500	µM	CDV	for	24	f	prior	to	infection.	
	
14.4.	CDV	activity	in	serial	rounds	of	EPCs	infection	
The	activity	of	CDV	against	B19V	 replication	was	assessed	 in	 serial	 rounds	of	 infection	 in	
which	 supernatants	 of	 infected	 EPCs	 were	 used	 as	 inoculum	 virus	 for	 consecutive	
infections,	under	constant	drug	exposure,	and	in	regular	medium	as	control.	In	detail,	EPCs	
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at	6	±	1	day	from	isolation	were	inoculated	with	the	viremic	serum	sample	at	104	moi,	then	
split	 and	 cultured	 with	 500	 µM	 CDV	 and	 without.	 After	 72	 h,	 infected	 cultures	 were	
collected	and	the	supernatants	were	used	to	inoculate	aliquots	of	the	same	initial	cellular	
population,	at	day	9	±	1	of	expansion	and	differentiation,	 in	a	second	round	of	 infection.	
Once	more,	 following	72	h,	 the	cell-culture	supernatants	were	used	 to	 infect	a	new	EPCs	
culture	at	day	6	±	1,	and	following	the	same	experimental	design,	at	day	9	±	1.	A	total	of	
four	rounds	of	infection	were	carried	out,	each	one	consisting	in	an	infection	cycle	of	72	h.	
Viral	replicative	activity	was	evaluated	determining	viral	DNA	amount	present	at	2	hpi	and	
72	hpi;	supernatants	were	analyzed	at	72	hpi	to	determine	the	yield	of	virus	released	from	
EPCs,	and	to	measure	the	viral	titers	used	in	the	subsequent	rounds	of	infection.		
	
Figure	24:	Effect	of	CDV	in	serial	rounds	of	infected	EPCs.	Log	B19V	DNA	(geq/20.000	cells)	is	plotted	as	function	
of	the	time	points,	for	the	different	rounds	of	infection,	and	in	the	two	experimental	conditions	(0	µM	CDV	in	red;	
500	µM	CDV	 in	blue).	Arrows	 indicate	 the	 reduction	 in	viral	amounts	and	 the	 reported	values	are	 the	 inhibition	
percentages	of	treated	EPCs	relative	to	untreated	cells.	
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In	the	treated	EPCs	and	in	their	supernatants,	a	progressive	reduction	of	B19V	replication	
was	observed.	Following	4	consecutive	infections,	for	a	total	of	12	days	of	drug	exposure,	
the	 percentage	 reduction	 of	 B19V	 DNA	 within	 cells	 was	 99.6	 ±	 1.13	 %,	 and	 in	 the	
supernatants	was	98.6	±	0.62	%.	
	
14.5.	CDV	activity	in	long-term	EPCs	infection	
The	 inhibitory	activity	of	500	µM	CDV	was	measured	 in	the	EPCs	throughout	a	prolonged	
viral	 infection.	 Cells	 at	 6	 ±	 1	 day	 from	 isolation	were	 infected,	 then	 split	 and	 cultured	 in	
presence	of	500	µM	CDV,	and	in	the	absence	of	the	drug.	Four	days	after	 infection,	fresh	
medium	with	or	without	CDV	was	added	to	the	cultures,	respectively.	
At	 different	 time	 post	 infection,	 up	 to	 8	 days,	 EPCs	were	 harvested	 and	 B19V	 DNA	was	
quantified	by	qPCR,	normalized	for	the	number	of	cells.	Similarly	to	what	was	obtained	in	
the	 serial	 rounds	 of	 infection	 when	 infection	 proceed	 within	 the	 differentiating	 EPCs	
population	and	in	the	presence	of	CDV,	B19V	replication	was	progressively	repressed;	the	
inhibitory	 effect	 of	 the	 drug,	 determined	 as	 percentage	 of	 the	 intracellular	 B19V	DNA	 in	
treated	EPCs	with	respect	to	untreated	EPCs	reached	at	the	late	stage	of	infection	the	81.71	
±	5.02	%.	The	analysis	of	B19V	DNA	in	the	cell-cultures	supernatants	at	8	dpi	confirmed	that	
CDV	led	to	severe	inhibition	of	B19V	yield,	reaching	the	80.82	±	8.27	%.	The	effects	of	the	
extended	 exposure	 to	 CDV	 on	 EPCs	 were	 evaluated	 in	 terms	 of	 cell	 viability	 and	
proliferation	(Table	2).		
	
	
Table	2:	Effects	of	CDV	in	prolonged-exposed	EPCs.	The	effects	of	CDV	(500	µM)	on	EPCs	
viability	and	proliferation	were	expressed	as	percentage	values,	relative	to	untreated	cells	(0	
µM	CDV).	
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Prolonged	 incubation	 with	 500	 µM	 of	 CDV	 did	 not	 reduce	 EPCs	 viability,	 while	 cell	
proliferation	rate	progressively	decreased	with	a	cytostatic	effect	nearly	at	30%	at	8	days	
upon	exposure.	
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15.	DISCUSSION	
	
The	human	pathogenic	parvovirus	B19	(B19V)	has	a	marked	tropism	for	human	erythroid	
progenitor	cells	(85,	86).	In	vitro,	only	few	myeloblastoid	cell	lines	support	viral	replication	
and,	even	so,	in	a	not	complete	permissive	environment,	yelding	to	a	very	limited	progeny.		
PBMC	isolated	from	peripheral	blood	can	be	cultured	and	differentiated	in	vitro	toward	a	
population	 of	more	mature	 erythroid	 cells,	 providing	 a	 culture	 system	 of	 primary	 target	
cells	highly	permissive	 to	B19V	replication	and	expression	and	suitable	 to	study	B19V	 life	
cycle	and	virus-cell	interactions	(92,	93).		
A	 systemic	 characterization	 of	 B19V	 replication	 and	 expression	 was	 assessed	 in	 PBMC-
derived	 EPCs	 cultured	 in	 medium	 containing	 cellular	 grow	 factors	 able	 to	 stimulate	 a	
progressive	differentiation	trough	the	erythroid	lineage.		
During	 the	culture	period,	EPCs	show	 increasing	expression	of	erythroid	specific	markers,	
such	as	CD36,	CD71	and	CD235a.	 The	presence	of	markers	 linked	 to	 the	 susceptibility	 to	
B19V	was	also	investigated.	Tropism	of	B19V	is	mainly	determined	by	the	presence	on	cell	
surface	of	 the	principal	 receptor,	globoside,	and	a	possible	 role	of	 coreceptors,	 like	α5β1	
integrin,	 in	 virus	 uptake	 was	 proposed	 (34,	 36).	 The	 distribution	 of	 globoside	 within	
differentiating	 EPCs	 followed	 closely	 that	 of	 other	 erythroid	markers,	 indicating	 that	 this	
cell	population	on	the	whole	is	potentially	susceptible	to	B19V	infection.	On	the	contrary,	
α5β1	integrins	are	expressed	at	constant	level,	 independently	of	the	differentiation	stage.	
B19V	productive	infection	was	showed	to	be	restricted	to	a	limited	phase	during	erythroid	
differentiation,	highlighting	the	close	relationship	between	virus	and	cellular	factors.	Thus,	
viral	genome	replication	and	expression	was	characterized	in	function	of	cell	differentiation	
stage.	
The	extent	of	viral	replication,	determined	by	qPCR,	as	well	as	the	fraction	of	productively	
infected	cells,	determined	by	flow-FISH	assay,	indicate	that	cells	can	support	B19V	more	at	
earlier	 differentiation	 stages,	 between	 6-9	 days,	 compared	 to	 later	 stages	 of	 erythroid	
differentiation	occurring	at	12–15	days,	while	 cells	at	 the	 first	days	post	 isolation	 (day	3)	
lead	to	an	abortive	 infection,	even	being	susceptible	to	B19V.	Furthermore,	 the	extent	of	
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viral	replication	is	correlated	to	the	fraction	of	productively	infected	cells	that	is	constantly	
lower	than	that	showing	the	presence	of	erythroid	markers	and	receptor	moieties.		
The	presence	and	distribution	of	 viral	 receptors	within	EPCs	will	 define	a	 susceptible	 cell	
population,	 but	 is	 not	 sufficient	 to	 classify	 a	 cell	 population	 supporting	 B19V	 replication.	
The	 capacity	 of	 cells	 to	 support	 a	 productive	 infection	 will	 be	 therefore	 regulated	 by	
intracellular	events	confined	to	a	particular	cell	differentiation	stage.		
A	 detailed	 analysis	 of	 viral	 macromolecular	 synthesis,	 obtained	 by	 qPCR	 and	 qRT-PCR,	
clearly	 indicates	 the	occurrence	of	 specific	patterns	 related	 to	 the	 specific	differentiation	
stages.	 The	 abortive	 infection	 in	 EPCs	 at	 a	 very	 early	 stage	 (3	 days)	 is	 demonstrated	 by	
absence	of	genome	replication	and	minimal	 transcriptional	activity.	This	pattern	 is	similar	
to	what	detected	 in	other	cell	 types	and	several	cell	 lines,	considered	susceptible	but	not	
permissive	 to	 B19V.	Determinants	 of	 viral	 restriction	may	 include	 inefficient	 initial	 steps,	
such	as	penetration,	uncoating,	nuclear	import	of	viral	genome,	as	well	as	failure	to	convert	
the	 parental	 ssDNA	 in	 dsDNA,	 thus	 preventing	 the	 generation	 of	 a	 functionally	 active	
genomic	template.	In	EPCs	at	later	stages	(6-18	days),	the	productive	pattern	of	infection	is	
constituted	 by	 biphasic,	 coordinated	 replication	 and	 transcription	 events.	 Assuming	 the	
occurrence	 of	 synthesis	 of	 the	 complementary	 strand,	 the	 active	 dsDNA	 is	 transcribed	
firstly,	since	total	RNA	is	detected	before	replication	starting.	Then,	in	a	second	phase,	both	
replication	 and	 transcription	 can	 occur	 on	 the	 amplifying	 genome,	 as	 by	 a	 progressive	
accumulation	of	viral	nucleic	acids	trough	the	course	of	infection.	
Production	of	the	whole	set	of	mRNA	is	another	key	factor	in	the	definition	of	a	permissive	
cellular	environment.	A	series	of	cis-acting	sequences	have	been	mapped	on	B19V	genome	
and	their	role	in	DNA	replication	and	RNA	processing	experimentally	determined.	In	mRNA	
processing	events,	two	pattern	of	expression	could	be	distinguished:	an	early	phase	where	
cleavage	 at	 pAp	 site	 is	 prevalent,	 splicing	 is	 relatively	 low,	 and	 mRNA	 for	 NS	 protein	 is	
produced	 in	 relatively	 higher	 abundance,	 and	 a	 late	 phase	where	 cleavage	 at	 pAd	 site	 is	
prevalent,	 splicing	 is	 relatively	 high,	 and	mRNAs	 for	 the	 VP	 and	 the	 11	 kDa	 proteins	 are	
produced	 in	 abundance.	 This	 pattern	 allows	 early	 production	 of	 NS	 protein	 that	 is	
necessary	for	viral	replication	and	late	accumulation	of	capsid	proteins	necessary	for	virus	
packaging	and	release.	
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Figure	25:	A	model	for	B19V	replication	and	expression.	Viral	genome	can	be	present	in	four	consecutive	
states,	 connected	by	 three	 state	 transitions:	 input	 ssDNA,	 initial	 dsDNA,	 replicating	 rfDNA,	 and	product	
ssDNA.	 Two	 functional	 profiles	 are	 identified	 as	 “early”	 (from	 dsDNA)	 and	 “late”	 (from	 rfDNA),	
characterized	 by	 a	 differential	 abundance	 and	 relative	 composition	 of	 transcriptome	 (compare	map	 in	
Figure	 10).	 Each	 profile	 is	 involved	 in	 regulative	 loops	 on	 genome	 state	 transitions.	 Erythroid	 specific	
factors	 are	 critical	 in	 regulating	 state	 transitions	 and	 are	 dependent	 on	 the	 differentiation	 and	
physiological	state	of	the	cell.		
	
	
In	our	experimental	conditions,	the	dynamics	of	macromolecular	synthesis	in	infected	EPCs	
is	in	agreement	with	observations	in	other	experimental	systems,	such	as	bone	marrow	and	
UT7/EpoS1	cells	(63,	64).	
However,	our	 results	 indicate	 the	strong	dependence	on	erythroid	differentiation-specific	
intracellular	events,	possibly	 interacting	with	viral	proteins,	 to	 regulate	a	 full,	productive,	
macromolecular	 synthesis.	 These	 factors	 would	 allow	 the	 definition	 of	 a	 complete	
productive	infection	cycle,	conditioning	the	switch	from	the	early	to	the	late	viral	phases.	
The	importance	of	such	cellular	factors	is	highlighted	also	by	the	impaired	release	of	virus	
from	 cells	 infected	 at	 the	 very	 late	 stage	 (18	 days),	 while	 cells	 supporting	 a	 complete	
macromolecular	synthesis	(6-9	days)	lead	to	production	and	release	of	new	infectious	virus.	
The	restriction	pattern	in	virus	release,	characterizing	the	very	late	stage,	could	be	ascribed	
to	 an	 inefficient	 translation	 and	 capsid	 protein	 production,	 as	 well	 as	 defective	 genome	
encapsidation	and	virus	packaging.		
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B19V	mediates	cell	 cycle	arrest,	 induces	apoptosis,	 interacts	with	DNA	Damage	Response	
pathway	 and	 blocks	 erythropoiesis	 (102-109).	 Productive	 infection	 is	 dependent	 also	 by	
erythropoietin	 signaling	 (97)	 and	 is	 enhanced	 by	 hypoxic	 condition	 (98,	 99),	 through	
activation	 of	 specific	 signal	 cascade.	 Comparative	 analysis	 of	 the	 erythroid-specific	
expression	profiles	during	differentiation	would	allow	 identifying	potential	cellular	 factors	
and	pathways	that	are	the	first	assumption	to	achieve	a	B19V	productive	infection.	
In	conclusion,	the	present	work	highlights	the	very	strictly	adaptation	of	B19V	to	a	specific	
cellular	 target	 not	 only	 identify	 in	 the	 erythroid	 lineage	 but	 also	 confined	 to	 a	 limited	
differentiation	 stage.	 This	 strictly	 adaptation	 is	 also	 the	 ‘strength’	 of	 the	 evolutionary	
success	of	B19V	whose	pathogenic	potential	affects	neither	the	more	undifferentiated	cells	
with	 staminal	properties,	nor	 the	 terminally	differentiated	cells	with	 scarce	potential	and	
lifespan	to	support	replication.	While	earlier	studies	indicated	that	B19V	infection	of	bone	
marrow-derived	cells	 increased	with	cell	differentiation	identified	a	permissive	population	
at	 the	 BFU-E	 and	 CFU-E	 stage	 (86),	 in	 the	 PBMC-derived	 EPCs	 system	 here	 described	
permissive	population	corresponds	to	proerythroblast	stage.	
A	 final	 remark	 is	 the	possibility	 to	obtain	 infectious	virus	 suitable	 for	 in	 vitro	 studies	and	
allowing	 to	overcome	the	dependence	 to	sera	of	viremic	patients	as	source	of	virus.	This	
evidence	is	in	contrast	with	previous	observations	that	showed	a	limited	virus	release	even	
in	permissive	EPCs	(202).	
	
The	 culture	 system	 described,	 highly	 permissive	 to	 B19V	 and	 representing	 in	 vitro	 the	
natural	 target	 cells	 infected	 in	 vivo,	 provide	a	 reference	 framework	 for	 identify	potential	
antiviral	drug	active	against	B19V.	To	this	purpose,	the	inhibitory	effect	of	Cidofovir	(CDV)	
on	B19V	replication	was	investigated	in	permissively	infected	EPCs	and	UT7/EpoS1	cells.		
In	both	cellular	systems,	a	direct	relationship	was	present	between	multiplicity	of	infection	
(moi)	and	detected	amount	of	viral	DNA,	as	demonstrated	by	the	linear	regression	curve	for	
2	hpi	(adsorbed/internalised	virus)	series	and	24	hpi	(for	EPCs)	and	72	hpi	(for	UT7/EpoS1).	
The	 effect	 of	 the	 different	 CDV	 concentrations	 on	 the	 amount	 of	 viral	 DNA	 produced	 in	
infected	cells	is	evidenced	by	a	Y-axis	shift	compared	to	control	series	without	drug.	A	dose-
dependent	 inhibitory	 effect	 of	 CDV	was	 evident	 in	UT7/EpoS1	 cells,	with	 a	 progressively	
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reduced	replicative	activity	of	B19V	in	presence	of	 increasing	CDV	concentrations,	up	to	a	
complete	 inhibition	 with	 500	 µM	 CDV.	 This	 effect	 was	 less	 evident	 in	 peripheral	 blood	
derived	EPCs,	where	only	the	500	µM	concentration	showed	a	significant	inhibition	of	viral	
replicative	activity.	Due	to	the	dose-dependent	relationship,	EC50	and	EC90	values	can	be	
determined	 only	 in	 UT7/EpoS1	 cells,	 and	 are	 comparable	 to	 those	 obtained	 for	 dsDNA	
viruses,	 having	 their	 own	 DNA	 polymerases	 (203).	 Cellular	 assays	 indicated	 that	 CDV	
exhibits	 any	 significant	 cytotoxic	 or	 cytostatic	 effect	 in	 both	 cellular	 systems,	 suggesting	
that	inhibitory	effects	are	specific	for	the	virus.	
The	different	activity	in	the	two	cellular	systems	may	be	ascribed	to	a	different	permeability	
of	 cells	 to	 the	 compound,	 or	 to	 different	 mechanisms	 of	 interference	 with	 the	 normal	
metabolism	of	nucleotides	(204).	A	critical	step	is	the	amount	of	drug	that	could	enter	the	
cells	and	be	converted	in	the	active	form.	Incorporation	of	CDV	during	DNA	synthesis	may	
hamper	 its	 template	 activity	 or	 causes	 chain	 termination.	 A	 different	 degree	 of	
incorporation	in	viral	DNA,	or	a	different	activity	of	DNA	repair	mechanisms,	can	contribute	
to	the	diverse	activity	of	CDV	in	normal	cells	like	EPCs	compared	to	a	myeloblastoid	cell	line	
like	UT7/EpoS1	(205).	
To	 deeply	 investigated	 the	 CDV	 action	 in	 EPCs,	 activity	 in	 pre-incubated	 or	 long-treated	
EPCs	with	500	µM	CDV	was	evaluated.	
Firstly,	intracellular	B19V	DNA	amounts	were	measured	in	EPCs	cultured	with	500	µM	CDV	
added	after	virus	infection	and	collected	48	hpi,	and	in	EPCs	pre-incubate	for	24	h	with	500	
µM	 CDV	 and	 then	 infected	 and	 cultured	 in	 presence	 of	 the	 drug	 for	 48	 h,	 for	 a	 total	
exposure	time	of	72	h.	Comparing	the	two	experimental	settings,	a	remarkable	increase	in	
antiviral	 activity	 was	 observed	 in	 cells	 subjected	 to	 pre-incubation,	 in	 which	 B19V	
replication	was	reduced	at	minimum	levels	(<8	%).	Considering	the	slow	cellular	uptake	of	
CDV,	 in	 EPCs	 treated	 following	 the	 viral	 adsorption	 period,	 B19V	 synthesis	 could	 start	
before	the	active	diphosphoryl	metabolite	of	CDV	reached	the	effective	intracellular	levels.	
As	 a	 consequence,	 CDV	 activity	 against	 B19V	 replication	 in	 this	 cellular	 context	 is	 lower	
than	which	can	be	obtained	with	a	pre-exposure.	
The	 inhibitory	 effect	 of	 500	 µM	 CDV	 against	 B19V	 replication	 was	 then	 assessed	 in	
prolonged	 infections	 of	 EPCs	 cultures	 in	 which	 the	 differentiation	 process	 of	 the	
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heterogeneous	 cellular	population	 is	 reproduced	according	 to	 two	experimental	 schemes	
that	mimic	 in	vitro	what	occurs	 in	the	bone	marrow	environment.	 In	the	first,	cell-culture	
supernatants	of	infected	EPCs,	cultured	with	and	without	CDV,	were	used	as	inoculum	virus	
for	subsequent	infections	of	cells	at	days	6	and	9	from	isolation.	Four	rounds	of	infection,	
each	one	consisting	in	a	72	h	infectious	cycle,	were	carried	for	a	total	exposure	time	of	12	
days.	In	continuously	treated	cells,	both	the	intracellular	B19V	DNA	amounts	and	the	viral	
progeny	 released	 from	 EPCs	 progressively	 decreased	 comparing	 to	 untreated	 cells,	
indicating	that	B19V	maintains	the	susceptibility	to	the	drug	even	upon	extended	exposure	
time.	
Finally,	EPCs	were	 inoculated	with	B19V	at	6	±	1	day,	and	cells	were	grown	with	500	µM	
CDV	and	without	for	8	days,	thus,	up	to	the	15	±	1	day	from	isolation.	B19V	DNA	amounts	in	
EPCs	 under	 constant	 CDV	 pressure	 progressively	 decreased	 at	 levels	 <20%	 compared	 to	
untreated	 cells;	 the	 observed	 inhibition	 of	 B19V	 replication,	 even	 at	 the	 late	 stage	 of	
infection,	could	be	ascribed	predominantly	to	a	selective	activity	of	CDV	towards	the	virus	
since	cell	proliferation	remained	close	to	70%.	
CDV	 antiviral	 activity	 was	 already	 demonstrated	 for	 dsDNA	 viruses	 (206),	 thus	 present	
results	not	only	extend	its	broad	spectrum	including	a	ssDNA	virus,	but	also	demonstrated	
for	the	first	time	an	inhibitory	activity	of	a	drug	against	B19V.	
This	 is	 promising	 for	 the	 development	 of	 antiviral	 drugs	 directed	 against	 a	 human	
pathogenic	virus	still	lacking	of	an	antiviral	treatment.		
Considering	 the	 limited	 activity	 of	 CDV	 in	 EPCs	 and	 the	nephrotossic	 side	 effects	 in	 vivo,	
related	 compounds	 would	 be	 investigated,	 such	 as	 lipid	 conjugates	 characterised	 by	 a	
greater	uptake	within	cells	(207).	The	improved	CDV	activity	in	human	primary	EPCs	upon	
extended	 exposure	 confirms	 that	 cellular	 uptake	 and	 conversion	 into	 active	metabolites	
affect	 the	 potency	 of	 the	 drug.	 The	 availability	 of	 new	 CDV	 analogs	 with	 increased	 cell	
membrane	 permeability,	 resulting	 in	 greater	 intracellular	 levels	 of	 active	 compound,	will	
lead	 to	 improved	 inhibitory	 activity	 as	 well	 as	 minor	 side	 effects	 if	 lower	 amounts	 of	
compound	are	sufficient	to	achieve	inhibitory	activity.	
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In	 conclusion,	 results	 confirm	 the	 restricted	 tropism	 of	 B19V	 to	 a	 limited	 phase	 of	 the	
erythroid	 lineage.	 Further	 investigation	 focused	on	 the	 change	 in	 the	 intracellular	 events	
during	 differentiation	 would	 allow	 the	 identification	 of	 cellular	 factors	 regulating	 viral	
permissiveness.	 On	 the	 other	 hand,	 differentiating	 EPCs	 in	 vitro	 provide	 a	 cell	 culture	
system	 suitable	 for	 screening	 of	 compounds	 with	 potential	 antiviral	 activity	 in	 a	 cellular	
environment	close	to	the	primary	target	cells	of	B19V	infection	in	vivo.	Finally,	cidofovir	is	
the	 first	 compound	 with	 a	 demonstrated	 inhibitory	 activity	 on	 B19V	 replication;	 thus,	
overall	 results	are	promising	 for	development	of	a	 specific	antiviral	 therapy	against	B19V	
infection.	
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